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9ABBREVIATIONS
AceCS1 cytoplasmic acetyl-CoA synthetase
AIM2 absent in melanoma 2
APC adenomatous polyposis coli
Arf alternative reading frame
AROS active regulator of SirT1
ASCL2 achaete-scute complex homolog 2
Ash2L ash2 (absent, small, or homeotic)-like
BER base excision repair
BMI1 B lymphoma Mo-MLV insertion region 1
BMP1 bone morphogenetic protein 1 
BRCA breast cancer 1
CARM1 coactivator-associated arginine methyltrans-
ferase 1
CCL human cancer cell line 
CDK cyclin-dependent kinase
CENP-A centromere protein A
ChIP chromatin immunoprecipitation 
CBP CREB-binding protein
CBX chromobox protein homolog
CHD chromodomain-helicase-dna-binding protein
CHK checkpoint kinase
CK2 casein kinase 2 
Col colagen
CR caloric restriction 
CREB cAMP response element-binding
DAP death-associated protein 
DBC1 deletions in tumour suppressor breast cancer 1
Des Desmin
DLC1 deleted in liver cancer 1),
DLL4 delta-like 4 
DNMT DNA methyltransferase 
DOT1 disrupter of telomere silencing
DSB double strand break 
EB embryoid body
EED embryonic ectoderm development
EGF  epidermal growth factor
(h) or (m)
ES(C)
(human) or (mouse) 
embryonic stem (cell)
EZH2 enhancer of zeste homolog 2
FBS fetal bovine serum
FGF fibroblast growth factor
F-L fibroblast-like cells 
Fn1 fibronectin
FOXO Forkhead box
FPR4 FK506-binding protein 4
GALR1 GALR1
GAPDH glyceraldehyde 3-phosphate dehydrogenase
Gata4 GATA binding protein 4
GCN5 general control of amino acid synthesis pro-
tein 5
GO gene ontology 
H2ABbd H2A Barr body-deficient
HAT histone acetyl transferase
HCP high CpG promoter 
HDAC histone deacetylase
HES7 hairy/enhancer of split 7 
HIC1 hypermethylated in cancer 1
HIC1 hypermethylated in cancer 1
HMT histone methyltransferase
HOXA5 homeobox A5 
HP1 heterochromatin protein 1
HPH homolog of polyhomeotic
HuR, HuD Hu antigen R, D
ICF immunodeficiency, centromere instability and 
facial anomalies
ICM inner cell mass   
ICP inermediate CpG promoter 
IKK inhibitor of kappa light polypeptide gene en-
hancer in B-cells, kinase
Ink inhibitor of cyclin-dependent kinase
iPS Induced pluripotent stem (cell)
ISWI imitation SWI/SNF
IVD in vitro-methylated DNA 
JMJ jumonji
JNK cJUN N-terminal kinase 
KDM lysine demethylase 
KMT lysine methyltransferase
KO knockout
Lama1 Laminin A1
LCP low CpG promoter 
LHX1 LIM (Lin11, Isl-1 & Mec-3) homeobox 1 
LINE1 long interspersed nuclear element 1
LPS lipopolysaccharide
MART Mono-ADP-ribosyltransferase
MBD methyl-binding domain 
MBT malignant brain tumor
MECP2 methyl-CpG binding protein 2 
MEF mouse embryonic fibroblasts 
mESC mouse embryonic stem cell
MGMT O-6-methylguanine-DNA methyltransferase
MHC myosin heavy chain 
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MLL mixed-lineage leukaemia 
MSK mitogen-and stress-activated protein kinase 
NAD nicotinamide adenine dinucleotide
NAMPT nicotinamide phosphoribosyl transferase 
NBS1 Nijmegen breakage syndrome 1
N-CoR nuclear receptor co-repressor
ncRNA non-coding RNA
Nes nestin
NES nuclear export signal 
NF-kB nuclear factor of kappa light polypeptide gene 
enhancer in B-cells
NHEJ non-homologous end joining 
NLS nuclear localization signal 
NODE nanog and Oct4-associated deacetylase
NPC neural precursor cell 
NPT normal primary tissue 
NPY neuropeptide Y
nt nucleotide
NTT normal tissue type 
OCT4 octamer-binding transcription factor 4
PARP poly-ADP-ribose polymerase
PAX6 paired box 6 
PBL peripheral blood lymphocytes
PcG Polycomb group 
PCAF p300/CBP-associated factor
PCNA proliferating cell nuclear antigen
PHD plant homeo domain
PGC1α proliferator-activated receptor gamma coactiva-
tor-1 α
POU5F1 POU (Pit1, Oct1-2, Unc86) domain, class 5, tran-
scription factor 1
PPARγ peroxisome proliferator-activated receptor γ 
PRC Polycomb repressive complex 
PRK1 protein-kinase-C-related kinase 1 
PRMT protein arginine N-methyltransferase
PUMA p53 upregulated modulator of apoptosis
PYCARD PYD (Pyrin) and CARD (caspase recruitment 
domain) domain containing
q-PCR quantitative polymerase chain reaction
q-(RT)-
PCR 
quantitative (retrotranscription) polymerase 
chain reaction
Rb retinoblastoma
RbBP retinoblastoma binding protein 
Rest RE1-silencing transcription factor
RING ring (Really Interesting New Gene) finger
RNF ring finger protein
RSK ribosomal protein S6 kinase
RUNX runt-related transcription factor
SALL4 sal-like 4
SAM S-adenosyl methionine 
SCML sex comb on midleg-like
SER-
PINE1
member 1-plasminogen activator inhibitor 
type 1, clade E 
SirT silent mating type information regulation 2 
homolog 1
SLC5A8 solute carrier family 5 (iodide transporter), 
member 8
SOX2 SRY (sex determining region Y)-box 2
Suv3-9h suppressor of variegation 3-9 homolog
Suv4-20h suppressor of variegation 4-20 homolog
Suz12 suppressor of zeste 12 homolog
SWI/SNF  mating type SWItch/sucrose non fermentable
Syp synaptophysin
TBX3 T-box 3 
Tdgf teratocarcinoma-derived growth factor
Tcfcp2l1 transcription factor CP2-like 1
TF transcription factor 
TGFβ tumour growth factor beta
TIMP1 tissue inhibitor of metalloproteinases inhibi-
tor 1
TNFα tumor necrosis factor α
TRD transcriptional repression domain 
TSG tumour suppressor genes 
UbC ubiquitin C
UNG uracil-DNA glycosylase
UTR untrascribed region
UTX ubiquitously transcribed tetratricopeptide re-
peat, X chromosome
VHL von Hippel-Lindau 
WB western blot 
WDR5 WD repeat domain 5
WNT6 wingless-type MMTV integration site family, 
member 6
WRN gene associated with Werner`s syndrome 
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SUMMARY
Understanding the molecular mechanisms involved in the control of cell differentiation during embryonic 
development is currently one of the main objectives of many laboratories worldwide.  This knowledge will provide 
a basis for the development of new strategies in the field of regenerative medicine, one of the most promising 
weapons to fight many human diseases.  Cell differentiation during embryonic development is controlled primarily 
by epigenetic factors, that is, mechanisms involved in the regulation of chromatin structure and gene expression. 
In this work, we studied the role of DNA methylation and certain histone modifications in embryonic stem cell 
differentiation.
Developmental genes are frequently silenced in human embryonic stem cells (hESC) by a bivalent histone-based 
chromatin mark; nonetheless, some gene promoters are hypermethylated in these cells.  We thus used methylation 
arrays to study the role of DNA methylation in hESC differentiation.  Our results confirmed that certain genes are 
repressed in hESC by promoter hypermethylation, and we identified some of those that are regulated by demethylation 
during ES differentiation.  Many of these genes are developmental genes that are also hypermethylated in adult 
somatic stem cells and, in some cases, are hypermethylated in cancer, a common feature of tumour suppressor genes 
(TSG).  We thus suggest that, for genes repressed by promoter hypermethylation in stem cells in vivo, the aberrant 
process in cancer could be understood as a defect in establishing an unmethylated promoter during differentiation, 
rather than as an anomalous process of de novo hypermethylation.
In studying chromatin modification in ESC differentiation, we found that the histone deacetylase SirT1 directly 
regulates developmental gene promoters in hESC.  SirT1 proved to be precisely downregulated during hESC 
differentiation by a molecular pathway involving the RNA-binding protein HuR and the arginine methyltransferase 
CARM1.  We demonstrated that SirT1 mRNA stability decreases soon after differentiation induction, as a 
consequence of a reduction in SirT1 mRNA-HuR binding.  This reduction was associated with loss of CARM1-
dependent HuR methylation at Arg217.  SirT1 downregulation led to reactivation of key developmental genes such 
as the neuro-retinal morphogenesis effectors DLL4, TBX3 and PAX6, which are epigenetically repressed by this 
histone deacetylase in pluripotent hESC.  We thus describe two new mechanisms for developmental gene inactivation 
in embryonic stem cells and for the controlled activation of their expression during lineage specification.
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INTRODUCTION
To introduce the work carried out in this PhD thesis, 
I will first describe the early steps of mammalian embryo 
development, the natural environment for cells used as the main 
experimental model: embryonic stem cells.  After an overview 
of epigenetic science, I will then summarise the state of art of 
epigenetic mechanisms involved in stem cell pluripotency and 
differentiation.
Developmental biology
Multicellular organisms are composed of different 
specialised cells.  In nearly all cases, the formation of a new 
individual begins with a single cell, the fertilized egg or 
zygote, which duplicates repeatedly to produce all the cells of 
the body.  Development is considered the process that leads 
to the formation of a complete organism from a single cell, 
through progressive changes.  As the most profound changes 
are observed between fertilization and birth, the study of animal 
development has traditionally been identified with embryology. 
The process of development nonetheless does not cease at birth 
for many organisms such as those that undergo metamorphosis, 
nor for mammals (including humans), whose bodies continue 
changing through adulthood and into old age.
Development fulfils two major objectives: it generates 
cellular diversity and order within each generation, and it 
ensures the continuity of life from one generation to the next. 
The formation of organized bodies has always been one of the 
great sources of wonder for humankind.  How can matter alone 
construct the organized tissues of the embryo?  How are all the 
instructions for the formation of the entire organism contained 
in that single cell?  In the past decades, developmental biology 
has uncovered some secrets of this miracle.
First steps in mammalian development: pluripotency 
and lineage commitment.  After mammalian egg fertilization, 
the derived zygote, the first cell of a new organism, begins to 
divide.  These first symmetric cleavages that give rise to 2, 
4, and 8 cells produce identical cells, blastomeres; these are 
classically considered the only totipotent cells, in the sense that 
each has the potential to give rise to any of the differentiated 
cells of the embryonic and extraembryonic tissues (Fig. I-1, 
left).  Cells in the compact 8-cell embryo divide again to form 
a 16-cell morula, constituted by a small group of internal cells 
surrounded by a larger group of external cells (Fig. I-1, centre) 
(Barlow et al., 1972).  The offspring of external cells give rise 
to the trophoblast (trophectoderm) cells, producing the tissue 
of the chorion, the embryonic portion of the placenta.  The 
embryo proper is derived from the descendants of the inner 
cells of the 16-cell stage, supplemented by cells dividing 
from the trophoblast during the transition to the 32-cell stage 
(Fleming, 1987; Pedersen et al., 1986).  These cells generate 
the inner cell mass (ICM), which will give rise to the embryo 
and its associated yolk sac, allantois, and amnion.  By the 64-
cell stage, the ICM (approximately 13 cells) and the trophoblast 
cells have become separate layers, neither contributing cells to 
the other group (Dyce et al., 1987; Fleming, 1987).  Thus, the 
distinction between trophoblast and ICM blastomeres represents 
the first differentiation event in mammalian development.  In 
the morula, during a process called cavitation, the trophoblast 
cells secrete fluid to create a cavity known as blastocoel.  The 
ICM is then positioned on one side of the ring of trophoblast 
cells; the resulting structure is termed blastocyst.  Isolation of 
the ICM at this stage and its propagation in vitro in appropriate 
conditions leads to the derivation of embryonic stem cell lines. 
These cells are defined as pluripotent since, although they can 
form any embryonic cell lineage, they have already passed the 
first differentiation step.
While the embryo moves through the oviduct on its way to 
the uterus, the blastocyst expands within the zona pellucida 
(the extracellular matrix of the egg), in which it finally creates 
a small opening and squeezes out through it (Fig. I-1, right) 
(Perona and Wassarman, 1986).  Trophoblast cells can now 
Figure I-1.  First embryo stages.  Morula 
(left) consisting of zona pellucida (1), 
blastomeres (2) and polar body (3).  
Blastocyst (centre) showing an inner cell 
mass (1), zona pellucida (2), trophoblast 
(3) and blastocoel (4).  Hatching 
blastocyst (right).  From the website www.
embryology.ch
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bind to the uterine epithelium (endometrium) by expressing 
specific receptors and adhesion molecules; these cells produce 
proteases that lyse the endometrial extracellular matrix, so 
that the blastocyst can bury itself in the uterine wall (Brenner 
et al., 1989).  The chorion secretes hormones that allow the 
uterus to retain the foetus, and further induces uterine cells to 
form the maternal portion of the placenta, the decidua, which 
becomes rich in blood vessels that will provide oxygen and 
nutrients to the embryo.  The first segregation of cells within the 
ICM results in formation of hypoblast (also termed primitive 
endoderm) and epiblast (Fig. I-2).  Hypoblast cells delaminate 
from the ICM to line the blastocoel, where they give rise to 
the extraembryonic endoderm, which forms the yolk sac.  The 
remaining ICM tissue above the hypoblast is now referred to as 
the epiblast.  Epiblast cells also cover all the internal surface of 
the cavity they are facing, the amniotic cavity.  Once the amnion 
lining is completed, it fills with a secretion called amniotic 
fluid.  Schematically, the amniotic cavity and primary umbilical 
vesicle together form two hemispheres with two layers (epi- 
and hypoblast) lying close to one another, representing the 
first embryonic structure.  The epiblast alone is responsible for 
embryo formation; however, the hypoblast develops into a part 
of the extraembryonic appendages.
The bilaminar germ disk evolves to a trilaminar embryo 
(Fig. I-3).  By day 17 in the human embryo, a thickening of 
the embryonic disc (primitive streak) is observed, due to cell 
proliferation and migration towards the median line along the 
rostro-caudal axis; it soon occupies roughly half the embryo. 
After the 19th day, the primitive streak grows through addition 
of cells at its caudal end.  At the anterior end, a groove begins 
to form (primitive groove).  Epiblast cells migrating through 
the primitive streak, between the two germinal layers, determine 
the formation of three new embryonic layers: the dorsal-lying 
cell layer facing the amniotic cavity, now called ectoderm; 
ventrally-lying cells that form the endoderm, which replaces the 
hypoblast, and cells residing between the last two, forming the 
mesoderm (Lawson et al., 1991).  At this stage, the embryonic 
disk is oval-shaped and the ectoderm is bathed in amniotic fluid. 
Viewed dorsally, the wide end represents the rostral region and 
the narrower end forms the caudal region.  Right and left halves 
are also defined.
In a few days, many different specialized cells form; the 
embryo itself and extaembryonic tissues are thus generated 
from a few identical cells.  From this point onward, several 
decisions must be taken, not only regarding the fate of each 
cell, to be able to establish a defined differentiation programme, 
but also regarding more complex patterning mechanisms that 
define the structure of the entire organism.  These mechanisms 
include definition of the three axes cited above (anteroposterior, 
dorsoventral, and left-right), organ formation, and integration 
of complex systems like the cardiovascular, musculoskeletal, 
and nervous systems.  These processes involve multilevel 
organization of the molecular information, that continues to 
unwind as long as the embryo develops and the complexity 
of the system increases.  This is achieved through several 
mechanisms, including cell-cell communication, signalling 
routes, and gene expression programs that are finely regulated 
in space and time.
As an example of a complex genetic mechanism involved 
in embryo patterning, we will only cite the anterior-posterior 
polarity specification by expression of Hox genes, homologues 
to the homeotic gene complex (Hom-C) of the fruit fly.  Mouse 
and human genomes contain four copies of the Hox complex 
per haploid set, located on four different chromosomes (Hoxa 
through Hoxd in the mouse, HOXA through HOXD in humans) 
(Boncinelli et al., 1988; Scott, 1992).  They are arranged in 
the same general order as their expression pattern along the 
anterior-posterior axis, with the most 3´ gene required for 
producing the most anterior structures, and the most 5´ gene 
specifying the development of the posterior abdomen.  Hox 
gene expression can be seen along the dorsal axis (in the neural 
tube, neural crest, paraxial mesoderm, and surface ectoderm) 
from the anterior boundary of the hindbrain through the 
caudal region.  Different body regions along the rostro-caudal 
axis are characterised by different constellations of Hox gene 
Figure I-2.  Bilaminar 
embryo after implantation.  
Syncytiotrophoblast (1), 
cytotrophoblast (2), epiblast (3), 
hypoblast (4), blastocyst cavity 
(5), maternal blood capillary (6), 
amniotic cavity (7).  From the 
website www.embryology.ch
Figure I-3. Trilaminar embryo 
after implantation. Primitive 
groove (1), ectoderm (2), extra-
embryonic mesoderm (3), 
definitive endoderm (4), invading 
epiblastic cells forming the 
intraembryonic mesoderm (5), 
hypoblast (6).  From the website 
www.embryology.ch
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expression, and these expression patterns create a code whereby 
certain Hox gene combinations specify a particular region (Hunt 
and Krumlauf, 1992).  This example is particularly instructive 
for understanding a common leitmotif in development: only 
the precise modulation of gene expression patterns both spatial 
(in different regions of the developing embryo) and temporal 
(during ontologic time) enables the correct, ordered formation 
of an organism.
Embryonic stem cells, in vitro differentiation and 
applications.  In 1998, two laboratories (Gearhart, 1998; 
Thomson et al., 1998) announced that they had derived human 
embryonic stem cells (hESC).  These cells were derived either 
from ICM of embryos that were not implanted into in vitro 
fertilization patients, or from germ cells from spontaneously 
aborted foetuses.  In both instances, the hESC were pluripotent, 
since they were able to differentiate in culture to form more 
restricted stem cells or differentiated cells; when injected into 
immunodeficient mice, they produced a teratoma containing 
many kinds of tissues.  Since then, hESC have become a 
powerful model with which to understand the biology of the first 
developmental steps.  Many efforts have been made to define 
the best conditions in which to maintain these cells in culture 
(Adewumi et al., 2007) and to induce specific differentiation.  In 
many cases, the goal is the optimization of all the protocols for 
their application in regenerative medicine.
ES cells are currently generated by immunosurgery –meaning 
the isolation and culture of ICM cells after enzymatic removal 
of the zona pellucida and complement-mediated disruption of 
trophoectoderm– or whole or partial embryo culture (Moon et 
al., 2006).  Establishment of ES cell lines depends on many 
factors, including culture conditions, feeder cell growth surface, 
culture medium composition (Ludwig et al., 2006; Nichols and 
Ying, 2006) and even genetic background (Yang et al., 2009).
There is hope that hESC can be used to produce new 
functional cells for pathological situations in which cell 
function is compromised.  First attempts at stem cell-based 
therapy were tested in mouse, where ES-derived glial stem cells 
were transplanted into mice with a genetic deficiency in glial 
function, and cured the defect (Brustle et al., 1999); ES-derived 
neural stem cells were able to divide and differentiate into 
functional neurons when injected into a damaged rodent nervous 
system (McDonald et al., 1999).  Since these demonstrations, 
many applications in regenerative medicine have been tested 
worldwide (Deb and Sarda, 2008).  Research in this field 
has focused on overcoming the main problems for clinical 
application, which include differentiation towards the desired 
lineages (Dhara and Stice, 2008; Shiba et al., 2009; Zhang et 
al., 2001), efficient differentiation to eliminate the potential 
tumorigenicity of these cells (Blum and Benvenisty, 2008), 
and overcoming host rejection (Bongso et al., 2008; Drukker 
and Benvenisty, 2004; Grinnemo et al., 2008).  The possibility 
of a model of in vitro-differentiated tissues of many kinds is 
also appealing for the world of drug discovery and validation 
(Jensen et al., 2009; Krtolica et al., 2009; Sartipy et al., 2007).
In the last few years, an important advance has been made 
through the mise-au-point of a technique to revert a fully 
differentiated cell back to its undifferentiated, pluripotent 
state.  These induced pluripotent stem (iPS) cells represent a 
novel, attractive model system for the study of epigenetic 
mechanisms operating during preimplantation development. 
By overexpressing key embryonic transcription factors (OCT4/
POU5F1 and SOX2) along with the transcriptional activators 
KLF4 and cMYC, the somatic epigenome is erased and its 
embryonic counterpart established (Hochedlinger and Plath, 
2009; Takahashi et al., 2007a; Takahashi et al., 2007b).  iPS 
cells have been derived by introducing different combinations 
of the above-cited and other factors, using viral or plasmid-
based gene transfer methods (Stadtfeld et al., 2008b), sometimes 
in conjunction with small molecules (Silva et al., 2008), or by 
direct introduction of recombinant proteins into cells (Zhou 
et al., 2009).  Many different cell types –differentiated and 
partially undifferentiated (Kim et al., 2009)– have also been 
used as a starting point (Aoi et al., 2008; Stadtfeld et al., 2008a), 
both from healthy donors and from patients (Ebert et al., 2009; 
Maehr et al., 2009).  The relevance of iPS cells as a model 
system for embryonic development has been corroborated 
by the successful derivation of cloned mice via tetraploid 
complementation (Boland et al., 2009; Kang et al., 2009b). The 
potential application of these cells in regenerative medicine is in 
principle even broader than that of hESC, because any cell in the 
adult body can become a source of all other cells; if necessary, 
genetic defects could be corrected before reimplantation.
The main concern for the application of the data generated 
in ES and iPS cells, both in basic science and translational 
application, are possible alterations derived from the prolonged 
in vitro culture necessary for cell expansion to numbers 
sufficient for biochemical analysis.  These extended culture 
regimens frequently lead to aneuploidy (Cortes et al., 2008), 
and are likely to induce aberrant mechanisms that increase 
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survival in culture, but are unrelated to the uterine environment. 
Comparison of biochemical markers between ICM cells and 
established mESC line demonstrated some alterations in ESC 
(O’Neill et al., 2006).  This discrepancy might not only be the 
result of culture adaptation of clonal ES cells, but could also 
reflect heterogeneity in the ICM cell pool and might account for 
the low efficiencies encountered during targeted differentiation 
of ES cells.
Epigenetics
A first definition of epigenetics was proposed by Conrad 
Waddington in 1942 (Waddington, 1942) as the study of 
how genotypes give rise to phenotypes through programmed 
changes during development.  New concepts were subsequently 
added to this original definition:  an epigenetic event would 
be something that affects gene expression without changing 
the nucleotide sequence, in a way that can be inherited 
through cell division and possibly through gamete formation 
(Holliday, 1987).  Today, epigenetics refers to heritable 
changes in gene activity and expression, as well as to stable, 
long-term alterations in the transcriptional potential of a cell 
that are not necessarily heritable (http://nihroadmap.nih.gov/
epigenomics/index.asp).  Epigenetics in this sense would 
include all mechanisms for unfolding the genetic programme in 
processes such as development, differentiation, stress response 
and pathological states.  Indeed, epigenetic modifications are 
stable but at the same time plastic, as they can be modulated by 
cellular or environmental factors (Reik, 2007).  This nuance of 
plasticity is the most striking feature of epigenetics, as it enables 
elaboration of the genetic information and its integration with 
the environment.  In other words, each gene is expressed in a 
defined space and time following the dictates of the epigenetic 
machinery that, by altering the physical structure of the genetic 
information, makes it readable or unreadable.  Chromatin 
structure, like the genetic information itself, can be inherited by 
cellular progeny, creating a new and stable level of information. 
Epigenetic mechanisms involve covalent chemical modification 
of DNA (methylation) or chromatin (histone modification) 
(Jenuwein and Allis, 2001) as well as other processes, mostly 
related to the former two, that regulate gene expression and 
chromatin structure (non-coding RNA, among others).
DNA, like a book, is organised into modules.  All the 
epigenetic machinery can be seen as a complex system 
of enzymes or structural proteins.  In response to a cell’s 
internal and external status, these proteins are able to write 
the instructions in their own language for the accessibility of 
the basic book of each cell, i.e., the genome.  Each page is 
represented by the nucleosome core particle.  When associated 
with other components, higher-order nucleosomal structures 
are formed, like book chapters or sections.  The epigenetic 
machinery is in charge of determining the accessibility of the 
pages to the readers of DNA, for example RNA polymerase. 
This ensures that the genetic information is stored, organized 
and read out in a correct spatio-temporal sequence during cell 
differentiation and organism development.  The epigenetic code 
used consists of a large number of small covalent modifications 
on DNA or histones (Jenuwein and Allis, 2001).  Among 
epigenetic proteins, we recognise enzymes that perform these 
covalent modifications, the “writers”, as well as enzymes able 
to eliminate them, the “erasers”.  Finally, other proteins, the 
“readers” of the epigenetic code, are able to recognise these 
modifications and join them to the effector function, opening 
or closing the chapter of the book.  Variations introduced into 
nucleosome array structures by this machinery determine 
differences in chromatin compaction that correlate closely with 
“open” versus “closed” states, which in general coincide with 
“active” versus “inactive” states of gene expression.
Chromatin structure
The basic repeating unit of chromatin is the nucleosome, 
first defined by Pierre Chambon in 1975 (Oudet et al., 1975). 
In 1997, the 2.8 Å crystal structure 
Figure I-4. Nucleosome cristal 
structure. DNA strands are in 
different colours.  DNA makes 
1.7 turns around the histone 
octamer to form a disk-like 
structure.  Atomic structure 
of the nucleosome core is 
composed by the H3 (green)-H4 
(yellow) tetramer and the H2A 
(red)-H2B (pink) dimer. From 
Khorasanizadeh, 2004.
21INTRODUCTION
of the nucleosome was resolved, revealing a ~147 bp double 
strand of DNA tightly wrapped in 1.7 left-handed superhelical 
turns around a core histone octamer (formed by two H2A-H2B 
dimers and one H3-H4 tetramer; Fig I-4).
Nucleosomes are joined by the linker DNA, together with 
a linker histone protein (H1) (Luger et al., 1997).  Specific 
interactions between nucleosomes determine the folding of a 
nucleosomal array (the primary structure of chromatin) into 
a 30 nm fibre (a secondary structure) and into large-scale 
configurations (tertiary structures) that constitute the entire 
chromosome (Khorasanizadeh, 2004).  Although the structure 
of the nucleosome core was further resolved at 1.9 Å resolution 
(Richmond and Davey, 2003), the precise structure of the 
compacted 30 nm fibre remains unknown, as its compactness 
impedes visualization of the spatial location of individual 
nucleosomes and the path of the DNA.
In general, the close interactions between DNA and histone 
proteins in a nucleosome lead to a high degree of structural 
condensation that, by default, impedes gene transcription. 
Histones nonetheless have positively charged, unstructured tails 
that protrude from the nucleosome core and can be modified 
in many amino acid residues.  There are at least 30 possible 
histone modification sites for each nucleosome, eight types 
of modification (methylation, acetylation, phosphorylation, 
ubiquitylation, sumoylation, ADP-ribosylation, proline 
isomerization and biotinylation), some of which can occur in 
different configurations (for example, lysine can be mono-, 
di- or trimethylated); a considerable number of combinations 
are thus possible.  The information contained in the different 
combinations of histone marks determines the functional state 
of the associated DNA; this language is often referred to as the 
histone code (Jenuwein and Allis, 2001).
Chromatin modifications
Chromatin in eukaryotic cell nuclei is not uniformly 
organized, but rather contains distinguishable chromatin 
states: euchromatin and heterochromatin.  This simplification 
Figure I-5. A visual scheme of 
chromatin modification enzymes 
and their target residues.  
See text for details (from 
Kouzarides, 2007).
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distinguishes two classes of chromatin, that in a low condensation 
state that is “accessible”, and that with a high degree of 
compaction that is “inaccessible” for transcription.  One of 
the critical functions of histone modifications is to establish 
and preserve these two states (Kouzarides, 2007).  Although 
this Introduction focuses on this aspect, histone modifications 
also play important roles in facilitating other DNA-associated 
functions, such as transcription, DNA repair, DNA replication, 
and chromosome condensation.  Many of these modifications, 
and the enzymes responsible for them, are shown in Fig. I-5.
They are generally classified as repressing and activating, 
as correlated with gene repression or induction.  Some 
modifications can nonetheless activate or repress in a context-
dependent manner.  For example, methylation of H3K36 or 
H3K9 has a negative effect when it occurs within the promoter 
region, and a positive effect if in the coding region (Vakoc et al., 
2005).  It is thus worth keeping in mind that the final outcome of 
chromatin modification depends not on the single mark, but on 
the whole complex of modifications and their context.
Acetylation.  Histone acetylation consists of the addition 
of an acetyl group to an ε-amino group of a lysine side chain, 
forming an amide bond.  Acetylation of lysine 14 or 9 in histone 
H3 (H3K14, H3K9), and/or of H4K16 are generally associated 
with active gene transcription.  Evidence supporting a positive 
link between acetylation of histone tails and transcriptional 
activity has long been established (Allfrey et al., 1964).  Gene 
activation by histone acetylation has a biophysical explanation. 
The lysine side chain is positively charged and can bind tightly to 
the negatively charged DNA to form a closed chromatin structure 
that impedes access of transcription factors.  Acetylation of 
lysine residues removes their positive charge and attenuates the 
charge interaction between histone tails and DNA.  Indeed, it 
was demonstrated in vitro that acetylation of H4 at H4K16 has 
a negative effect on the formation of the 30 nm fibre and the 
generation of higher-order structures (Shogren-Knaak et al., 
2006).  In addition to this simple mechanism, acetylated lysines 
also act as docking sites for other proteins that play the role 
of “readers”, mainly other chromatin-modifying enzymes and 
basal transcription machinery.  One protein domain, termed the 
bromodomain, binds specifically to acetylated lysines (Mujtaba 
et al., 2007) facilitating transcriptional activation; this domain is 
often found in enzymes that help activate transcription, including 
SWI/SNF, an ATP-dependent chromatin-remodelling complex. 
Histones are acetylated in lysines by “writer” enzymes termed 
histone acetyl transferases (HAT), which transfer an acetyl 
group from the high-energy donor acetyl-coenzymeA to a lysine 
ε-amino group.
Acetyltransferases are divided into three main families, 
GNAT, MYST, and CBP/p300 (Sterner and Berger, 2000). 
Many HAT are components of large multi-subunit complexes 
associated with transcription initiation, recruited to promoters 
by interaction with DNA-bound activator proteins (Utley et 
al., 1998).  In general, these enzymes modify more than one 
lysine and only a few HAT show some substrate selectivity. 
Histone acetylation is reversed by the “eraser” enzymatic action 
of the histone deacetylases (HDAC).  HDAC are grouped into 
classes I, II and III based on sequence homology to their yeast 
orthologues Rpd3, HdaI and Sir2, respectively (De Ruijter et 
al., 2003; Gregoretti et al., 2004), and class IV, which has only 
one member (HDAC11).  Classes I, II, and IV are referred to as 
“classical” HDAC and comprise 11 family members, whereas 
class III members are called sirtuins (Michan and Sinclair, 
2007).  Classical HDAC and sirtuins differ in their catalytic 
mechanisms.  Classical HDAC are Zn2+-dependent enzymes, 
harbouring a catalytic pocket with a Zn2+ ion at its base that can 
be inhibited by Zn2+-chelating compounds such as hydroxamic 
acids.  In contrast, sirtuins have a mechanism of action that 
requires NAD+ as an essential cofactor (Michan and Sinclair, 
2007).  The biology of sirtuins, and in particular of SirT1, will 
be discussed later in this Introduction.  Similar to transcriptional 
coactivators with HAT activity, many transcriptional corepressor 
complexes such as mSin3a, NCoR/SMRT and NURD/Mi-2 
contain subunits with HDAC activity (Denslow and Wade, 
2007).
Phosphorylation.  Phosphorylation consists of adding a 
phosphate to an hydroxyl (OH-) group of serine or threonine 
residues, thereby adding a negative charge that leads to general 
decondensation of the chromatin fibre (Roth and Allis, 1992). 
The biophysical role of histone phosphorylation has not been 
demonstrated rigorously in vitro as for acetylated H4K16 but 
its role in mitosis, apoptosis and gametogenesis are suggestive 
of this mechanism (Ahn et al., 2005; Krishnamoorthy et al., 
2006).  Phosphorylated residues on histones are also bound 
by 14-3-3 protein, linking this modification to transcriptional 
activation (Winter et al., 2008a; Winter et al., 2008b).  As many 
cell signalling pathways related to protein phosphorylation, 
this modification is an excellent link between activation of 
kinase signalling pathways in response to stimuli and gene 
expression.  For example, growth factor stimulation induces 
rapid phosphorylation of histone H3 at Ser 10 (H3S10) at c-Jun 
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and c-Fos promoters, mediated by mitogen-and stress-activated 
protein kinase (MSK)1, MSK2 and RSK2 kinases (Nowak and 
Corces, 2004; Sassone-Corsi et al., 1999; Soloaga et al., 2003). 
H3S10 phosphorylation is detected after activation of NFκB-
regulated genes; in response to inflammatory cytokines, IκB 
kinase-α (IKK-α) phosphorylates H3S10 at NFκB-responsive 
promoters (Anest et al., 2003; Yamamoto et al., 2003).  Other 
histone residues can also be phosphorylated: threonine 11 of 
histone H3 (H3T11) is phosphorylated by protein-kinase-C-
related kinase 1 (PRK1), leading to transcriptional regulation 
in response to stimulation with androgen receptor agonists 
(Metzger et al., 2008).
Methylation.  Methylation occurs on the functional group 
of lysines or arginines.  This modification is functionally 
more complex than the others for several reasons:  i) within 
any histone, multiple lysines or arginines can be modified, ii) 
individual lysine residues can be mono-, di-, or trimethylated, iii) 
arginine residues can be mono- or dimethylated, and these can 
be dimethylated in a symmetric or asymmetric fashion, iv) all 
the core histones can be methylated depending on physiological 
setting (Shi and Whetstine, 2007) and finally, v) methylation 
of distinct residues has opposite functional consequences on 
gene activation.  In the case of methylation, global charge of the 
residue is unaffected by the modification; the final effect is thus 
mainly determined by different “reader” proteins that link these 
marks with other effectors.  Histone methylation is recognized by 
chromo-like domains of the Royal family (chromo, tudor, MBT) 
and the unrelated PHD domains.  Proteins with a chromodomain, 
such as HP1, can bind specifically to methylated lysine.  HP1 is 
a transcription-silencing protein that interacts with HDAC; its 
binding to methylated H3K9 results in histone deacetylation, 
eventually leading to gene silencing.  H3K4 trimethylation is 
recognized by the chromodomain protein CHD1, which can 
further recruit HAT to activate target gene transcription.
These various methylation reactions are mediated by 
“writers” termed histone methyltransferases (HMT), enzymes 
that use an S-adenosyl methionine (SAM) high-energy methyl-
donor to transfer the methyl group onto the histone residue. 
Each of these enzymes has its own activation pathways and its 
own specificity.
Arginine methylation is catalyzed by the protein arginine 
N-methyltransferases (PRMT) family of enzymes (Bedford 
and Richard, 2005).  Arginine can be monomethylated, 
symmetrically dimethylated and asymmetrically dimethylated, 
with each combination showing potentially different functional 
consequences (Bedford, 2007).  Ten mammalian PRMT 
(PRMT1-10) have been identified to date.  CARM1, sometimes 
referred to as PRMT4, can methylate histone H3 at arginine 2, 
17, and 26 (H3R2, H3R17, H3R26) and enhances transcriptional 
activation driven by nuclear receptors, acting as a coactivator 
(Chen et al., 1999; Schurter et al., 2001).  PRMT1 is also required 
for transcriptional activation by nuclear receptors, methylating 
arginine 3 of histone H4 (H4R3) (Chen et al., 1999; Strahl et 
al., 2001; Wang et al., 2001).  Several coactivators capable of 
histone-modifying activities can cooperate synergistically; e.g., 
CARM1 activity can cooperate with CBP, PCAF, and p300, 
which are involved in histone acetylation (Daujat et al., 2002). 
This protein family also targets many non-histone proteins 
(Wolf, 2009).
Lysine methylation is operated by “writers” called 
lysine methyltransferases (KMT), typically specific in their 
histone targets; their output can be activation or repression of 
transcription (Kouzarides, 2007; Shilatifard, 2006).  Almost 
all histone KMT characterized to date contain a SET domain 
(named after Drosophila melanogaster Su (var)3-9, Enhancer 
of zeste (E (z)), and trithorax (trx)).  SET domain-containing 
enzymes can catalyze methylation of specific lysines on histones 
H3 and H4.  DOT1L, the mammalian ortholog of the yeast 
histone methyltransferase Dot1, differs from all other known 
histone KMT, as it both lacks a SET domain and cannot modify 
free histones, instead requiring a nucleosomal substrate (Feng 
et al., 2002; Min et al., 2003; Ng et al., 2002; Van Leeuwen 
et al., 2002).  DOT1L catalyzes mono-, di-and trimethylation 
of histone H3K79, a residue located in the nucleosome core. 
Although different histone KMT can share substrate specificity, 
it is likely that each enzyme can regulate different genes or cell 
processes.
Three methylation sites on histones are implicated in 
activation of transcription, H3K4, H3K36 and H3K79 (Berger, 
2007; Kouzarides, 2007; Martin and Zhang, 2005; Shilatifard, 
2006).  H3K4, both di- and trimethylated, is enriched at actively 
transcribed genes (Bernstein et al., 2005; Santos-Rosa et al., 
2002).  Whereas dimethyl-H3K4 modification appears to be 
distributed throughout the body of active genes,, trimethyl-
H3K4 modification is localized specifically at the 5′ end of 
these genes (Barski et al., 2007; Guenther et al., 2007; Pokholok 
et al., 2005).  SET domain-containing protein MLL is the 
mammalian H3K4-specific KMT (Milne et al., 2002; Nakamura 
et al., 2002) and is only detected in a multi-subunit complex 
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with the conserved structural components RbBP5, ASH2L, 
and WDR5.  MLL1 localizes with RNA polymerase II to the 
5´ end of 90% of actively transcribed genes, where trimethyl-
H3K4 is also found (Guenther et al., 2005).  H3K36 methylation 
seems to facilitate transcription elongation.  Dimethyl-H3K36 
and trimethyl-H3K36 are in fact enriched at the 3’ ends of 
transcribed genes (Bannister et al., 2005; Barski et al., 2007; Li 
et al., 2002b; Rao et al., 2005).  H3K79 methylation correlates 
with transcriptional activation (Kouskouti and Talianidis, 2005; 
Morillon et al., 2005), and DOT1L in mammals preferentially 
occupies the proximal transcribed region of active genes and 
correlates with the presence of dimethyl-H3K79 and trimethyl-
H3K79 (Steger et al., 2008).
Three methylation sites on histones are linked to 
transcriptional repression: H3K9, H3K27 and H4K20 (Berger, 
2007; Kouzarides, 2007; Martin and Zhang, 2005; Shilatifard, 
2006).  Methylation at H3K9 is implicated in the silencing of 
euchromatic genes and in the formation of silent heterochromatin 
domains.  Repression involves recruitment of H3K9-specific 
KMT (SUV3-9h1 and SUV3-9h2) and HP1 to the promoter 
of repressed genes.  H3K27 methylation is implicated in 
several silencing phenomena including HOX gene silencing, 
inactivation of the X chromosome in females, and genomic 
imprinting (Cao and Zhang, 2004).  At the core of this silencing 
system is the Polycomb group (PcG) proteins (Ringrose and 
Paro, 2004), usually found in multiprotein complexes termed 
Polycomb repressive complexes (PRC).  PRC2 contains EZH2, 
EED, SUZ12, and RbBP4, whereas the PRC1 complex consists 
of >10 subunits, including BMI1 and the Polycomb proteins 
(CBX2, CBX4, CBX7, CBX8), HPH1-3, RING1-2, and SCML) 
(Kerppola, 2009; Levine et al., 2004).  Many PcG target genes 
are involved in developmental patterning, morphogenesis, and 
organogenesis (Boyer et al., 2006; Bracken et al., 2006; Lee 
et al., 2006b).  Functionally, EZH2 is the catalytically active 
component of PRC2, acting as a H3K27-specific KMT (Cao and 
Zhang, 2004).  PRC can inhibit transcription by preventing ATP-
dependent nucleosome remodelling by the SWI/SNF complex 
as well as by directly blocking the transcription initiation 
machinery (Dellino et al., 2004; Francis and Kingston, 2001). 
PRC1 has ubiquitin E3 ligase activity that targets H2AK119, 
associated with gene repression (Cao et al., 2005; Wang et al., 
2004).  In vitro, PRC2 also shows KMT activity towards H1K26 
(Kirmizis et al., 2004), tethering HP1 to chromatin (Daujat et al., 
2005) and influencing high-order chromatin structure.  EZH2 
also recruits DNA methyltransferases (DNMT) to selected 
target genes (Viré et al., 2006).  H4K20 is monomethylated by 
PR-Set7/Set8 (Nishioka et al., 2002; Xiao et al., 2005), whereas 
the murine Suv4-20h1 and Suv4-20h2 isoforms have been 
implicated in trimethyl-H4K20 (Schotta et al., 2004).
Several families of lysine demethylases (KDM) have been 
identified, which eliminate methyl marks associated with 
gene repression or activation; KDM usually form part of large 
multiprotein complexes that synergise with HDAC, KMT and 
nuclear receptors to control developmental and transcriptional 
programs.  Two types of demethylase domain have been 
reported thus far, with distinct catalytic reactions: the LSD1 
domain and the Jumonji C (JmjC) domain (Cloos et al., 2008; 
Klose et al., 2007).  LSD1 can function both as a KDM specific 
for mono- and dimethyl-H3K4 (Shi et al., 2004) and mono- 
and dimethyl-H3K9 (Metzger et al., 2005), and for nonhistone 
substrates such as p53 (Huang et al., 2007).  Enzyme specificity 
is determined partly by its association with different complexes, 
thereby allowing it to participate in transcriptional regulation, 
heterochromatin spreading and stress-induced responses (Cloos 
et al., 2008).  At difference from LSD1, the JmjC domain-driven 
demethylase reaction allows demethylation of a trimethylated 
histone tail.  There are 27 JmjC domain proteins within the 
human genome, 15 of which demethylate specific lysines or 
arginines in the H3 tail (Takeuchi et al., 2006).
Ubiquitylation.  This very large modification has been 
found on H2A (K119) and H2B (K120 in human and K123 in 
yeast).  Ubiquitylation of H2AK119 is mediated by the Bmi/
Ring1A protein found in human PRC1 and is associated with 
transcriptional repression (Wang et al., 2004).  In contrast, 
H2BK120 ubiquitylation is mediated by human RNF20/RNF40 
and UbcH6 and activates transcription (Zhu et al., 2005).  The 
mechanism of ubiquitin function is still unclear; it is likely to 
recruit additional factors to chromatin, but might also act to 
maintain chromatin open by a ‘‘wedging’’ process, given its 
large size.
Sumoylation.  Sumoylation is another very large 
modification, and shows some similarity to ubiquitylation. 
This modification takes place on all four core histones, and 
specific sites have been identified on H4, H2A, and H2B 
(Nathan et al., 2006).  Sumoylation antagonises both acetylation 
and ubiquitylation, which occur on the same lysine residue; 
consequently, this modification is repressive for transcription in 
yeast.
ADP ribosylation.  This histone modification can be 
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divided into two major groups: mono-ADP ribosylation and 
poly-ADP ribosylation, mediated by MART (Mono-ADP-
ribosyltransferases) or PARP (poly-ADP-ribose polymerases), 
respectively (Hassa et al., 2006).  Although the function of these 
enzymes has often been linked to transcription, evidence that 
the catalytic activity is involved is lacking.
Proline isomerization.  Prolines exist in either a cis or 
a trans conformation.  These conformational changes can 
severely distort the polypeptide backbone.  An enzyme, FPR4, 
isomerizes different prolines in the H3 tail (Nelson et al., 2006). 
Isomerization of H3P38 regulates H3K36 methylation levels, 
as the appropriate proline isomer is likely to be necessary 
for the recognition and methylation of H3K36 by the SET2 
methyltranferase as well as for its demethylation (Chen et al., 
2006b).  The catalytic cleft of the JMJD2 demethylase is very 
deep and may necessitate a bend in the polypeptide (mediated 
by proline isomerization) to accommodate the methyl group at 
H3K36.
Histone crosstalk
The existence of several modifications within a short stretch 
of the same histone tail makes crosstalk likely.  Different 
mechanisms have been reported, including the following: i) 
histone modifications cannot coexist on the same residue, and are 
mutually exclusive, as in the case of acetyl- and methyl-H3K9 
(Fischle et al., 2003); ii) protein binding could be disrupted 
by an adjacent modification; i.e., phosphorylation of serine 
10 inhibits HP1 binding to methylated H3K9 (Fischle et al., 
2005); iii) catalytic activity of an enzyme can be compromised 
by modification of its substrate recognition site; isomerization 
of H3P38 affects the H3K36 methylation by SET2 (Nelson et 
al., 2006); iv) an enzyme could recognize its substrate more 
effectively in the context of a second modification, as is the case 
of the GCN5 acetyltransferase, whose action on H3 is enhanced 
by phospho-H3S10 (Clements et al., 2003);  v) modifications on 
different histones can affect each other; ubiquitylation of H2B 
is necessary for methylation of trimethyl-H3K4 and dimethyl-
H3K79 (Briggs et al., 2001; Dover et al., 2002; Sun and Allis, 
2002).
Histone variants
The vast majority of histones in eukaryotic cells are 
expressed during the S phase and deposited on nucleosomes 
during DNA replication.  Variants of histone H3 and H2A are 
nonetheless synthesised throughout the cell cycle and deposited 
in a replication-independent manner, conferring specialised 
function on nucleosomes (Henikoff et al., 2004a).  Centromere 
protein A (CENP-A) is an H3 variant with an essential role in the 
assembly of centromeric nucleosomes (Henikoff et al., 2004b). 
It has a very different N-terminal tail from that of histone H3, 
presenting the opportunity for alternative posttranslational 
modifications.  H3.3 is deposited primarily in transcriptionally 
active chromatin and gene regulatory sites (Chow et al., 2005; 
Mito et al., 2005; Mito et al., 2007).  The H2A variant H2AZ is 
implicated in both gene activation and repression.  It is localised in 
small regions flanking transcription start sites and larger regions 
proximal to telomeres or centric heterochromatin (Albert et al., 
2007; Barski et al., 2007; Guillemette et al., 2005).  In ESC, 
it binds to promoters of developmentally important genes, like 
the PcG protein Suz12 (Creyghton et al., 2008).  H2AX has a 
unique C-terminal extension, important for its phosphorylation, 
which has an important role in DNA repair (van Attikum and 
Gasser, 2005).  MacroH2A also has an extra C-terminal motif 
that binds sirtuin metabolite O-acetyl-ADP-ribose (Kustatscher 
et al., 2005) and is substituted in nucleosomes of the inactive 
X chromosome in female mammals (Costanzi and Pehrson, 
1998), while also regulating key developmental genes in human 
male pluripotent cell autosomes (Buschbeck et al., 2009). 
Finally, deposition of the H2ABbd (Barr body-deficient) variant 
correlates with transcriptionally active chomatin (Chadwick and 
Willard, 2001; Chadwick and Willard, 2003).
ATP-dependent chromatin remodelling
Another group of chromatin regulators, referred to as 
ATP-dependent chromatin remodelling complexes, uses 
ATP hydrolysis to alter histone-DNA contacts (Hogan and 
Varga-Weisz, 2007; Saha et al., 2006).  They share a common 
ATPase subunit of the SNF2 superfamily of DNA helicase/
ATPase.  ATP-dependent nucleosome remodelling factors are 
classed into subfamilies, depending on the presence of other 
domains within the ATPase-containing subunit.  The four main 
subfamilies characterized to date are the SWI/SNF, ISWI, CHD, 
and INO80 subfamilies (Hogan and Varga-Weisz, 2007).  These 
complexes mediate different nucleosome remodelling activities, 
ranging from subtle shifting of nucleosome positions to histone 
exchange or complete ejection of nucleosomes (Langst and 
Becker, 2004).  All can basically unwrap DNA segments from 
the nucleosome surface and translocate them through the 
nucleosomes (Kassabov et al., 2002; Strohner et al., 2005). 
These complexes are involved in many fundamental processes 
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such as transcription, DNA repair, DNA replication and 
chromosome structure maintenance, and are finely regulated at 
many levels (Hogan and Varga-Weisz, 2007; Saha et al., 2006). 
They are often targeted by specific histone modifications and 
transcriptional regulators, as is the case of CHD1, which binds 
methylated H3K4 through its tandem chromodomain (Sims 3rd 
et al., 2005)
DNA methylation
DNA methylation is the simplest and perhaps best-studied 
epigenetic modification.  In mammals, it generally consists of 
the addition of a methyl group to the 5-carbon of a cytosine 
followed by a guanine (CpG) in the DNA sequence.  Throughout 
the mammalian genome, the CpG dinucleotide is found at 
a frequency much lower than expected, probably because 
methylation of cytosine leads to its conversion to thymine upon 
deamination; this impedes its recognition by the uracile-DNA 
glycosylase and the base-excision repair pathway.  It nevertheless 
reaches a frequency close to that predicted in sequences that 
span the 5`end of many genes, regions termed CpG islands.  A 
CpG island is thus defined by the occurrence of this dinucleotide 
(see methods).  CpG islands are usually found in the regulatory 
regions of vertebrate housekeeping genes; they are often 
protected from methylation, enabling constitutive expression of 
these genes.  During development, a subset of CpG islands is 
subjected to dynamic methylation modifications linked to tissue 
differentiation and formation.  Once differentiation is complete, 
tissue-specific methylation is established in each cell type and 
is generally maintained throughout the cell’s life.  Promoter 
methylation accounts for only a small part of overall genome 
methylation; roughly 70% of all CpG are methylated and the 
majority are located in repetitive sequences such as endogenous 
retroviruses, L1 elements and Alu elements, most of which 
are derived from transposable elements (Yoder et al., 1997). 
Methylation maintains these sequences silent, making the event 
of amplification and new insertion in the genome extremely rare 
(Callinan and Feinberg, 2006).  It has in fact been proposed that 
DNA methylation might have evolved as a genome-defence 
system to prevent the chromosomal instability, translocations 
and gene disruption caused by reactivation of these transposable 
DNA sequences (Yoder et al., 1997).
At least two additional genetic mechanisms, genomic 
imprinting and X chromosome inactivation, rely on DNA 
methylation in normal cells.  Genomic imprinting occurs in some 
genes whose expression is always restricted to either the maternal 
or the paternal allele; imprinting requires DNA methylation at 
one of the two parental alleles to ensure monoallelic expression. 
A similar gene-dosage reduction is involved in X-inactivation in 
females (Heard and Disteche, 2006). 
The “writers” of these modifications are members of the DNA 
methyltransferase (DNMT) family of enzymes.  DNMT1 is the 
most abundant methyltransferase in somatic cells (Bender et al., 
1999); it localizes to replication foci (Leonhardt et al., 1992) 
and interacts with the proliferating cell nuclear antigen (PCNA) 
(Chuang et al., 1997). When a new DNA strand is synthesised, 
the methyl-CpG site is copied to an antisense CpG on the other 
strand, creating a hemi-methylated site.  DNMT1 specifically 
recognises these hemi-methylated CpG (Pradhan et al., 1999) 
and transfers a methyl group to the unmethylated cytosine ring; 
in this way, methylation can be transmitted to both daughter 
cells.  These features explain the stability of the modification, 
which enables it to be inherited in cell division.  DNMT1 is 
necessary for correct embryonic development, imprinting and 
X-inactivation (Beard et al., 1995; Li et al., 1993; Li et al., 
1992).  DNMT3A and DNMT3B are required for the wave of de 
novo methylation that occurs in the genome following embryo 
implantation and of newly integrated retroviral sequences in 
mESC (Okano et al., 1999).  Moreover, Dnmt3a and Dnmt3b 
knockout (KO) mice show severe developmental defects 
that cause death at the newborn and early embryonic stages, 
respectively.  DNMT3B mutations underlie ICF syndrome, a 
rare disorder characterised by immunodeficiency, centromeric 
instability, and facial abnormalities (Hansen et al., 1999). 
These observations, coupled with in vitro data indicating that 
the DNMT3 enzymes show equal preference for hemi- and 
unmethylated DNA substrates, have led to the term “de novo 
methyltransferases” to describe DNMT3 (Okano et al., 1999). 
The fourth member of the family, DNMT2, has to date no clearly 
ascribed function in DNA methylation (Jeltsch et al., 2006), but 
transfer RNA methyltransferase activity has been reported (Goll 
et al., 2006).
The “eraser” responsible for reversion of this modification 
has not yet been identified univocally in animals (although it is 
described for plants (Choi et al., 2002)); some candidates have 
nonetheless been proposed (Kangaspeska et al., 2008; Ma et 
al., 2009; Metivier et al., 2008).  Although there are numerous 
exceptions, most genome methylation is not maintained during 
meiosis and gamete formation (Abdalla et al., 2009).  The 
entire genome undergoes global demethylation in gametes, and 
methylation is subsequently re-established in early embryonic 
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stages (Bestor, 2000) (see section on Epigenetics of pre-
implantation development).
DNA methylation is linked to transcriptional silencing. 
Early experiments showed that DNA methylation leads to 
formation of a compacted, nuclease-resistant chromatin state 
(Keshet et al., 1986).  It was proposed that the methyl group 
could interfere with protein binding to its cognate DNA 
sequence, such as a transcription factor (Bell and Felsenfeld, 
2000; Hark et al., 2000; Holmgren et al., 2001; Tate and Bird, 
1993).  In most cases, however, methyl-CpG attracts rather 
than repels proteins; the “readers” for this modification are a 
family of proteins that contain the methyl-binding domain 
(MBD).  These proteins link the CpG methyl group to complex 
chromatin remodelling machinery that turns off transcription 
and locks the chromatin in a condensed state (Hendrich and 
Bird, 1998).  Methyl-CpG binding protein 2 (MECP2) was the 
first to be described (Lewis et al., 1992), and later gained in 
interest, as it is mutated in individuals with Rett syndrome (Wan 
et al., 1999).  MECP2 has two domains: the MBD recognizes 
a symmetrically methylated-CpG dinucleotide (Wakefield et 
al., 1999), and a transcriptional repression domain interacts 
with several other regulatory proteins with HDAC activity 
(Jones et al., 1998; Nan et al., 1998).  Other MBD-containing 
proteins have also been described, MBD1, MBD2, MBD3 and 
MBD4 (Ballestar and Esteller, 2002).  Except for MBD4, which 
is involved in repairing DNA mismatches, the MBD family 
members belong to similar HDAC-containing complexes.  All 
MBD proteins interact specifically with methylated DNA except 
MBD3 (targeted to methylated DNA through association with 
MBD2).  An unrelated protein, Kaiso, also binds methylated 
DNA and interacts with a HDAC complex, N-CoR (Yoon et al., 
2003).  Other levels of crosstalk between DNA methylation and 
histone modifications have been described:  DNMT and MBD 
proteins can recruit the H3K9 methylase SUV3-9h1 (Fuks et al., 
2003a; Fuks et al., 2003b); DNMT also interact with KMT such 
as EZH2 in the PRC2 complex, as described above, and with 
HDAC complexes (Fuks et al., 2000; Rountree et al., 2000).
DNA methylation and cancer
Cancer development is thought to proceed via an evolutive 
process, in which a succession of proliferatively advantageous 
genetic changes, including mutations in tumour suppressor genes 
(TSG) and oncogenes as well as chromosome abnormalities, 
leads to the progressive conversion of normal cells into tumour 
cells (Aaltonen et al., 1993; Hahn et al., 1999; Hanahan and 
Weinberg, 2000; Kinzler and Vogelstein, 1997).  Epigenetic 
changes based mainly on the silencing of key regulatory genes 
are also implicated extensively in cancer development.
Global hypomethylation in cancer.  Loss of DNA 
methylation at CpG dinucleotides was the first epigenetic 
abnormality to be identified in cancer cells (Feinberg and 
Vogelstein, 1983); it is caused mainly by hypomethylation 
of repetitive DNA sequences, of coding regions and introns. 
This hypomethylation provokes activation of aberrant mitotic 
recombination, leading to chromosome rearrangements (Eden et 
al., 2003; Karpf and Matsui, 2005), reactivation of intragenomic 
endoparasitic DNA such as L1 and Alu repeats (Bestor, 2005), 
and disruption of genomic imprinting.
Hypermethylation of tumour suppressor genes in 
cancer.  Methylation of CpG islands in gene promoter regions 
is associated with aberrant silencing of transcription and is a 
mechanism for inactivation of TSG in addition to mutation 
(Baylin and Ohm, 2006; Esteller, 2008; Feinberg, 2004; Jones 
and Baylin, 2007).  Nearly 50% of the genes that cause familial 
forms of cancer when mutated in germ-line are known to undergo 
methylation-associated silencing in various sporadic forms of 
cancer (Jones and Baylin, 2002).  A long list of hypermethylated 
genes has now been obtained from various human neoplasias, 
converting this modification in a common hallmark of all types 
of human cancer (Esteller, 2007).  Examples of genes with this 
aberrant methylation include p16INK4a, p14ARF, p15INK4b, 
adenomatous polyposis coli (APC), death-associated protein 
(DAP) kinase, p73, E-cadherin, von Hippel-Lindau (VHL), 
retinoblastoma (Rb), LKB1/STK11 and the oestrogen and 
progesterone receptors (Esteller, 2007).  The importance of 
epigenetic gene silencing in cancer is also highlighted by 
the growing awareness that such changes can predispose to 
mutational events observed after promoter hypermethylation of 
DNA repair genes such as MLH1, BRCA1, MGMT, and the 
gene associated with Werner`s syndrome (WRN) (Herman and 
Baylin, 2003; Jacinto and Esteller, 2007a; Jacinto and Esteller, 
2007b).  It was suggested that the tumour-specific targeting 
of DNA methylation is pre-programmed by EZH2-containing 
PRC2, which normally has a role in marking embryonic genes 
for repression (Ohm et al., 2007; Schlesinger et al., 2007; Viré 
et al., 2006).  The EZH2 system nonetheless does not contribute 
to de novo methylation of all tumour suppressor genes in cancer, 
since several tumour suppressor genes were not enriched with 
trimethyl-H3K27 when tested in normal cells.  It thus appears 
that both gene targeting and adaptive mechanisms are involved 
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in de novo methylation in cancer (Esteller, 2008).
Sirtuins 
Class III histone deacetylases are also termed sirtuins 
because of their homology to Saccharomyces cerevisiae Sir2, 
an enzyme implicated in epigenetic silencing of telomeres, 
ribosomal DNA and mating-type genes (Guarente, 1999). 
Sirtuins require NAD+ as a metabolic cofactor to exert their 
enzymatic activity.  The catalytic domain, highly conserved 
from Archea to man, can carry out two types of reactions: 
deacetylation and ADP ribosylation.  In deacetylation, NAD+ 
is hydrolyzed to generate nicotinamide, 2’-O-acetyl-ADP-
ribose and a deacetylated target, whilst in ADP ribosylation, 
ADP-ribose binds to target protein and nicotinamide is released. 
NAD+ is involved in the transfer of electrons generated through 
intermediary metabolism pathways; the NAD+/NADH ratio is 
therefore an important sensor of the redox state of the cell and of 
metabolism.  Two feedback mechanisms fine-tune the catalytic 
activity of sirtuins; nicotinamide is an enzyme inhibitor, as it 
competes directly with NAD+ for binding to the catalytic domain 
(Landry et al., 2000), and NAD+ levels control the activity of 
these enzymes (Sandmeier et al., 2002).  The NAD+/NADH 
ratio is itself regulated by other enzymes such as nicotinamide 
phosphoribosyl transferase (NAMPT), which uses nicotinamide 
to regenerate NAD+, thereby promoting sirtuin activity (Yang 
et al., 2006).  Sir2-compacted chromatin is characterised 
by hypoacetylation of lysine residues in the N-terminal 
tails of histones H3 and H4 (Braunstein et al., 1993); a very 
distinctive mark, hypoacetylation of H4K16, is a signature of 
Sir2 silencing (Guarente, 1999; Robyr et al., 2002; Suka et al., 
2001).  In addition to epigenetic silencing, Sir2 has a role in 
DNA repair, recombination, and DNA replication (Blander and 
Guarente, 2004; Gartenberg, 2000; Guarente, 1999).  A very 
interesting role ascribed to Sir2 involves increased replicative 
lifespan, meaning the number of cell divisions that a mother 
cell can engage in during its life (Guarente, 1999).  In the worm 
Caenorhabditis elegans, in D. melanogaster and possibly in 
mammals, Sir2 family members are also involved in lifespan 
(Baur et al., 2006a; Tissenbaum and Guarente, 2001).  One 
proposed mechanism to explain the relationship between Sir2 
and lifespan is caloric restriction (CR), which is known to 
increase lifespan in organisms from yeast to mammals (Cohen 
et al., 2004b; Guarente, 1999).  CR produces a more oxidative 
metabolic state, reflected by high levels of NAD+.  This in turn 
activates sirtuins and facilitates survival mechanisms such as 
inhibition of senescence, activation of stress response pathways 
like FOXO-dependent signalling, and inhibition of apoptosis. 
Levels of one mammalian Sir2 homologue, SirT1, are increased 
under CR conditions in rats (Cohen et al., 2004b), although 
other studies postulate that CR-induced lifespan might be 
independent of these enzymes (Kaeberlein et al., 2005; Tsuchiya 
et al., 2006).
Mammals have seven sirtuin family proteins, termed SirT1 
to SirT7.   In vivo, SirT1, -2 and -3 behave preferentially as 
protein deacetylases, whereas SirT4 and -6 appear to have mono-
ADP-ribosyl-transferase activity (SirT5 and -7 activity have 
not yet been fully carachterised) (Saunders and Verdin, 2007; 
Vaquero et al., 2007b).  SirT1, -2, -3 and -6 have high activity 
on histone proteins, in particular on H4K16 and H3K9 residues 
(Vaquero et al., 2004).  These are the only enzymes known thus 
far to deacetylate acetyl-H4K16 in higher eukaryotes (Michan 
and Sinclair, 2007; Vaquero et al., 2007b).  Sirtuins (except 
for SirT6) are also implicated extensively in modification of 
non-histone proteins (Saunders and Verdin, 2007).  SirT1 and 
-6 appear to be mainly nuclear, whereas SirT2 is preferentially 
cytoplasmic; SirT3, -4 and -5 are mitochondrial, and SirT7 is 
nucleolar (Michishita et al., 2005).  In any case, none of these 
localisation is completely fixed, as various sirtuins can be 
translocated from one cell compartment to another in response 
to external or internal stimuli, developmental stage or other 
factors (Saunders and Verdin, 2007; Yamamoto et al., 2007).
SirT1
SirT1 is without doubt the most interesting mammalian 
sirtuin to date, with a staggering variety of functions, substrates, 
interactions and regulatory processes.  It is a 747 amino acid 
protein of ~80 kDa and is expressed in all organs, although 
higher levels tend to be found in energy-dependent tissues 
(Michishita et al., 2005).
SirT1 functions
SirT1 has been implicated in processes as varied as 
metabolism, differentiation, cancer and HIV infection (Fig I-6). 
Beginning with evidence at the organism level, several groups 
have used targeted gene disruption to study SirT1 function at 
the organism level.  SirT1 mutant mice generated by various 
targeting strategies have distinct phenotypes.  SirT1 KO mice 
in R1 mESC (derived from 129Sv × 129Sv-CP embryos), 
carrying a truncation mutation through replacement of exons 5 
and 6 with a hygromycin gene, show prenatal or perinatal death 
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in half of individuals; the remainder are smaller but survive 
to adulthood, suffer defects in gametogenesis and sterility, 
eyelid-opening problems, chronic lung infection and pancreatic 
atrophy (McBurney et al., 2003b).  No global defects were 
detected in gene silencing in these mutant mice (McBurney 
et al., 2003a).  Another KO was generated in TC1 mESC 
(129SvEv/C57BL/6 background) by deleting exon 4.  Up to 
90% of these mutants died perinatally, with developmental 
defects of the retina and heart, and the remaining 10% survived 
to weaning (Cheng et al., 2003).  As cells from this KO showed 
p53 hyperacetylation following DNA damage and increased 
ionizing radiation-induced apoptosis in thymocytes, SirT1 
deficiency was suspected to activate p53, leading to lethality 
in mutant mice.  A more severe mutation was generated from 
TC1 cells by deleting exons 5 and 6 (as no truncated protein is 
detected, it is considered a null mutation), which led to death of 
all homozygotic mouse embryos by embryonic day E17.5-E18.5 
(Wang et al., 2008).  Mutant embryos analysed at E10.5–E12.5 
showed an altered pattern of histone modification, i.e., reduced 
levels of trimethyl-K9 and increased acetylation of H3K9, 
reduced chromosome condensation, and loosely compacted 
chromosomes in metaphase.  This chromatin phenotype 
provoked formation of chromosome bridges, chromosome 
breaks, unequal chromosome segregation, and aneuploidy, 
accompanied by impaired microhomology-mediated DNA 
damage repair and double-strand break (DSB) repair in SirT1 
mutant cells.
Overall, this puzzling variety of results suggests that SirT1 
acts in early development, in a role that is not likely to be 
essential, since mice pass through early embryonic stages and 
in some cases reach adulthood; SirT1 might have a modulatory 
effect on basic developmental processes, apparently dependent 
on genetic background.  Mice with moderate overexpression 
of Sirt1 (a two- to four-fold increase) were also recently 
generated (SuperSirt1); they bear a single complete copy of 
the Sirt1 gene in its natural genomic context.  These mice are 
phenotypically indistinguishable from wt mice, indicating that 
SirT1 overexpression in development is probably compensated 
in the long term throughout this process.  Differences have 
been detected at the metabolic level; these include increased 
energy expenditure accompanied by increased food intake and, 
on a high-fat diet, lower lipid-induced inflammation, improved 
glucose tolerance, and protection from hepatic steatosis (Pfluger 
et al., 2008).
SirT1 and metabolic regulation.  As demonstrated by the 
phenotype of the SuperSirt1 mouse and based on numerous in 
vitro data, SirT1 has a preponderant function in metabolism 
processes.  SirT1 is upregulated in fasting conditions.  It appears to 
be involved in two important metabolic mechanisms: regulation 
of the activity of certain metabolic enzymes and regulation of 
endocrine signalling.  For example, SirT1 deacetylases AceCS1, 
the cytosolic isoform of acetyl-CoA synthetase involved in fatty-
acid formation from acetate (Hallows et al., 2006), enhancing its 
activity.  SirT1 also promotes insulin production in pancreatic 
βcells (Bordone et al., 2006; Moynihan et al., 2005), hepatic 
gluconeogenesis through interaction and deacetylation of the 
transcription regulator PGC1α (Rodgers et al., 2005), and it 
inhibits adipogenesis through its action on the transcriptional 
activator peroxisome proliferator-activated receptor γ (PPARγ) 
(Picard et al., 2004).
SirT1 and cell survival.  SirT1 is a key enzyme in the 
Figure I-6. SirT1 functions (adapted from 
Vaquero, 2009).
WAT, white adipose tissue; GNG, glucagon
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regulation of cell survival, especially in oxidative and genotoxic 
stress conditions (Giannakou and Partridge, 2004; Haigis and 
Guarente, 2006).  Through modulating processes such as 
DNA damage sensing, DNA repair and detoxifying machinery 
induction, inhibition of apoptosis and of senescence, cell 
proliferation, and autophagy stimulation, SirT1 mediates cell 
survival and rescue processes from tissue degeneration.  SirT1 
deacetylates  FOXO family proteins (Brunet et al., 2004; Motta 
et al., 2004; Van Der Horst et al., 2004) and NFκB (Yeung et 
al., 2004), thereby promoting transcriptional activation of DNA 
repair and DNA detoxifying machinery, and repressing cell 
cycle control genes and apoptosis induction mediated by these 
transcription factors.
SirT1 also deacetylates p53, inhibiting p53-dependent 
apoptosis and senescence (Luo et al., 2001; Vaziri et al., 
2001).  SirT1-/- mouse embryonic fibroblasts (MEF) show p53 
hyperacetylation (Cheng et al., 2003), and an inhibitory effect 
on p53 translocation to mitochondria after stress has been 
reported in mES (Han et al., 2008).
SirT1 also interacts and targets DNA repair machinery. 
Its binding and deacetylation of NBS1, a checkpoint protein 
involved in DNA damage sensing and induction of DNA repair 
(Yuan et al., 2007), induces DNA repair and cell survival.  SirT1 
binds to and deacetylates Ku70, involved in DSB repair through 
non-homologous end joining (NHEJ), thereby promoting its 
binding to the pro-apoptotic factor Bax, sequestering it and 
inhibiting apoptosis induction (Cohen et al., 2004a).  After 
DSB, SirT1 is recruited to the damage site, an event that 
correlates with chromatin compaction and silencing in the same 
region (O’Hagan et al., 2008).  This recruitment seems to be 
associated with SirT1 relocalisation from its native site, which 
induces a change in the gene expression pattern that resembles 
mammalian aging (Oberdoerffer et al., 2008).  Nonetheless, the 
effective role of SirT1 in the DNA repair process is unknown.
SirT1 regulates certain major players in cell cycle control, 
such as Rb and E2F1.  Rb acetylation inhibits its phosphorylation-
dependent binding to E2F, a key event in the cell cycle; this 
suggests that SirT1-mediated Rb deacetylation promotes its 
phosphorylation and cell proliferation (Wong and Weber, 
2007).  SirT1 also binds and deacetylates E2F1, inhibiting its 
pro-apoptotic activity and inducing cell proliferation (Wang et 
al., 2006).
SirT1 and chromatin regulation.  The main biological 
form of SirT1 is a homotrimer complex of ~350 kDa (Vaquero 
et al., 2004), but in stem cells it forms the unusual PcG-related 
complex PRC4, functionally similar to PRC2 (Kuzmichev et al., 
2005).  Like all sirtuins, SirT1 lacks the ability to bind directly 
DNA and must be recruited to the target DNA regions, although 
SirT1-targeted genes are only beginning to be identified (Lara 
et al., 2009).
A model for SirT1 action in chromatin remodelling postulates 
that, following the arrival of SirT1 to chromatin, it deacetylates 
H4K16 and H3K9, and recruits histone H1 directly, which it 
deacetylates at K26 (Vaquero et al., 2004) (Fig. I-7); H1K26 
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1986; Parseghian et al., 2001; Parseghian et al., 2000). SirT1 not
only interacts and recruits histone H1, it can also deacetylate
histone H1 at lysine K26 in vitro and in vivo (Vaquero et al., 2004).
There are findings that suggest a role for H1K26 deacetylation in
heterochromatin formation, although this has yet to be demon-
strated. Firstly, acetylation of H1 N-terminal domain could act
similarly as in the core histones, weakening intra- and inter-
nucleosomal interactions and thus favoring a less compacted
chromatin structure (Vaquero et al., 2004). Secondly, H1K26 is
methylated by the Polycomb protein Ezh2, homolog of Drosophila
E(Z) (Kuzmichev et al., 2004). Since in mammals, as in Droso-
phila, SirT1 coexists with Ezh2 in the PRC4 complex, deacetylation
of H1K26Ac by SirT1 could allow coordinated methylation by
Ezh2. Thirdly, HP1 proteins bind to dimethylated H1bK26 through
its chromodomain, an interaction inhibited by phosphorylation of
the adjacent serine 27 (Daujat et al., 2005; Nielsen et al., 2001a).
This mechanism might explain the targeting of HP1 to certain
regions in the absence of H3K9 methylation in Xenopus (Meehan
et al., 2003). Finally, H1b is also present in a complex formed by
L3MBTL1, core histones, HP1γ and retinoblastoma (Rb). The
MBT (malignant brain tumor) factor L3MBTL1 promotes hetero-
chromatin formation through binding to mono- and di- methylated
H4K20 and H1K26me3 (Trojer et al., 2007).
 Upon arrival of SirT1, loss of the active chromatin mark
H3K79me2 is observed (Fig. 4). Loss of this mark—which is
involved in transcriptional active chromatin, DNA damage re-
sponse and meiotic checkpoint control and is located in the
globular domain of histone H3 (Feng et al., 2002; Kouskouti and
Talianidis, 2005)—spreads a few kilobases away from the pro-
moter regions. Interestingly, this modification is very important for
establishing the boundaries of ScSir2p silencing in S. cerevisiae,
since it inhibits the spread of the ScSir2p/3p/4p complex and is
absent in Sir2-silenced regions (Ng et al., 2002). Nevertheless,
the mechanism behind that loss is not understood. Whether SirT1
is directly involved, or if the mechanism requires histone ex-
change activity or a demethylase activity, should be addressed in
future studies.
 Lastly, SirT1 arrival promotes the establishment of hetero-
chromatin marks, particularly H3K9me3 and H4K20me1, which
spread throughout the coding region of the gene (Vaquero et al.,
2004). The mechanism involved in the establishment of these
marks is known for H3K9me3, but not for H4K20me1. SirT1
promotes the establishment of H3K9me3 through an intimate
functional relationship with Suv39h1, the main enzyme respon-
sible for the modification (Vaquero et al., 2007a). Suv39h1 was
the first lysine methyltransferase ever described (Rea et al.,
2000)and is a key player in chromatin organization, through
maintenance of H3K9me3 levels in both pericentromeric and
telomeric CH (Peters et al., 2001). It is also involved in formation
of FH in certain regions (Nielsen et al., 2001b). The importance of
this activity is reflected by several pieces of evidence. Firstly, loss
of both Suv39h1 and its close relative Suv39h2 (Suv39DN) during
murine development leads to a complete loss of H3K9me3 in the
pericentromeric heterochromatin as well as to a substantial re-
Fig. 4. Model of SirT1-mediated facultative heterochromatin. Upon recruitment by a
DNA-binding factor (TF), SirT1 promotes histone deacetylation, particularly of H4K16Ac and
H3K9Ac, as well as recruitment and deacetylation of H1 (upper panel). This arrival correlates
with loss of the active mark H3K79me2. Next, SirT1 recruits and deacetylates Suv39h1, which
becomes “superactive” (middle panel) and methylates the neighboring nucleosomes. This in
turn attracts HP1 and triggers the spread of heterochromatin, resulting in the formation of the
30 nm fiber (lower panel). OAADPR, O-Acetyl-ADPribose; SAM, S-adenosyl-methionine.
SirT1 SirT1NAD          Nicotinamide + OAADPR
Nicotinamide + OAADRP        NAD
+
+
?
H3K79me2  demethylase
Histone exchange activity
H1 H1 H1H1
H1
SirT1SirT1
10 nm
30 nm
Suv39h1
SirT1Suv39h1
HP1
HP1 HP1
SAM
TF
TF
TF
TF
Suv39h1
H1 H1 H1 H1 H1 H1
H1 H1 H1
HP1
OR
TFH4K16Ac H3K9Ac H3K79me2 H3K9me3 Transcription Factor  Ac-H1, Ac-Suv39h1
and Reinberg, 2007).
Current evidence suggests that SirT1 is actu-
ally involved in both forms of heterochromatin.
Among the most important and distinctive fea-
tures of SirT1 is that, in contrast to other Class
I and II HDACs, it is more than just a histone
deacetylase: due to its remarkable capacity to
bind to many factors and target many sub-
strates, SirT1 is actually a coordinator of hetero-
chromatin formation (Vaquero et al., 2004; Va-
quero et al., 2007b) (Fig. 4).
 The main biological form of SirT1 is an
homotrimer complex of ca. 350 kDa (Vaquero et
al., 2004). One other biochemically stable SirT1-
containing complex, PRC4, has been described
(Kuzmichev et al., 2005). Like other sirtuins,
SirT1 lacks the ability to directly bind DNA and
must be recruited to the target DNA regions.
Although numerous SirT1-targeted genes are
unidentified, all data suggest that SirT1 partici-
pates in the regulation of many genes via forma-
tion of FH by coordinating several events (Fig. 4)
(Vaquero et al., 2004).
 The first event, arrival of SirT1 to chromatin,
results in deacetylation of H4K16Ac and H3K9Ac,
and direct recruitment of the linker histone H1, a
key factor in the formation of the 30 nm fiber
(Hansen, 2002). In fact, SirT1 seems to interact
specifically with one of the five somatic variants,
H1b (also known as H1.4), which is particularly
enriched in heterochromatin and assembled into
chromatin during late S-phase (D’Incalci et al.,
Figure I-7. Model of SirT1-linked 
heterochromatin formation.  After 
recruitment by a TF, SirT1 promotes histone 
de-acetylation, particularly of H4K16 
and H3K9, as well as recruitment and 
deacetylation of H1. This arrival coincides 
with loss of the active mark dimethyl-
H3K79. Next, SirT1 recruits and de-
acetylates Suv39h1, increasing its activity 
and methylates neighbouring nucleosomes. 
This in turn attracts HP1 and triggers 
heterochromatin spread.
Adapted from Vaquero, 2009.
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can be then methylated by EZH2 (Kuzmichev et al., 2004), 
which coexists with SirT1 in the PRC4 complex.  Thereafter, 
HP1 protein binds to dimethylated H1K26 through the HP1 
chromodomain (Daujat et al., 2005; Nielsen et al., 2001).  At 
the same time, the active chromatin mark dimethyl-H3K79 is 
lost, over a stretch of a few kilobases from the promoter regions 
(Feng et al., 2002; Kouskouti and Talianidis, 2005).  Lastly, 
SirT1 promotes the establishment of heterochromatin marks, 
specifically trimethyl-H3K9 and methyl-H4K20, in the former 
case by interaction with Suv3-9h1 (Vaquero et al., 2007a). 
SirT1 induces Suv3-9h1-dependent H3K9 trimethylation by 
deacetylation of H3K9 and recruitment of Suv3-9h1 through its 
N-terminal region.  Moreover, its binding to Suv3-9h1 increases 
its methyltransferase activity in vitro and in vivo, probably 
through a conformational change.  Finally, SirT1 deacetylates 
K266 of Suv3-9h1, a residue located in the catalytic SET 
domain, rendering the enzyme more active.
SirT1 and its interplay with Suv3-9h1 and EZH2 could 
be also involved in DNA methylation.  Both Suv3-9h1 and 
EZH2 bind directly to DNMT1 –and to DNMT3A in the case 
of Suv3-9h1– and direct DNA methylation to specific genes 
(Fuks et al., 2003a; Viré et al., 2006).  SirT1 associates with the 
promoters of aberrantly silenced TSG in cancer cells, and SirT1 
inhibition leads to their re-expression (Pruitt et al., 2006).  In 
an experimental model in which a DNA DSB was induced in 
a reporter construct containing the E-cadherin promoter, SirT1 
was found to bind to the region surrounding the DNA break in 
the reporter construct; this binding is necessary for DNMT3B 
recruitment and the subsequent heritable DNA methylation of 
the reporter gene promoter (O’Hagan et al., 2008).
Finally, SirT1 is also involved in the degradation of the H2A 
variant H2A.Z, which is associated with active chromatin and 
is essential in development.  Deacetylation of H2A.Z by SirT1 
in condition of cardiac hypertrophy induces cell growth and 
inhibits apoptosis (Chen et al., 2006a).
SirT1 in development and differentiation. , SirT1 levels 
are high in mESC and decrease after differentiation (Kuzmichev 
et al., 2005), indicating an antagonistic relationship of SirT1 in 
differentiation.  Evidence shows that SirT1 function is important 
in two of the most metabolically-dependent tissue types, skeletal 
muscle and adipose tissue.  Upon fasting, SirT1 upregulation 
induces silencing of certain key genes in both tissues to inhibit 
differentiation.  In skeletal muscle, myogenin and myosin heavy 
chain (MHC) genes are silenced by SirT1 through the binding and 
deacetylation of transcription factor MyoD and the HAT PCAF 
(p300/CBP associating factor) (Fulco et al., 2003).  In adipose 
tissue, SirT1 inhibits activation of genes such as fatty acid-
binding protein (aP2) through recruitment of the corepressors 
NCoR and SMRT to the PPARγ-response genes, resulting 
in mobilisation of fat as well as inhibition of differentiation 
(Picard et al., 2004).  Recent data suggest that differentiation 
in nerve tissue is likewise dependent on metabolic changes 
and regulated by SirT1.  Under oxidative stress, mouse neural 
precursor cells (NPC) stop proliferating and differentiate into 
astroglial cells (rather than neurons) through a SirT1-dependent 
mechanism (Prozorovski et al., 2008).  This mechanism relies 
on modulation of Hes1 by SirT1, which induces silencing of the 
pro-neuronal gene Mash1.
Regulation of Sirt1 expression
SirT1 expression is regulated in a complex manner at the 
transcriptional as well as at the post-transcriptional level.
SirT1 at the transcriptional level.  In conditions of 
oxidative stress, two transcription factors have been identified 
that modulate SirT1 expression: E2F1 and HIC1 (Chen et al., 
2005; Wang et al., 2006).  Oxidative stress is known to stabilize 
E2F1, which binds directly to the SIRT1 promoter at position -65 
bp, leading to increased SIRT1 transcription (Wang et al., 2006). 
Conversely, HIC1 (hypermethylated in cancer 1) is a negative 
regulator of SirT1 expression (Chen et al., 2005), binding to 
positions at −1116 bp and −1039 bp within the SIRT1 promoter. 
Furthermore, p53 binds to two sites within the SIRT1 promoter 
(−178 bp and −168 bp), repressing SirT1 expression (Nemoto 
et al., 2004).  In the absence of nutrients, SIRT1 transcription 
is induced through nuclear translocation of FOXO3a, which 
interacts with p53, thereby inhibiting p53 suppressive activity.
SirT1 at the mRNA level.  HuR, a ubiquitously expressed 
RNA binding protein (Brennan and Steitz, 2001), associates 
with the 3′ untranslated region of SirT1 mRNA in physiological 
conditions (Abdelmohsen et al., 2007), leading to increased 
SirT1 mRNA stability and elevated protein levels.  By contrast, 
the complex of HuR with SirT1 mRNA is disrupted by oxidative 
stress, leading to SirT1 downregulation.  HuR binding to SirT1 
mRNA is itself regulated by checkpoint kinase 2 (CHK2)-
mediated phosphorylation, which in turn is activated through 
oxidative stress.  This explains how HuR binding affinity to 
SirT1 transcript is reduced in these conditions.  Methylation 
at Arg217 by the arginine methyltransferase CARM1 also 
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regulates HuR transcript-stabilising activity; LPS treatment 
of mouse neutrophils leads to HuR methylation-mediated 
stabilisation of TNFα transcript (Li et al., 2002a).  CARM1-
mediated methylation also regulates a HuR homolog, HuD, in 
this case by inhibiting p21cip1/waf1 mRNA stabilization in 
PC12 cells (Fujiwara et al., 2006).
MicroRNA (miR) are short 18–24 nt RNA that inhibit 
transcription or translation of mRNA.  In human cells, miR34a 
binds the 3’ UTR of the SirT1 mature transcript and inhibits 
its translation.  miR34a inhibition of SirT1 leads to an increase 
in acetylated p53 and to expression of p21 and PUMA, 
transcriptional targets of p53 that regulate the cell cycle and 
apoptosis, ultimately provoking apoptosis in colon cancer cells 
(Yamakuchi et al., 2008).
SirT1 at the protein level.  Phosphorylation is another 
important mechanism of SirT1 regulation.  Large-scale mass 
spectrometry studies on HeLa nuclear cell extracts identified 
Ser27 and Ser47 as potential phosphorylation sites located 
within the SirT1 N-terminal domain (Beausoleil et al., 2004; 
Beausoleil et al., 2006).  JNK2-dependent phosphorylation of 
Ser27 was first demonstrated to greatly affect SirT1 protein 
stability in cancer cells, and is the main element responsible 
for SirT1 overexpression in certain cancers (Ford et al., 2008). 
CyclinB/Cdk1 was later shown to phosphorylate SirT1, possibly 
in two residues (Thr530 and Ser540), enhancing its activity 
(Sasaki et al., 2008).  Ser659 and Ser661 were identified as 
casein kinase 2 (CK2) phosphorylation sites (Zschoernig and 
Mahlknecht, 2009).  CK2 also phosphorylates the conserved 
residues Ser154, Ser649, Ser651 and Ser683 of mouse SirT1, 
increasing its deacetylation rate and substrate-binding affinity. 
CK2-mediated phosphorylation increases the ability of SirT1 to 
deacetylate p53 and to protect cells from apoptosis after DNA 
damage (Kang et al., 2009a).  cJUN N-terminal kinase (JNK1) 
was identified as a SirT1 kinase in conditions of oxidative 
stress; it requires phosphorylation-mediated activation of JNK1 
and affects SirT1 Ser27, Ser47, and Thr530.  The effect of 
these modifications is to induce SirT1 nuclear localization and 
enhance its enzymatic activity selectively on histone H3, but not 
on p53 (Nasrin et al., 2009).
SirT1 protein is also sumoylated on lysine residues. 
Sumoylation has regulatory effects on its substrates, such as 
alteration of subcellular localization, protein–protein interactions 
and enzymatic activity (Verger et al., 2003).  Desumoylation is 
catalysed by a family of specific isopeptidases called the SENP 
desumoylases (Yeh et al., 2000).  SirT1 is sumoylated at Lys734 
in the normal state, whereas genotoxic stress leads to SENP1-
driven desumoylation of SirT1, impairing deacetylase activity 
and thereby promoting activation of its apoptotic substrates and 
inducing cell death (Yang et al., 2007).
Subcellular localization is an additional regulatory tool for 
SirT1 activity.  SirT1 is indeed subject to nucleocytoplasmic 
shuttling during oxidative stress (Jin et al., 2007; Tanno et 
al., 2007); in these conditions, cytoplasmic accumulation of 
SirT1 sequesters it from its nuclear substrates, rendering it 
unable to inactivate its predominantly anti-apoptotic substrates. 
Consequently, cytoplasmic localization of SirT1 appears to 
sensitize cells to oxidative stress-mediated apoptosis.  SirT1 
localisation is also implicated in differentiation of neural 
precursor cells (NPC); SirT1 was found in cytoplasm of 
embryonic and adult NPC and in response to differentiation 
stimuli, localised transiently in the nucleus, where it induces 
neuron differentiation (Hisahara et al., 2008).
SirT1 regulation via protein-protein interactions can be 
mediated by distinct proteins.  AROS (active regulator of 
SirT1) is a positive regulator of SirT1, increasing its deacetylase 
activity (Kim et al., 2007), whereas DBC1 (deletions in tumour 
suppressor breast cancer 1) acts as a SirT1 inhibitor, binding its 
catalytic pocket (Kim et al., 2008b).
Epigenetic mechanisms in embryonic stem cell differentiation
Early in development, the first zygote-derived cells must 
perform two different functions.  One is self-renewal, which 
is the ability to expand the cell population that maintains a 
certain degree of potency until a definite developmental stage 
is reached.  The other function is totipotency (for the zygote 
and first cell divisions; pluripotency for the ICM and derived 
cultured ES cells), the ability to maintain the potential to give 
rise to any differentiated cell of the adult body.  To achieve 
totipotency, germ cell epigenetic states must first be reset, and 
the zygotic genome must then be activated to allow expression 
of appropriate genes in subsequent development (Morgan et al., 
2005; Reik, 2007).  When a differentiation step is to be initiated, 
each cell must be able to modify its gene expression programme 
to change its phenotype.  To simplify a complex scenario that 
has only begun to be described, a stem cell appears to have a 
globally open chromatin structure that keeps pluripotency-
maintenance genes active and differentiation genes silenced, 
in a reversible, highly plastic way.  Following differentiation 
33INTRODUCTION
towards a definite lineage, a stem cell must a) downregulate 
pluripotency genes definitively, b) activate expression of genes 
for the necessary differentiation phenotype, and (Fig. I-8) c) 
lock differentiation genes for other lineages into a silent state. 
Moreover, these processes must be precisely regulated in space 
and time.  All of these skills are conferred on a stem cell mainly 
by the action of the epigenetic machinery.
Epigenetic events in pre-implantation phases.  Two 
cycles of DNA methylation characterise gametogenesis and pre-
implantation development in mammals (Fig. I-9).  In the first 
week of embryonic development, primordial germ cells arise in 
the extraembryonic region posterior to the primitive streak, and 
are designated to regain the capacity to form a new organism 
(Hayashi et al., 2007; Saitou et al., 2002).  Primordial germ 
cell differentiation involves a wave of genomic demethylation, 
which resets differentially methylated loci, including imprinted 
and allele-specific regions, followed a few days later by 
methylation (Lees-Murdock and Walsh, 2008).  Mature sperm 
and oocytes remain highly methylated until fertilization, 
after which a second cycle of demethylation and gradual 
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Figure I-8.  Epigenetic regulation of hESC differentiation.  hESC differentiation involves inactivation of pluripotency genes 
(repressive transitions) and activation of developmental genes (activating transitions).  Many pluripotency genes are inactivated 
during differentiation through promoter hypermethylation.  The best-known mechanism involved in developmental gene silencing 
in hESC is bivalent mark/Polycomb-mediated inactivation, whose resolution is responsible for developmental gene activation 
during differentiation.
Figure I-9. Changes in DNA 
methylation during mammalian 
development.    Note the very rapid 
changes in DNA methylation during: (i) 
gametogenesis - de novo methylation 
gives rise to substantially methylated 
genomes in the sperm and egg (albeit 
with differences in both the overall 
level of methylation and the pattern 
of methylation in these genomes), and 
in (ii) in the early embryo, a wave of 
genome-wide demethylation occurs 
at the preimplantation stage (morula 
and early blastula), and is succeeded 
shortly afterwards by large-scale de 
novo methylation beginning at the 
pregastrulation stage.  The latter is 
particularly pronounced in somatic 
lineages, and to a lesser extent in 
trophoblast lineages giving rise to 
placenta and yolk sac, but does not 
occur in the primordial germ cells 
(which will eventually give rise to 
sperm and egg cells).
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re-methylation of parental genomes occurs.  The paternal 
genome is rapidly demethylated by an active mechanism, 
since it occurs in the absence of replication or transcription 
(Mayer et al., 2000; Oswald et al., 2000).  Various DNA repair 
enzymes have been proposed to carry out active demethylation 
in mammals (Gehring et al., 2009; Niehrs, 2009), and a role 
was recently suggested for the de novo methyltransferases 
DNMT3A and DNMT3B (Kangaspeska et al., 2008; Metivier 
et al., 2008).  Coincident with the first embryonic cleavage 
divisions, the zygotic genome gradually becomes demethylated 
until the morula stage.  This probably occurs through a passive 
mechanism, whereby newly replicated DNA strands fail to 
be methylated by DNMT1, resulting in an overall increase in 
unmethylated DNA (Rougier et al., 1998).  This is due to sex-
specific splicing events that control DNMT1 activity in early 
embryos by regulating its translation or nucleo-cytoplasmic 
localisation (Mertineit et al., 1998).  De novo DNA methylation 
begins after blastocyst formation; cells that comprise the ICM 
show higher methylation levels than those of the trophectoderm 
(Santos et al., 2002), probably due to differential regulation of 
DNMT3B expression, decreased in extra-embryonic tissues and 
increased in ICM-derived cells (Hirasawa and Sasaki, 2009).
Histone modification also undergoes specific regulation 
during preimplatation development.  Following fertilization, 
sperm chromatin is decondensed by exchange of arginine-
rich protamines for histones, and becomes associated with 
hyperacetylated and hypomethylated H4 (Adenot et al., 
1997).  In contrast, oocyte chromatin displays abundant H3K4 
methylation before and after fertilization (Lepikhov and Walter, 
2004; Van Der Heijden et al., 2005).  In the male pronucleus, 
H3K4 is monomethylated shortly after fertilization, but it is 
not until 8-10 hours post-fertilization that the trimethylated 
form is observed.  Female pronuclear chromatin is methylated 
extensively on H3K9, a repressive mark, whereas only the 
monomethylated form is found in the male pronucleus (Arney 
et al., 2002; Cowell et al., 2002; Liu et al., 2004; Santos et 
al., 2005).  Trimethyl-H3K27 is enriched in maternal, but not 
paternal chromatin following fertilization (Erhardt et al., 2003). 
By the four-cell stage, all blastomere nuclei show equivalent 
levels of methyl-H3K27, methyl-H3K4, and methyl-H3K9. 
Many developmental gene promoters were recently shown to 
be wrapped on histones rather than on protamines already in the 
mature sperm, and are pre-marked with distinctive chromatin 
domains.  Dimethyl-H3K4 is enriched at certain developmental 
promoters and trimethyl-H3K4 localizes to a subset of these 
promoters, including regions in HOX clusters, ncRNA, and 
paternally expressed imprinted loci, while trimethyl-H3K27 
is enriched at developmental promoters repressed in early 
embryos.  Furthermore, developmental promoters are generally 
DNA hypomethylated in sperm, and are methylated during 
differentiation (Hammoud et al., 2009).
There is also a discrepancy in histone methylation levels 
between cells of the ICM and the trophectoderm.  Pluripotent 
cells in the ICM show extensive H3K27 methylation, but in the 
trophectoderm, methyl-H3K27 is only detected on the inactive 
X chromosome.  Substitution of canonical for variant histones 
also contributes to epigenetic regulation in preimplantation 
embryos (Santenard and Torres-Padilla, 2009).
Epigenetics of embryonic stem cells.  ES cells are thought 
to be an adaptation of cell culture conditions, because the 
properties of the ICM are transient in nature, whereas cultured 
ESC divide indefinitely without losing pluripotency.  Epigenetic 
changes during ESC differentiation in culture might nonetheless 
provide an informative model for events that regulate early 
embryonic development.
ES cells must retain pluripotency while proliferating rapidly 
in culture.  A group of transcriptional regulatory proteins are 
critical for pluripotency maintenance of both ES cells and the 
ICM (Jaenisch and Young, 2008).  The POU5F1 (OCT4) and 
NANOG transcription factors are necessary for correct ICM 
and ESC differentiation (Chambers et al., 2003; Nichols et al., 
1998) and, in conjunction with the high-mobility-group SOX2 
protein, directly control the expression of genes important 
for both pluripotency and developmental pathways (Boyer 
et al., 2005).  This network activates genes needed for ESC 
survival and proliferation, while repressing target genes that are 
activated only during differentiation (Loh et al., 2006; Sharov et 
al., 2008). With increasing research into the ES transcriptional 
network, other factors are added continually to this core “trio”. 
. A notable addition is zinc finger transcription factor sal-like 
protein 4 (SALL4) (Wu et al., 2006; Yang et al., 2008; Zhang 
et al., 2006). Co-expression and coregulation of these factors 
is univocally associated to pluripotency.  OCT4, NANOG, 
SOX2 and SALL4 are able to regulate their own expression and 
control a set of target genes through mutual heterodimerization 
and/or shared promoter occupancy, forming a self-reinforcing 
circuit of pluripotency (Chew et al., 2005).  In mESC, Nanog 
and Oct4 are associated to each other, and recruit specific 
repression complexes to their target genes, including elements 
of the NuRD and Sin3A complexes.  A previously undescribed 
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Hdac1/2- and Mta1/2-containing complex, defined as NODE 
(Nanog and Oct4-associated deacetylase), might be the main 
effector of gene repression mediated by these factors (Liang et 
al., 2008).  OCT4 NANOG SOX2 and SALL4 also associate to 
other components of the epigenetic machinery such as the PRC1 
components EED, SUZ12, or the HMT G9A (Loh et al., 2006; 
Ura et al., 2008).  SALL4 has a specific role in pluripotency 
factor/epigenetic modifier crosstalk, as it binds cooperatively 
with PRC1 and PRC2 to trimethyl-H3K27 at some promoters, but 
does not require these repressive complexes for binding at other 
sites (Yang et al., 2008).  Detailed analysis of the pluripotency 
network showed that Nanog plays the leader role for generation 
and maintenance of the ground state of pluripotency, both in 
vivo (in the epiblast) and in vitro (in hESC and iPS generation) 
(Silva et al., 2009).
In addition to regulating a network of developmentally 
important genes in ESC, OCT4 positively regulates expression 
of the di- and trimethyl-H3K9 demethylases KDM3A (JMJD1A) 
and KDM4C (JMJD2C) (Loh et al., 2007).  Undifferentiated 
ES cells appear to have a more open chromatin structure than 
differentiated cells (Meshorer and Misteli, 2006; Meshorer 
et al., 2006) and are depleted of trimethyl-H3K9 (Meshorer 
et al., 2006).  Activation of H3K9-specific demethylases by 
the core pluripotency regulatory machinery would cause an 
overall reduction in trimethyl-H3K9, directly linking the 
ES cell pluripotency circuitry to the formation of an open 
chromatin structure (Loh et al., 2007).  In addition to post-
translational chromatin modification, CHD1 remodelling of 
chromatin structure also performs its function by maintaining 
an open chromatin state in ES cells, localizing mainly in 
active gene promoters.  Downregulation of this factor leads to 
heterochromatin accumulation and loss of pluripotency, as cells 
can no longer give rise to certain lineages (Gaspar-Maia et al., 
2009).
As stated above, ES cells must maintain its differentiation 
genes silenced.  This is achieved at least in part through the 
creation of bivalent chromatin domains.  These domains are 
termed “bivalent”, as they contain overlapping regions of the 
transcriptionally permissive histone modification trimethyl-
H3K4 and the transcription silencing mark trimethyl-H3K27, 
mediated respectively by the mixed-lineage leukaemia (MLL) 
complex and the EZH2 component of PRC2 (Bernstein et al., 
2006; Schuettengruber et al., 2007).  Bivalent domains maintain 
silencing of developmentally important genes –primarily 
transcription factors such as the Hox and other tissue-specific 
genes– while simultaneously keeping them poised for either 
repression or activation, depending on the developmental 
lineage for which the ESC are destined (Bernstein et al., 2006). 
In essence, this bivalent configuration is thought to enable 
retention of developmental plasticity by these genes.
Histone KDM are responsible for the resolution of bivalent 
chromatin domains (Cloos et al., 2008).  For example, Hox gene 
expression is strongly upregulated following ES differentiation, 
and trimethyl-H3K27 demethylase KDM6A (formerly UTX) 
binding at HOX promoters is increased concomitantly; this 
leads to a reduction in di- and trimethyl-H3K27 and dissociation 
of PRC2 (Agger et al., 2008; Lan et al., 2007). Strikingly, Jarid2 
(JMJ), a H3K27 demethylase, is physically associated to the 
PRC2 complex in stem cells, and is required for efficient PRC2 
binding to its target, but also inhibits K27 methylation, thus 
acting as an internal modulator of PRC2 during development 
(Peng et al., 2009; Shen et al., 2009).  Other bivalent domain-
marked genes require stable repression within specific 
developmental pathways.  This is achieved by the tandem action 
of PRC2 and the trimethyl-H3K4 demethylase KDM5A (also 
known as JARID1A), whose recruitment results in increased 
trimethyl-H3K27 and decreased trimethyl-H3K4 at these 
promoters (Pasini et al., 2008).
There are other important modifications implicated in the first 
stages of developing embryo.  In the mouse embryo, H3R26 and 
R17 methylation levels are heterogeneously distributed as early 
as four-cell stage blastomeres; cells with higher levels of this 
mark are more likely to contribute to ICM, while lower levels 
target cells to mural trophoectoderm.  This observation indicates 
that the only real totipotent cell might in fact be the zygote. 
CARM1, the enzyme responsible for these modifications, thus 
seems to be necessary for blastomere and ICM cell pluripotency; 
CARM1-overexpressing cells strongly upregulate Nanog and 
Sox2 (Torres-Padilla et al., 2007).  CARM1 is also needed for 
ES cell self-renewal and pluripotency, as CARM1 knockdown 
downregulates pluripotency genes, leading to differentiation. 
CARM1 associates with Pou5f1 and Sox2 promoters, which 
have detectable levels of R17/26 histone H3 methylation (Wu 
et al., 2009).
Compared to differentiated cells and cancer cells, hESC 
possess a unique DNA methylation signature (Ball et al., 2009; 
Bibikova et al., 2006; Deng et al., 2009; Fouse et al., 2008; 
Meissner et al., 2008), supporting the concept that a specific DNA 
methylation pattern could contribute to the pluripotent state.  A 
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genome-wide DNA methylation study in several somatic cell 
types and sperm was the first to highlight a relationship between 
promoter DNA methylation and promoter activity, which 
apparently depends on promoter CpG content (Weber et al., 
2007).  Promoters with low CpG levels showed no correlation 
between activity (defined by RNA polymerase II occupancy, not 
in itself an indicator of full transcriptional activity, especially 
in ES cells (Efroni et al., 2008; Guenther et al., 2007)) and 
methylated CpG abundance.  Low CpG promoters (LCP) would 
be methylated regardless of their activity status, intermediate 
CpG promoter (ICP) activity would correlate inversely to the 
extent of methylation, and high CpG promoters (HCP) would 
only weak or no methylation, even when inactive.  Genome-
wide high-resolution DNA methylation profiling across 
promoter regions was later carried out in mESC, superimposing 
chromatin state maps (histone modifications) on a given DNA 
methylation “background” (Fouse et al., 2008); over 6100 genes 
that were hypermethylated over the promoter regions examined 
were annotated.  DNA methylation in mESC occurs primarily 
in ICP and LCP, or in non-CpG island regions of HCP.  Gene 
ontology analysis of the methylated genes showed that these 
genes encode sensory perception and signalling molecules, 
suggesting that methylated genes are involved mainly in late 
differentiation and signal transduction processes, and are not 
expressed in mESC, whereas unmethylated promoters associated 
with transcription, RNA and protein metabolic processes, cell 
survival and proliferation.  This suggests that unmethylated 
promoters show reasonable correlation with genes that are 
active in ESC.
DNA methylation appears to be associated to specific 
histone marks (Meissner et al., 2008).  For promoters occupied 
by histones methylated at H3K4 and/or H3K27, occupancy of 
promoter sequences by an activating histone mark (i.e., H3K4) 
correlates negatively with DNA methylation, while occupancy 
by a repressive histone mark (i.e., H3K27) is positively 
correlated with DNA methylation.  Promoters that lack both 
histone marks are highly methylated, and DNA methylation 
status is a good predictor of gene expression.  During cell 
differentiation, hypermethylation can occur at CpG island 
promoters and at CpG-rich sequences outside promoter regions 
(Meissner et al., 2008).  Remarkably, the authors claim that 
almost no demethylation is detected, and focus their attention 
mainly on HCP; they suggest that DNA methylation-mediated 
epigenetic repression increases globally during lineage 
specification.  Many of the identified targets of differentiation-
coupled de novo DNA methylation are stem cell- and germ-
line-specific gene promoters (Farthing et al., 2008; Mohn et 
al., 2008).  One interpretation of this selectivity is that DNA 
methylation might stably repress the pluripotency program 
and prevent its aberrant reactivation and de-differentiation 
under physiological conditions.  Experimental support for this 
model comes from a recent report showing that somatic cell 
reprogramming into iPS is greatly enhanced by treatment with 
the DNA methyltransferase inhibitor 5-azacytidine (Mikkelsen 
et al., 2008).  DNA methylation profiling of iPS compared to 
the primary fibroblasts from which they were derived clearly 
shows a large group of genes that are demethylated upon 
reprogramming, related mainly to pluripotency (Doi et al., 
2009).  At the same time, many developmental genes are 
hypermethylated during reprogramming and correlate inversely 
with the presence of a bivalent mark.  Genetic and molecular 
data are thus compatible with a role for DNA methylation in the 
shut-down of pluripotency and, eventually, cell specification.
A powerful single-base mapping method was recently used 
to define the hESC methylome (Lister et al., 2009).  Around one-
quarter of all methylation is in a non-CG context (mCHG and 
mCHH, where H = A, C or T), a phenomenon nearly undescribed 
in animals, although there were some reports (Ramsahoye et al., 
2000; Woodcock et al., 1987).  Methylation in nonCG contexts 
shows enrichment in gene bodies and depletion in protein-
binding sites and enhancers; it disappears after induced hESC 
differentiation, and is restored in iPS.  Hundreds of differentially 
methylated regions were also identified proximal to genes 
involved in pluripotency and differentiation (Lister et al., 2009).
In any case, the role of DNA methylation in lineage 
specification has not been elucidated exhaustively.  Functional 
data demonstrate that treatment with the DNA demethylating 
drug 5-aza-2′-deoxycytidine greatly enhances cardiomyocyte 
differentiation from hES (Xu et al., 2002) or from the embryonic 
carcinoma cell line P19 (Choi et al., 2004), and endothelial 
differentiation from mES (Banerjee and Bacanamwo, 2010). 
Genes involved in this differentiation effect are still unidentified. 
Only a few genes with a LCP appear to be the only ones prone to 
promoter demethylation during differentiation.  We thus studied 
this phenomenon further to identify a more defined function of 
promoter methylation in lineage specification.
OBJECTIVES
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The epigenetics of stem cells has been of central interest in biology in recent decades.  Since human ESC became 
available to developmental and molecular biologists, and high-throughput techniques now provide the possibility of 
rapid, large-scale analysis of the epigenetic panorama, much effort has been dedicated to the detailed description of 
stem cell epigenetics.  Our research focussed on two aspects of stem cell epigenetics: DNA methylation and histone 
modification by the histone deacetylase SirT1.
Embryonic stem cells have a unique epigenetic signature.  Bibikova et al. described 23 genes whose promoter 
methylation status was unique to hESC; DNA methylation was also reported to stably inactivate pluripotency genes 
during hESC differentiation.  Certain late differentiation genes, generally bearing a low density CpG promoter and 
not showing the bivalent mark, are frequently hypermethylated in stem cells.  Nevertheless, developmental gene 
activation through promoter demethylation has not been fully investigated.  We approached this point to specifically 
define genes methylated in hESC as compared to normal tissues.  As promoter hypermethylation is a hallmark of 
many cancers, we also analysed similarities in gene promoters hypermethylated in stem cells and in cancer; this 
could aid in understanding the aberrant process of cancer promoter methylation, and because an important concern 
for stem cell therapeutic application is the potential for tumour transformation.
It has long been known, and was recently confirmed in undifferentiated hESC, that most developmental genes 
are repressed by Polycomb repressive complexes.  A specific signature in hESC, the bivalent mark, is observed at the 
developmental promoters, mediated mainly by PRC2 and other complexes with histone methyltransferase activity. 
Although the role of histone methylation in developmental gene regulation has been characterised extensively, 
histone acetylation in this context is less well-studied.  The histone deacetylase SirT1 was previously implicated in 
tissue differentiation processes, i.e. muscle, adipose tissue and neurons.  SirT1 is highly expressed in stem cells and 
colocalises on chromatin with components of the PRC.  SirT1-deficient (KO) mice show marked developmental 
defects, although in many cases they pass through early embryonic stages.  We studied SirT1 in early hESC 
differentiation, to determine its role in modulating gene expression though chromatin modification.
The concrete objectives of this study were to:
1. Characterise the role of DNA methylation in human embryonic stem cell differentiation, with special 
 attention to demethylation-mediated gene regulation.
2. Determine the role of SirT1/histone modification-mediated gene regulation during embryonic stem cell 
 differentiation.
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Stem cell line culture, differentiation and treatment
Human stem cell lines.  Cell pellets and/or DNA/RNA were 
obtained from the following laboratories: Shef-1 (Servicio de 
Inmunologia, HUCA, Oviedo, Spain), Shef-4, Shef-5, Shef-7, 
H7, H14 (Centre for Stem Cell Biology, University of Sheffield, 
Sheffield, UK), H181 (Centro Andaluz de Biología y Medicina 
Regenerativa, Seville, Spain), I3 (Institute of Reconstructive 
Neurobiology, University of Bonn, Germany); cells were 
cultured and passaged following protocols established by each 
laboratory.  The laboratories involved in the establishment and 
maintenance of these cell lines are members of the European 
project ESTOOLS (LSHG-CT-2006-018739); participant 
laboratories in ESTOOLS use only hESC lines derived from 
IVF embryos that will not be transferred into the uterus.  These 
embryos were donated for research in accordance with the legal 
requirements of the country of origin.  All donors gave written 
informed consent.  The cell lines were established from different 
embryos and were maintained under distinct conditions, thereby 
ensuring the independence of results for type of line and culture 
conditions.
Stem cell culture.  MEF (passage 2, Stem Cell Technologies) 
were thawed and expanded for 3 or 4 further passages in MEF 
medium [DMEM/F12 1:1 with 15% foetal bovine serum (FBS; 
Sigma) 1X non-essential amino acid mix (NEAA; Lonza) 1X 
glutamine (Lonza), 0.1 mM β-mercaptoethanol (BME; Sigma)], 
treated for 3 h with 10 µg/mL mitomycin C (Sigma), washed and 
seeded (3.5 x 105 in a 25 cm2 gelatin-coated flask); once attached 
overnight (o/n), hESC were seeded on this feeder layer.  Shef1 
was cultured in hESC medium [KO-DMEM, 20% KO serum 
replacement (Gibco), 1X NEAA, 1X glutamine, 0.1 mM BME, 
4 ng/ml basic-FGF (Peprotech)], with daily medium changes. 
After four to five days, hESC colonies were treated with 1 mg/
ml collagenase IV (Gibco) in KO-DMEM for 5-10 min, washed 
to remove collagenase solution before colony detachment, then 
mechanically disrupted with a pipette or sterile glass beads, and 
divided 1:3 to 1:4.  Differentiated colonies normally appeared 
at a low rate and were scraped or aspirated before passaging or 
collecting.  Cells for pellets or for further differentiation were 
collected by collagenase IV treatment until colony detachment, 
which was interrupted before the feeder layer was disrupted.
Stem cell differentiation.  For differentiation of embryoid 
bodies (EB), hESC colonies were detached and incubated as 
floating aggregates for 15 days (or as indicated) in ultra-low 
attachment flasks (Corning) with hESC medium lacking bFGF. 
Medium was changed after 24 h to eliminate cell debris and 
apoptotic cells normally present the day after detachment; 
subsequently, medium was changed every 48 h.  For further 
differentiation to fibroblast-like (F-L) cells (Li et al., 2009), 
15-day EB were attached to gelatin-coated plates and cultured 
in DMEM with 15% FBS, 1X NEAA, and 1X glutamine for 
a further 15-20 days, passaging with trypsin two or three 
times.  Cells finally appeared as a monolayer of fibroblasts and 
keratinocyte-like cells.
For in vitro neural differentiation (Pankratz et al., 2007), 
detached hESC colonies were cultured like EB for four days 
to initiate the differentiation process, then conditioned for an 
additional 2 days in neural medium (NM) [DMEM/F12, NEAA 
1X, 2 µg/ml heparin for FGF stabilization, and the supplement 
N2 (Gibco)].  At day six, aggregates were attached on a laminin-
treated substrate (20 µg/ml in culture medium, 37°C, 12 h) 
and were maintained in NM with 20 ng/ml bFGF.  Attached 
aggregates flattened over 1-2 days, columnar cells developed 
and formed neural tube-like structures.  At day 15, columnar 
cells in the centre of colonies were enzymatically separated with 
1X dispase  (Stem Cell Technologies) and grown as floating 
spheres for one more week in NM with bFGF, then reattached 
to a polyornithine/laminin substrate and cultured in neurobasal 
medium (Gibco), N2, 1X NEAA, supplemented with brain-
derived neurotrophic factor (10 ng/ml; Peprotech), glial cell 
line-derived neurotrophic factor (10 ng/ml; R&D Systems), 
N6,2′-O-dibutyryladenosine 3′,5′-cyclic monophosphate 
sodium salt (1 µM; Sigma-Aldrich), ascorbic acid (200 M; 
Sigma-Aldrich), and laminin (20 µg/ml) until neurite processes 
were clearly observed (1-2 weeks).  Marker expression for both 
differentiated cell types were confirmed by q-RT-PCR.
Mouse stem cells derivation, culture and differentiation. 
Mouse TC1 ES cells and the knockout ES line (SirT1∆ex4/∆ex4) 
were a gift of Dr. Frederick Alt’s laboratory (Cheng et al., 
2003).  Sirt1 transgenic ES cells were derived by the CNIO 
Transgenic Mouse Unit.  Sirt1 transgenic (+/+;tg/.) and WT 
ES cells were established de novo from blastocysts obtained by 
in vitro fertilisation of WT C57BL/6 oocytes with sperm of a 
Sirt1 transgenic (+/+;tg/.) male (Pfluger et al., 2008) following 
standard protocols (Nagy et al., 2003).  After fertilisation, 
embryos were cultured in KSOM (37ºC, 3 days) until they 
reached the blastocyst stage, then plated in ES cell medium with 
feeders until outgrowth of the inner cell mass was observed. 
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mESC medium is composed of high glucose DMEM with 15% 
FBS, LIF (1000 U/ml), 1X NEAA, Glutamax and BME.  For 
EB differentiation, cells were trypsinised and seeded in the same 
medium without LIF; medium was every 24-48 h for 15 days.
Primary cells and tissues.  Primary CD34+ haematopoietic 
stem cells were purified from cord blood (CB) samples obtained 
from healthy newborns with maternal informed consent.  CB 
harvesting procedures and informed consents were approved 
by the Local Hospital Ethics Board.  Mononuclear cells were 
isolated using Ficoll-Hypaque (Amersham Biosciences). 
CD34+ cells were purified by positive selection using anti-CD34 
microbeads (Miltenyi Biotech).  Immunomagnetic CD34+ cell-
containing cell suspensions were passed through Pro-MACS 
immunomagnetic columns (Miltenyi Biotech).  The flow-
through contained the purified CD34+ fraction.  The purity was 
80% ± 12% (n = 2) (Figure I-10), as measured by flow cytometry 
(FACSCanto, Becton Dickinson) using a fluorochrome-
conjugated anti-CD34 antibody (BD Biosceinces).
Lymphocytes and neutrophils from peripheral blood of 
healthy volunteers were separated by centrifugation, using 
Histopaque-1077 (Sigma).  Lymphocyte-enriched fractions were 
obtained by collecting the upper cushion of mononuclear cells 
and granulocytes (mainly neutrophils) following haemolysis 
of the remaining pellet.  RNA from breast, liver, heart, muscle, 
lung, colon, and lymph node samples were obtained from 
Ambion; DNA from breast, heart, brain, muscle, colon, brain 
and sperm was obtained from Biochain.  Participating subjects 
were informed and gave written consent to all procedures.
Cancer cell lines.  MDA-MB-231, Hela, CasKi, SiHa, 
HCC1937, BT-474, LoVo, HCT115, DLD1, Co115, HT29, 
SW48, HCT116, RKO (ATCC) were cultured in DMEM with 
10% FBS, 1X NEAA, 1X glutamine, 1X penicillin-streptomycin 
(Gibco) at 37°C in a 5% CO2 incubator and were passaged by 
trypsinization when confluent.  U937, HL60, AKATA, Raji, 
Ramos, Karpas, and Farage (ATCC) cell lines were maintained 
in the same conditions in RPMI medium with 10% FBS, 1X 
NEAA, 1X glutamine, 1X penicillin-streptomycin, and passaged 
by adding fresh medium, according to cell growth rate.
DNA methylation analysis
DNA methylation is a chemical modification in the 5 
position of the cytosine aromatic ring, where a methyl group is 
added.  It is generally found in a cytosine followed by a guanine 
at its 3’ (with some exceptions described in the Introduction), 
and is thus symmetrically detectable on both DNA strands. 
CpG dinucleotides in the genome are concentrated in repetitive 
sequences and in regions spanning promoters and gene regulatory 
regions, called CpG islands.  A CpG island is technically defined 
as a 200-bp window moving across a sequence of interest at 1-bp 
intervals, with a C + G content >50% and an observed/expected 
CpG frequency of >0.6 (Gardiner-Garden and Frommer, 1987), 
or a 500-bp moving window with a C + G content of >55% 
and an observed/expected CpG frequency of >0.65.  The latter 
definition provides more accurate association of CpG islands 
with the 5′ region of genes and excludes most Alu repeats (Takai 
and Jones, 2002).  As stated in the introduction, CpG island-
containing promoters are further classified by some authors as 
HCP (high CpG promoter, which contains a 500 bp region with 
a GC content ≥0.55 and a CpG observed/expected ratio ≥0.6), 
LCP (low CpG promoter containing no 500 bp interval and with 
a CpG observed/expected ratio ≥0.4), and ICP (intermediate 
CpG content promoter with CpG density between HCP and 
ICP) (Mikkelsen et al., 2007; Weber et al., 2007).
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Fgure I-10.  Flow cytometry analysis of CD34+ cell purity 
after positive selection using anti-CD34 microbeads.  
Detection signals were obtained using an anti-CD34 and an 
anti-CD45 antibody.
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Techniques used for CpG detection are always based on the 
differential recognition or the distinct chemical behaviour of a 
methylated vs. an unmethylated CpG.  Differential recognition 
can be performed by a methylation-sensitive restriction enzyme 
(as in the amplification of intermethylated sites detailed 
below (Jorda et al., 2009)) or an antibody (methyl-DNA 
immunoprecipitation; meDIP (Jacinto et al., 2008)), whereas 
differential chemical reactivity is the principle of the bisulphite 
modification and the related techniques reported in the following 
sections.
DNA extraction. Extraction was performed with the Phase 
Lock Gel DNA extraction protocol (Eppendorf; for samples >5 
x 106 cells) or with QIAamp DNA Blood Mini Kit (Qiagen; for 
small samples).
Amplification of intermethylated sequences (AIMS). 
Purified genomic DNA (1 µg) was digested sequentially with 
SmaI (Roche, 1U, 16 h, 25ºC) and XmaI (NEB; 5U, 6 h, 
37ºC).  Oligonucleotide adaptors Blue and MCA-Blue (see 
supplementary primer table) were annealed by heating (65ºC) 
and gradual cooling at RT for 60 min.  Digested DNA was 
ligated with adaptors, 1 µmol/µg DNA, incubating with T4 
DNA ligase (NEB 800U, 16 h, 16ºC).  The ligation product was 
purified with GFX PCR DNA and Gel Band Purification Kit 
(Amersham) and amplified by PCR using the following primers 
(see primer table) and conditions: PCR primer Set1 CTG 
(denaturalisation 15 sec at 95ºC, annealing-extension 1 min at 
74ºC, 29 cycles) and Set2 CTA (denaturalisation 15 sec at 95ºC, 
annealing 45 sec at 68ºC, extension 1 min at 72ºC, 30 cycles). 
PCR products were resolved in 6% polyacrylamide 8 M urea 
denaturing electrophoresis gels (4-5 h, 55W) and developed by 
silver staining.  Indicated bands were extracted manually from 
the gel, and DNA resuspended in water, re-amplified with the 
corresponding primer and cloned in a pGEM-T easy vector 
(Promega).  Positive plasmid clones were sequenced and blasted 
to the human genome in the NCBI Blast website.
Bisulphite modification.  Genomic DNA was treated 
with sodium bisulphite (Sigma) either using the EZ-DNA 
methylation gold kit (Zymo Research) or manually.  This salt 
reduces the aromatic ring of an unmethylated cytosine, leading 
to an intermediate product that deaminates spontaneously. 
Subsequent addition of the NaOH base causes desulphonation 
of the ring, which is finally converted to a uracil ring (Fig. I-11). 
The reaction cannot occur on a methylated cytosine.  The final 
effect is a DNA sequence change in a methylation-specific 
manner.  DNA is depleted of all cytosines but those that are 
methylated.  Uracils behave differently in base pairing, preferring 
an adenine to a guanine.  Detection reactions are based either on 
hybridization to a probe that contains G (detecting methylation) 
or A (detecting unmethylation) in the position of interest, or on 
PCR amplification with primers specific for the modified DNA. 
The amplification product is sequenced, and will contain a C if 
the original DNA was methylated or a T if it was unmethylated.
For the manual chemical reaction, 1 µg DNA (50 µL, final 
volume) was denatured with 5.7 µL of 3 M NaOH (37ºC, 10 min), 
then incubated with 33 µL of 16 mM hydroquinone and 530 µL 
of 4M sodium bisulphite (NaHSO
3
; Sigma) pH 5.0 (50ºC, o/n). 
After purification by Wizard DNA-Clean Up kit (Promega) and 
elution in 50 µL H
2
O, the reaction was terminated with 5.7 µL 
of 3 M NaOH (37ºC, 15-20 min).  DNA was precipitated by 
adding 1 µL glycogen (10 mg/mL) solution, 17 µL of 7.5 M 
ammonium acetate and 450 µL cold absolute ethanol.
Bisulphite sequencing of multiple clones.  DNA 
methylation was determined by PCR analysis.  The region of 
interest was amplified from modified DNA with standard PCR, 
using primers designed by Methyl Primer Express Software 
(primer table).  PCR products were analysed in 2% agarose 
gel electrophoresis and DNA was extracted using QIAquick 
Gel Extraction Kit and ligated into a pGEM-T easy plasmid. 
The plasmid was transformed in competent bacterial cells by 
the heat shock method and the transformation was plated onto 
LB/ampicillin/IPTG/X-Gal plates.  A minimum of six white 
colonies of each sequence and sample were processed by 
miniprep (Montage Plasmid MiniprepHTS 96 Kit, Millipore) 
and plasmids were sequenced automatically to determine 
their degree of methylation.  Sequences were aligned with the 
Figure I-11.  Bisulphite 
modification reaction.
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Bioedit program and T (unmethylated) and C (methylated) were 
counted manually in potentially methylated CpG sites.
DNA methylation profiling using bead arrays
Goldengate arrays.  The GoldenGate Methylation Cancer 
Panel I spans 1,505 CpG loci selected from 807 genes of which 
28.6% contain one CpG site per gene, 57.3% contain two CpG 
sites, and 14.1% have three or more sites.  Selected genes fall into 
various classes, including tumour suppressor genes, oncogenes, 
genes involved in DNA repair, cell cycle control, differentiation, 
apoptosis, X-linked, and imprinted genes.  For each CpG site, 
four probes were designed: two allele-specific (ASO) and two 
locus-specific oligonucleotides (LSO).  Each ASO–LSO pair 
corresponded to either the methylated or unmethylated state of 
the CpG site (Fig. I-12).
Bisulphite conversion of DNA samples was done using the 
EZ DNA methylation kit (Zymo Research).  After bisulphite 
treatment, remaining assay steps were performed exactly using 
Illumina-supplied reagents and conditions.  Once processed, 
image analysis and intensity data extraction were performed to 
obtain a value for the fluorescent signals from the methylated and 
unmethylated allele spot.  Background intensity computed from 
a set of negative controls was subtracted from each analytical 
data point.  The ratio of fluorescent signals was then calculated 
from the two alleles: a relative methylation value was quantified 
and standardized over a range from 0.0 to 1.0 (effectively 0% 
and 100% likelihood of gene promoter hypermethylation, 
respectively).  In this study, all sequences with at least 70% 
likelihood of hypermethylation (hybridization signal ≥ 0.7) 
were considered hypermethylated for each specific sample, 
whereas sequences whose equivalent signal was below 30% 
(hybridization signal < 0.3) were considered hypomethylated.
To identify gene promoters that could be hypermethylated 
in a large number of samples of a specific group (hESC, NTT, 
and CCL), we selected all sequences whose hybridization signal 
was ≥ 0.7 in at least 25% of the samples for each group.  In 
general, sequences were classified by a stepwise algorithm. 
First, according to the percentage of hESC hypermethylated in 
each specific probe set; sequences that were hypermethylated 
in ≥25% and <25% of samples were therefore considered 
hypermethylated and unhypermethylated, respectively. 
Figure I-12.  Goldengate assay workflow.  (A) Only the top 
strand of the genomic DNA sequence of interest is shown. If 
other CpG sites are present in the vicinity of the target CpG 
site, it is assumed that they have the same methylation status 
as the site of interest. (B) Through a bisulphite conversion 
step, unmethylated cytosines are converted to uracils, while 
methylated cytosines remain unchanged.  (C) For each CpG 
site, two pairs of probes are designed: an ASO (gold) and a 
LSO (green) probe pair for the methylated state of the CpG 
site and a corresponding ASO-LSO pair for the unmethylated 
state. Pooled oligos anneal to the target sequence. All loci 
are assayed simultaneously.  (D) Extension occurs from 
the matched ASO toward the LSO.  (E) Ligation (purple) of 
the extended ASO to the corresponding LSO created PCR 
templates. The ligated products are then amplified by PCR 
using fluorescent-labelled common primers, and hybridised to 
a bead array bearing the complementary address sequences.  
(F) The Illumina code (blue) contained within the LSO is 
hybridised to a complementary sequence on the bead array. 
Two fluorophores are then used to distinguish methylated from 
unmethylated loci. Locus one above shows an unmethylated 
site, locus two semi-methylated, and locus three, fully 
methylated. (from the Illumina website)
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Sequences were then tested for hypermethylation in hCCL 
and classified according to the percentage (≥ 25% or < 25%) 
of hypermethylated samples in each probe set.  Finally, the 
percentages of normal tissue types that were hypermethylated 
in each probe set were calculated, and sequences were classified 
as hypermethylated in all normal tissue types (100% of samples 
with signal ≥ 0.7), unmethylated in all normal tissue types 
(100% of samples with signal < 0.3) or unmethylated in some 
but not all samples (signal < 0.3 in at least one, but not all, 
samples).  This algorithm allowed most sequences in the array 
to be assigned to one of the 12 groups described in Table 2.  To 
determine the enrichment for a specific histone modification, all 
sequences were classified according to publicly available data 
on histone modification and Polycomb occupancy (Lee et al., 
2006a; Mikkelsen et al., 2007; Zhao et al., 2007).  A χ-square test 
was performed to identify significant differences in frequencies 
between the groups of sequences.  Up to 27 tests were conducted 
so that Bonferroni-adjusted, two-tailed probabilities of < 0.0018 
(0.05/27) were considered significant.
Infinium Methylation Assay.  The HumanMethylation27 
BeadChip interrogates 27,578 CpG sites per sample at single-
nucleotide resolution, in the proximal promoter regions of 
transcription start sites of 14,475 consensus coding sequencing 
(CCDS) in the NCBI Database (Genome Build 36).
In addition, 254 assays cover 110 miRNA promoters.  On 
average, two assays are present per CCDS gene and from 3 to 
20 CpG sites for >200 cancer-related and imprinted genes.  The 
assay is performed in a very similar way to that described above. 
After bisulphite conversion (Fig. I-13), each sample 
was whole-genome amplified (WGA) and enzymatically 
fragmented.  The product was later purified and processed 
following manufacturer’s instructions.  During hybridisation, 
the WGA-DNA molecules anneal to locus-specific DNA 
oligomers linked to individual bead types.  The two bead types 
correspond to each CpG locus —one to the methylated (C) 
and the other to the unmethylated (T) state.  Allele-specific 
primer annealing was followed by single-base extension using 
dinitrophenol- and biotin-labeled ddNTP.  After extension, the 
array was fluorescently stained, scanned, and the intensities 
of the unmethylated and methylated bead types measured.  To 
obtain DNA methylation values, analysis was performed using 
BeadStudio software (Illumina).  DNA methylation beta values 
are continuous variables between 0 and 1, representing the ratio 
of the intensity of the methylated bead type to the combined 
locus intensity.
mRNA quantification
RNA extraction and real-time RT-PCR analysis.  Total 
RNA was isolated with TRIzol Reagent (Invitrogen).  Cell 
pellets were resuspended in 1 ml TRIzol and, after addition 
of 200 µl chloroform and phase extraction of RNA, aqueous 
phase was isolated.  RNA was precipitated with isopropanol and 
finally resuspended in H
2
O, after which 2 µg of total RNA were 
treated with Turbo RNAse-free DNAse (Ambion; 37ºC, 10 min) 
and reverse-transcribed using the High Capacity cDNA Reverse 
Transcription Kit according to manufacturer’s protocols. 
Approximately 1/100 of the RT reaction (corresponding to 20 
ng of original RNA) was normally tested in triplicate in real-
time PCR.  Quantitative real-time RT-PCR was performed in 
Figure I-13.  Infinium assay scheme.  The Infinium Methylation 
Assay uses two different bead types to detect CpG methylation.  
The U bead type matches the unmethylated CpG site; the M 
bead type matches the methylated site.  In the top panels, 
the unmethylated CpG target site matches with the U probe, 
enabling single-base extension and detection.  It has a single-
base mismatch to the M probe, which inhibits extension.  If 
the CpG locus of interest is methylated (bottom panels), the 
reverse occurs. (From the Illumina website)
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some cases (see primer table) using 2X TaqMan PCR Master 
Mix and TaqMan Gene Expression Assays, pre-designed 
validated assays containing a primer pair and a TaqMan probe 
for the transcript of interest (Applied Biosystems).  In other 
cases, we performed q-RT-PCR with SYBR Green Universal 
PCR Master Mix, associated with primers we designed with 
Primer Express software, generally extracting from the Ensembl 
database the most abundant transcript sequence for each gene 
and choosing an amplicon overlapping an exon-exon junction, 
to avoid amplification in possible genomic DNA contamination 
(see primer table for primers and assays).  Some samples were 
assayed by the low-density TaqMan Human and Mouse Stem 
Cell Pluripotency Array and the ABI PRISM 7900 sequence-
detection system (Applied Biosystems).  These low-density 
cards are pre-loaded with 96 validated Taqman assays.  The 
Pluripotency Arrays contain 6 control genes, 42 genes related 
to pluripotency and 50 differentiation genes.  These cards are 
loaded with diluted cDNA-2 X Taqman Master Mix with a 
microfluidic system that allows automatic sample distribution 
in all 384 wells by centrifugation.
mRNA stability assay.  Cells were treated with 5 µg/ml 
actinomycin D (Sigma) at the times indicated and immediately 
resuspended in TRIzol reagent for RNA extraction.
mRNA immunoprecipitation.  Pellets were homogenized 
in lysis buffer [100 mM KCl, 5 mM MgCl
2
, 10 mM Hepes, pH 
7.0, 0.5% Nonidet P-40, 1 mM dithiothreitol (DTT), RNase 
OUT (100 U/ml), and complete protease inhibitor cocktail 
(1:1000)], centrifuged and protein concentration was measured 
in the supernatant using the Bradford assay.  Fresh whole-cell 
lysate was first precleared with 15 µg IgG1 mouse control (BD 
Pharmingen), and 25 µl of beads (protein A-Sepharose, Sigma; 
4ºC, 30 min).  Beads were incubated overnight with 30 mg 
of IgG1 or anti-HuR antibody (Santa Cruz Biotechnologies), 
washed twice using NT2 buffer (50 mM Tris-HCl, pH 7.4, 
150 mM NaCl, 1 mM MgCl
2
 and 0.05% Nonidet P-40) and 
incubated with the cleared lysate (4°C, 1 h).  The pellet was 
washed four times in NT2 buffer, then resuspended in 100 µl 
NT2 buffer containing 20 U RNase-free DNase I (Invitrogen; 
37°C, 15 min), washed with NT2 buffer, and eluted in 100 µl 
NT2 buffer containing 0.1% SDS and 0.5 mg/ml proteinase 
K (Roche; 55°C, 15 min) and collected.  RNA was extracted 
with acid phenol-chloroform and precipitated overnight in the 
presence of 5 µl glycoblue (Ambion), 25 µl sodium acetate pH 
5.2, and 625 µl 100% ethanol.
Protein detection and analysis
Western blot analysis.  For protein analysis, cells were 
lysed with RIPA (50 mM Tris HCl, pH 8, 150 mM NaCl, 1% 
NP-40, 0.5% sodium deoxycholate, 0.1% SDS, complete 
protease inhibitor cocktail) or directly in Laemmli buffer (4X 
= 4% SDS, 20% glycerol, 10% BME, 0.004% bromophenol 
blue and 0.125 M Tris-HCl, pH 6.8) and analysed by Western 
blot.  SDS polyacrylamide gel electrophoresis (PAGE) was 
performed using gels with a polyacrylamide concentration 
ranging from 8% to 12% (up to 15% for histone H4), based on 
the size of the protein to be detected.  Protein were transferred to 
PVDF membranes (Immobilon, Millipore) by semi-dry transfer 
(Biorad or Invitrogen) and, after blocking with 5% fat-free milk 
(Difco), were incubated with primary antibodies to α-tubulin 
(Sigma-Aldrich), SirT1, phospho-Ser27 SirT1, p53, acetyl-
lysine-382 of p53, OCT4 and SOX2 (all from Cell Signaling 
Technologies), acetyl-K16 of histone H4 (Active Motif), HuR 
and V5 (Invitrogen), methyl-HuR  (Li et al., 2002), CARM1 
(Biovision), NANOG (R&D Biosystems) and E-cadherin 
(Becton Dickinson).  Secondary antibodies used were HRP 
conjugated-anti-mouse IgG, -rabbit IgG and -goat IgG 
(Amersham).  Membranes were later developed with ECL or 
ECLplus reagents (Amersham) and exposed to autoradiography 
films (Agfa or Amersham).  To purify nuclear and cytoplasmic 
fractions, cytosolic proteins were first extracted by incubating 
the cell pellet in RSB buffer (10 mM Tris, pH 7.4, 10 mM NaCl, 
3 mM MgCl
2
, 0.1% NP40, complete protease inhibitor cocktail) 
for 15 min on ice with gentle vortexing, then separated from the 
nuclear pellet by centrifugation.
Immunofluorescence.  EB were suspended in 50 µL HF 
(Hank's Balanced Salt Solution [Invitrogen], 2% FBS), fixed 
and permeabilised with 100 µL Intraprep Reagent 1 (Beckman 
Coulter; 37°C, o/n).  After washing five times each for 1 h with 
HF 4% BSA, EB were resuspended in 100 µL Intraprep Reagent 
2 and 5 µL 4% BSA with the appropriate primary antibody 
(37°C, o/n).  They were then washed 5 times, resuspended in 
100 µL HF with 5 µL 4% BSA with the secondary antibody. 
For imaging, hEB were dispensed onto a microscope slide, 
mounted in a drop of Mowiol (10% (w/v) Mowiol (Sigma), 
25% glycerol (w/v) and 0.1 M Tris-HCl, pH 6.8, 2.5% DABCO 
(v/v)), then covered with a coverslip.  hEB were then imaged 
by laser-scanning confocal microscopy.  Adherent cells were 
fixed in 3.7% formaldehyde (10 min, 37°C), washed 3x in PBS, 
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permeabilised with 100% methanol (3 min, RT), washed 3x in 
PBS, and blocked (1 h) in PBS with 5% BSA.  Primary antibody 
was added in 2% BSA in PBS and incubated 2 h.  Cells were 
then washed 3x in PBS and secondary antibody was added 
in PBS with 10% FBS.  Cells were then incubated (2 h, RT), 
washed 3x in PBS, and imaged in Mowiol.  The first antibody 
was anti-SirT1, followed by Alexa448 goat anti-rabbit IgG 
(Molecular Probes).
HuR phosphorylation assay
Phosphorylated-HuR (Ser) was immunoprecipitated using 
an agarose-conjugated anti-phosphoserine antibody (Sigma). 
Samples were homogenised in modified RIPA buffer (50 mM 
Tris-HCl, pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 150 
mM NaCl, 1 mM EDTA, complete protease inhibitor cocktail, 
complete phosphatase inhibitor cocktail, 1 mM orthovanadate, 
1 mM NaF), and 100 µg of total protein were incubated 
overnight with 25 µl agarose-conjugated anti-phosphoserine in 
a total volume of 500 µl.  Immunoprecipitated HuR was washed 
three times with lysis buffer and the pellet dissolved in SDS 
sample buffer, boiled (95°C, 5 min), and after centrifugation 
the supernatants was loaded onto polyacrylamide gels.  Finally, 
HuR phosphorylation (immunoprecipitation) was detected 
by Western blot using an anti-total HuR monoclonal antibody 
(Santa Cruz Biotechnology).
High-performance liquid chromatography (HPLC). 
Histones were prepared by acid extraction of protein from the 
cell pellet by two rounds of lysis in 0.25 M HCl (o/n, 4ºC) 
followed by centrifugation and acetone precipitation.  Once 
total basic protein was obtained, histone H4 was purified by 
reverse-phase HPLC on a Jupiter C18 column (Phenomenex) 
with an acetonitrile gradient (20−60%) in 0.3% trifluoroacetic 
acid, using a HPLC gradient system (Beckman-Coulter).
Top-down mass spectrometry.  High-resolution mass 
measurements for exact mass determination were carried 
out using an APEX Qe Fourier transform mass spectrometer 
(Bruker Daltonics) equipped with a 9.4 tesla superconducting 
refrigerated cryomagnet and external electrospray ion source 
(Dual source).  The spectra were externally calibrated with 
Arginine cluster in positive ion mode in the mass range 350–
1400 m/z.  The stock solutions of histone samples were diluted 
1:20 in 50% methanol + 0.2% formic acid and introduced into 
the electrospray ion source using a syringe pump with a flow 
of 2 µL/min.  Spectra were acquired over a mass range of 200–
3000 m/z using 1M data points.  After sine apodization, spectra 
were processed with DataAnalysis 3.4 (Bruker Daltonik GmbH) 
using SNAP2 for quantification.
Transfection, heterologous protein expression and 
knockdown
RNA interference.  siRNA transfection mix was prepared 
by separately adding 5 µl 20 mM siRNA (small interference 
RNA; see primer table) to 75 µl OptiMEM (Gibco) and 1.5 
µl Lipofectamine RNAiMAX (Invitrogen) to another 75 µl 
OptiMEM aliquot.  After 5 min, diluted siRNA was mixed 
with Lipofectamine, mixed and incubated 1 h to allow complex 
formation.  For siRNA transfection in hESC, a single cell 
suspension was generated.  hESC flasks were washed with 
PBS and treated with Accutase (Millipore) diluted 1:10 in 
PBS (3 ml per T75 flask).  After several minutes incubation 
at RT, with tapping and constant checking for colony 
disgregation, incubation was terminated when colonies were 
nearly completely disgregated, but neither the feeders nor the 
differentiated edges.  The cell suspension was collected and 
attached cells were washed again with PBS.  Remaining clumps 
in the suspension were disgregated by pipetting and cells were 
passed through a cell strainer (40 µm) to eliminate clumps and 
feeders.  After centrifugation, cells were resuspended in mTeSR 
(Stem Cell Technologies) at 37ºC.  Finally, cells were counted 
and brought to a final concentration of 2.5 x 105 cells/ml, seeded 
at 0.5 ml/well in a Matrigel (BD Biosciences)-precoated 12-well 
plate, and 150 µl siRNA mix was added immediately, drop by 
drop, and further mixed by gentle tapping.  After 24 h, mTESR 
medium was substituted daily for three or four days.
For EB formation, the same transfection protocol was 
scaled up to P-100 plates.  At day 2 post-transfection, cells were 
scraped and aggregates resuspended in EB formation medium 
as above.  These aggregates were collected at days 3 and 8 post-
Eb induction.
Plasmid construction and transfection.  The full-
length HuR cDNA was obtained from RZPD Deutsches 
Ressourcenzentrum für Genomforschung GmbH.  The HuR 
(WT)-V5 was constructed by PCR amplification using 
the 5´oligonucleotide containing the V5 tag sequence and 
subcloned into pCDNA 3.3 TOPO vector (Invitrogen).  The HuR 
(R217K)-V5 and HuR (R217A)-V5 mutants were constructed 
using the QuickChange kit for site-directed mutagenesis 
(Stratagene) with two complementary oligonucleotides and 
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the pCDNA-HuR (WT)-V5 plasmid as template.  Primers 
are shown in the primer table.  All plasmids were cloned by 
competent bacteria transformation, as described in the bisulphite 
sequencing section, and final plasmids for hESC transfection 
were obtained with the Genopure Plasmid Midi kit (Roche).  For 
plasmid transfection, Shef-1 hESC were prepared as a single 
cell suspension as described in the siRNA interference section. 
Cells (2 x 106) were pelleted for each reaction and transfected 
with 4 µg plasmid using the Human Stem Cell Nucleofector 
kit 2 (Amaxa; Lonza) with the transfection programme A-23 
and following supplier’s instructions.  Nucleofected hESC were 
seeded in 6-well Matrigel-coated plates and maintained for 3 
days in mTESR1, with daily medium changes.
Chromatin analysis
Chromatin immunoprecipitation.  Samples for ChIP 
assay were collected by fixing with 1% formaldehyde final 
concentration (Sigma) for 15 min, then arresting the reaction 
with glycine (0.125 M final concentration), washing twice with 
PBS supplemented with complete protease inhibitor cocktail, 
and resuspended in SDS lysis buffer (1% SDS, 10 mM EDTA, 
50 mM Tris-HCl, pH 8.1; 200 µl/106 cells).  After lysis (10 
min, on ice), lysates were sonicated in a Branson Sonifier 450 
bath (Diagenode; 20 min at maximal intensity, 30 sec on/off 
cycles).  Soluble sonicated chromatin was then separated by 
centrifugation from cell debris and approximate concentration 
measured by Nanodrop (260 nm).  Chromatin (5-10 µg) were 
then diluted 1:10 in ChIP dilution buffer (0.01% SDS, 1.1% 
Triton-X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.1, 167 
mM NaCl ) and immunoprecipitated (o/n, 4ºC) with 5-10 µg 
antibody [anti-acK9H3 (Millipore), -AcK16H4, -SirT1 and 
anti-H3 (Abcam)].  Immune complexes were collected with 
Salmon Sperm DNA/Protein A Agarose-50% Slurry (1 h, 80 
µl/sample), washed sequentially with low salt (0.1% SDS, 1% 
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 150 mM 
NaCl), high salt (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 
20 mM Tris-HCl, pH 8.1, 500 mM NaCl), LiCl (0.25 M LiCl, 
1% NP40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl, 
pH 8.1) and TE (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) 
buffers, then eluted with 500 µl elution buffer (1% SDS, 0.1 M 
NaHCO
3
), decrosslinked (0.2 M NaCl, o/n, 65ºC), treated with 
Proteinase K (0.01 M EDTA, 0.04 M Tris-HCl, pH 6.5, and 20 
mg Proteinase K; 1 h, 45ºC), phenol-chloroform-extracted and 
precipitated.
ChIP-on-chip.  For the ChIP-on-chip assay, we used the 
Agilent Human Promoter ChIP-on-chip Microarray Set.  It 
contains, in two 244K chips, probes that cover from -5.5 kb 
upstream to +2.5 kb downstream of the transcription start sites 
for ~17,000 of the best-defined human transcripts represented 
by RefSeq, sourced from UCSC hg18 (NCBI Build 36.1, March 
2006).  SirT1-immunoprecitated DNA (4 µg) fragments and the 
corresponding unbound fractions were Cy3- and Cy5-labelled 
and hybridised to the array slides at the CNIO Genomic facility, 
following manufacturer’s instructions (Fig. I-14).  Results were 
analysed using the Agilent DNA Analytics program (Lee et al., 
2006a).  In Table S13, we show the probes considered positive 
after applying feature extraction protocol, setting the following 
criteria: (i) blank subtraction normalization, maximum distance 
(in bp) for two probes to be considered neighbours = 500; (ii) a 
probe is considered bound if P[X bar] <10−3 and either central 
probe of the peak has P[X] < 10−3 and at least two neighbouring 
probes have P[X] <10−2 or at least one of the neighbours has 
P[X] < 5·10−3.  Gene ontology was examined with DAVID 
(Dennis et al., 2003) (Huang et al., 2009), a web-based tool. 
Results are shown in Table S14 as a GO chart and in Table S15 
as GO clustering.
Figure I-14.  ChIP on chip flowchart. From Agilent website.
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Quantitative ChIP.  q-PCR reactions on immunoprecipitated 
DNA were performed with human-specific primers, designed 
with the Primer Express software to amplify the genomic region 
surrounding the SirT1-binding probe for each gene, 2X SYBR 
Green PCR Master Mix using the 7900HT Fast Real-Time PCR 
System (Applied Biosystems).  The enrichment factor refers to 
the copy number of a gene of interest in the bound fraction after 
ChIP with the appropriate antibody, divided by the corresponding 
copy number of that gene in the unbound form for that antibody. 
For SirT1, immunoprecipitation data are expressed as the 
percent enrichment of the SirT1 immunoprecipitated sample 
relative to the negative control (no antibody).  For histone mark 
immunoprecipitation, where two samples (ES and EB) were 
compared, data were further normalised for the total histone H3 
signal.

RESULTS
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RESULTS
PART I:  DNA methylation in hESC differentiation and 
developmental gene activation
DNA methylation study by amplification of intermethylated 
sites in hESC differentiation
We first approached the study of DNA methylation changes 
during human embryonic stem cell differentiation in vitro 
through the AIMS technique.  We used DNA from hESC Shef-1 
and I3 and their differentiated counterparts (Shef-1 embryoid 
bodies [EB] and I3 neural precursors [NP]).  AIMS is based 
on the differential enzymatic digestion of genomic DNA with 
methylation-sensitive and -insensitive isoschizomers, followed 
by restrained PCR amplification of methylated sequences. 
Further processing allows visualization of amplified DNA 
on a sequencing gel and identification of bands of interest by 
cloning and sequencing.  We observed several bands whose 
unequal appearance indicated distinct methylation status in the 
undifferentiated-differentiated pair (Fig. 1).
By cloning and sequencing these bands, we identified 23 
methylated sites, eight of which appeared to be differentially 
methylated in at least one cell line (Table 1), five of them 
were identified as repetitive sequences, in which methylation 
is concentrated mainly in the genome, and two were mouse 
sequences, probably due to DNA contamination from MEF, used 
as feeders in the hESC culture.  This method was not suitable 
for genomic analysis in our system, and the CpG identified were 
too often found in repetitive sequences or in intergenic regions 
for which a functional correlation with gene expression was 
improbable.  We therefore turned to other, more global methods 
using a promoter-focused approach.
Promoter methylation profiling in hESC, normal tissues and 
cancer using Goldengate array
We scaled up the analysis to determine which promoters are 
regulated by DNA methylation during hESC differentiation, 
using Goldengate Methylation Arrays, Cancer Panel 1 (Illumina). 
These commercial arrays contain 1,505 sequences (from 807 
genes) chosen on the basis of their importance to cell behaviour 
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Figure 1.  AIMS analysis of genomic DNA from undifferentiated embryonic stem cells (ES) and differentiated embryonic bodies 
(EB) or neural precursor (NP) samples of Shef-1 and I3 cell lines.  Control DNA samples of normal lymphocyte (NOR) and 
tumour tissue (TUM) are shown for each gel (right).  Sequenced bands cited in Table 1 are indicated (arrow); letters refer to 
nomenclature in Table 1, first column.
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in cancer and differentiation, and include genes reported to be 
differentially methylated, as well as tumour suppressor genes, 
oncogenes and genes coding for factors involved in cell cycle 
check point.  The main advantages of this assay are that it 
permitted simple, rapid analysis of a considerable number 
of samples, rendering statistical analysis possible, and the 
promoter-directed design.  In this platform, we compared DNA 
methylation status in eight independently isolated hESC lines 
and 21 normal human primary tissues (NPT) corresponding to 
six normal tissue types (NTT).  As this array is cancer-directed, 
we included 21 human cancer cell lines (CCL) to determine 
whether the hESC promoter methylation profile resembles 
that observed in cancer cells (Bibikova et al., 2006).  Given 
the variety of sample origins, we selected autosomal genes 
(766) from the arrays to exclude DNA methylation-dependent 
X-inactivated genes (Fig. 2).
Unsupervised clustering of the samples using exclusively 
the methylation signals of the autosomal genes contained in 
the arrays (1,421 sequences) enabled correct classification 
of each sample within its corresponding group (hESC, NPT, 
or CCL) (Fig. 2), confirming that each sample group has a 
specific DNA methylation signature (Bibikova et al., 2006). 
An overall appraisal of the array results confirmed that some 
genes are repressed by promoter hypermethylation during hESC 
differentiation, but this phenomenon is uncommon among the 
genes represented in this array.  On the contrary, we determined 
that a considerable proportion (12.5%, 177/1421) of gene probes 
undergo demethylation during ES differentiation to at least one 
normal tissue.  Moreover, a large proportion of these genes are 
hypermethylated in cancer.  We thus classified the gene probes in 
the array relative to their methylation status in the three sample 
types (hESC, CCL, and NPT), in a way that we consider helpful 
for understanding both the process of promoter demethylation 
during hESC differentiation and the possible relationship 
between hESC and cancer promoter hypermethylation (Fig. 3A; 
Tables 2 and S2).  We found that 65.31% (928/1,421) of the 
sequences were not frequently hypermethylated in hESC (array 
signal ≤ 0.7 in ≥ 25% (2/8) of samples) and that half (464/928) 
were frequently hypermethylated in CCL (array signal > 0.7 in 
≥ 25% (6/21) of samples).  The vast majority of these sequences 
(99.78%, 463/464) were unmethylated in at least one NTT 
Name Chromosome
Adjacent gene 5’ or 
containing sequence
Adjacent gene 3’
Differential 
methylation
AIMS_CTA_AB 9 3115: ZMYND19 12137: ARRDC1
AIMS_CTA_AC rep   
AIMS_CTA_AD 11 126: FAM99A 30386: KRTAP5-6
AIMS_CTA_AG Mm6   
AIMS_CTA_M rep   Yes
AIMS_CTA_O rep   Yes
AIMS_CTA_P rep   Yes
AIMS_CTA_R1 5 127449: FLJ44606 144559: MEGF10
AIMS_CTA_R2 6 JARID2  
AIMS_CTA_T 10 RSU1  
AIMS_CTA_V Mm11   
AIMS_CTA_Z 3 BOC  Yes
AIMS_CTG_B 2 HDAC4  Yes
AIMS_CTG_G 11 123528: MYEOV 222452: CCND1
AIMS_CTG_H 8 28526: HOOK3 8708: FNTA
AIMS_CTG_H3 17 6051: CRLF3 1408: ATAD5
AIMS_CTG_I 10 546166: GLRX3 367378: TCERG1L
AIMS_CTG_L 11 123: FAM99A 30386: KRTAP5-6 Yes
AIMS_CTG_M X 58798: KLF8 220390: UBQLN2
AIMS_CTG_N 2 147984: SERPINE2 250328: FAM124B
AIMS_CTG_N2 19 GNA11  
AIMS_CTG_Q rep   Yes
AIMS_CTG_Q2 16 ATP2A1  Yes
Table 1.  Identification of sequenced bands in AIMS gels (Fig. 1).  Chromosomal location and distance from adjacent 5’ 
and 3’ genes are shown; where no distance is indicated, the sequence falls within the gene cited.
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hESC hNPT hCCL IVD
Figure 2.  Unsupervised cluster analysis of hESC, hCCL, and NPT based on correlation of methylation profiles of 1,421 
sequences.  Methylation levels vary from fully methylated (red) to fully unmethylated (white) sequences.  The last two rows 
correspond to in vitro-methylated DNA (IVD), used as a positive control for methylation.
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analyzed (array signal < 0.3 in ≥ 1/6 NTT).  This finding is 
consistent with the view that genes aberrantly hypermethylated 
in cancer (i.e., not hypermethylated in normal tissues) are not 
hypermethylated in hESC (Ohm et al., 2007).  We called this 
group of genes classical Class A cancer hypermethylated genes 
(Tables 2 and S1).
We found that 34.69% (493/1,421) of the sequences were 
frequently hypermethylated in hESC; most of these (79.72%, 
393/493) were also frequently hypermethylated in CCL.  Again, 
many (32.32%, 127/393) were unmethylated in at least one of 
the NTT analysed (Fig. 2; Tables 3 and S1).  In contrast to Class 
A cancer hypermethylated genes, those of this group were also 
frequently hypermethylated in hESC; we thus propose that they 
form a distinct category, which we have termed Class B cancer 
hypermethylated genes.  Of the 697 sequences frequently 
hypermethylated in cancer and unmethylated in at least one 
of the NTT analyzed, 444 (66.70%) and 127 (18.22 %) were 
classified as Class A and Class B genes, respectively (Fig. 3A; 
Tables 2 and S2).  This indicates, contrary to predictions, that 
a substantial proportion (~20%) of cancer methylated genes is 
also frequently hypermethylated in hESC.
Not all genes frequently hypermethylated in CCL were 
completely unmethylated in all NPT analysed (Fig. 3; Tables 
2 and S1).  Hypermethylation frequency in NPT is only of 
moderate importance for Class A cancer methylated genes, as 
most of them (78.83%; 350/444 sequences) are unmethylated in 
NPT.  On the other hand, only 20 sequences corresponding to 
Class B genes were unmethylated in all NTT analysed (Table 2).
When a gene is methylated in some but not all normal tissues, 
this methylation is probably involved in the specification of a 
tissue type during development (Zhao et al., 2007).  If the gene 
is not hypermethylated in hESC, tissue type-dependent selective 
methylation must occur; in contrast, if the gene is frequently 
hypermethylated in hESC, it is probably selectively demethylated 
upon differentiation, as an epigenetic mechanism that facilitates 
tissue specification.  Conversely, when a gene is unmethylated 
in all normal differentiated cells and hypermethylated in stem 
cells, the loss of promoter methylation that necessarily occurs 
during differentiation is more likely to be involved in early 
differentiation processes than in tissue specification (Zhao et 
al., 2007).  We therefore defined two subcategories for both 
Class A and B cancer methylated genes: subcategory I for genes 
always unmethylated in normal tissues, and subcategory II for 
genes sometimes methylated in normal tissues (Fig. 3; Tables 2 
and S2).  The percentage of Class A-II and B-II genes is quite 
similar (7.53% and 6.61%; Table 2).  The percentage of genes 
in Class A-I (24.63%) is nonetheless much higher than that in 
Class B-I (1.41%).  Genes in these four categories (A-I, A-II, 
B-I, B-II) represent 58.2% of all sequences in the methylation 
arrays.  Considering the methylation status of the three groups 
(hESC, NPT and CCL), we clustered most remaining genes 
in the array into eight additional categories (Table 2).  These 
included, for example, two categories of genes that we define as 
being constitutively methylated (methylated in hESC, CCL and 
all NTT; 11.19%) or constitutively unmethylated (unmethylated 
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Figure 3.  DNA methylation profiling in hESC, NPT and CCL.  (A) Methylation profiles of Class A-I (350), A-II (94), B-I (20), 
and B-II (107) genes in hESC (8), NPT (21), and CCL (21) samples obtained in Illumina arrays.  The methylation levels varied 
from fully methylated (red) to fully unmethylated (white).  The right-hand columns show the methylation status of histone H3 
and Polycomb occupancy of the same genes obtained from previously published data (Lee et al., 2006a; Mikkelsen et al., 2007; 
Zhao et al., 2007).  Blue, methylation at K4 and K27; orange, methylation at K4 alone; green, no methylation at K4 or K27; 
black, presence of the Polycomb protein SUZ12.  (B) Enrichment of Polycomb protein SUZ12, the bivalent chromatin signature 
(K4/K27) or the absence of both marks (none) in Class A and B genes (top), and Class I and II genes (bottom).
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in hESC, CCL, and all NTT; 28.43%).  We suggest that DNA 
methylation is not important for regulation of the genes in 
these categories.  The classification of genes according to their 
methylation status in hESC, CCL and NTT, and the interpretation 
of the biological role of DNA methylation in the genes in each 
group is summarized in Table 2.  Table S2 lists the genes in each 
group.
It is important to note here that all the previously described 
percentages refer to the 807 genes included in methylation 
arrays, whereas the overall percentage of genes in each group 
might be different if the entire genome were considered.  The 
classification threshold that we employed to identify genes 
frequently hypermethylated in hESCs (more than 70% of 
promoter CpG methylation in more than 25% of samples 
analyzed)  is that which is commonly used to define a gene as 
being frequently hypermethylated in cancer (Fraga et al., 2008). 
To assess whether our observations hold true for astringent 
classification thresholds we re-examined our data in search of: 
i) sequences hypermethylated in most of the hESCs analyzed 
(array signal > 0.7 in ≥ 75% (6/8) of the hESCs) and, ii) 
sequences “fully methylated” in some of the hESCs analyzed 
(array signal > 0.8) in ≥ 25% (2/8) of the hESCs (Table S3).  We 
found that 5 B-I and 84 B-II sequences fitted the first criterion, 
and 13 B-I and 86 B-II sequences fitted the second (Table S3), 
which indicates that our conclusions remain valid even with 
these stricter classification thresholds.
Prolonged in vitro culture of hESC is associated with 
instability of DNA methylation (Allegrucci et al., 2007; Maitra 
et al., 2005).  To assess whether promoter hypermethylation of 
Class B genes is associated with the in vitro culture process, 
we compared our data with those of Bibikova et al. (Bibikova 
et al., 2006).  These authors used the Goldengate methylation 
platform to compare the methylation status of the 1505 CpG 
sites contained in the arrays in 10 hESC lines at low and high 
passage numbers.  Although they found methylation changes 
with passage number, these changes were small compared to 
the differences among cell types.  They found that five genes 
(ASCL2, GALR1, MEST, NPY, and SLC5A8) were consistently 
hypermethylated with passage number (increase in methylation 
level > 0.34 in at least two cell lines (20%)).  Three of those 
genes (ASCL2, NPY, and SLC5A8) are members of Class B-I, 
but none was a Class B-II gene.  This comparison suggests that 
prolonged in vitro culture was only responsible for promoter 
hypermethylation of a small fraction of Class B genes (3/97, 
3%), and that the effect was greater in Class B-I genes.
It was recently proposed that developmental genes are 
silenced in ESC by a Polycomb-dependent bivalent histone-
based chromatin mark (Bernstein et al., 2006; Lee et al., 
2006a), which is thought to predispose to aberrant DNA 
promoter hypermethylation of TSG in cancer (Ohm et al., 2007; 
Schlesinger et al., 2007; Widschwendter et al., 2007).  As we 
found that a subset of cancer methylated genes can also be 
methylated in hESC, we investigated the relationship between 
promoter hypermethylation and the Polycomb-dependent 
histone modification pattern in hESC.  We compared our 
methylation data for Class A-I, A-II, B-I, and B-II genes with the 
previously reported histone modification profile and Polycomb 
occupancy of the same genes in embryonic stem cells (Lee et 
al., 2006a; Mikkelsen et al., 2007; Zhao et al., 2007) (Fig. 2; 
Table S4).  Consistent with an earlier report (Widschwendter 
et al., 2007), we found that ~35% of the sequences frequently 
hypermethylated in cancer and unmethylated in at least one 
of the NTT analysed contained chromatin-repressive marks at 
their promoters (228-277/697 harboured meK27, and 236/697 
contained SUZ12).  Comparison of our methylation data with 
those of Mikkelsen et al. (Mikkelsen et al., 2007), we observed 
that the great majority (96.4%) of genes harbouring meK27 also 
contained meK4, and that only ~30% of the genes frequently 
hypermethylated in cancer presented the bivalent chromatin 
domain (trimethyl-K4/ trimethyl-K27) in hESC (Table S4).
When we compared chromatin patterns and Polycomb 
occupancy in the Class A-I, A-II, B-I, and B-II genes, we 
found that each group had a specific chromatin signature (p < 
0.00001).  Class A genes were more enriched in Polycomb and 
bivalent marks (47.5% and 45.5-57.3% of genes, respectively) 
than Class B genes (19.7% and 21.4-32.7%, respectively) (p 
< 0.00001) (Fig. 3B; Table S5).  Enrichment of the bivalent 
mark in Class A genes is primarily due to the low levels of this 
chromatin signature in Class B-II genes (Table S4).  Levels 
of meK4/meK27 in Class B-I genes were similar those in 
Class A genes (p < 0.00001; Table S5).  Class II genes were 
much less frequently occupied by Polycomb proteins and had 
fewer bivalent marks (33.3% and 26.5-38.8%s, respectively; 
p < 0.00001) than did Class I genes (45.7% and 47.6-59.3%, 
respectively; Fig. 3B; Table S5).  Lower levels of the bivalent 
mark in Class II genes were due primarily to the low levels of 
this chromatin signature in Class B-II genes (Table S5); Class 
A-II genes had similar meK4/meK27 levels to those of Class I 
genes (p < 0.00001; Table S5).  We thus conclude that class B-II 
gene promoters are depleted of both histone marks and are likely 
to be kept silenced in hESC by promoter hypermethylation 
61RESULTS
rather than a Polycomb-dependent, histone modification-based 
mechanism.
TSG repressed by promoter hypermethylation in hESC
To test the hypotheses based of the data from methylation 
arrays, we focused on four Class B genes (frequently 
hypermethylated in cancer and hESC) widely reported to 
have tumour suppressor properties and that are frequently 
hypermethylated in cancer.  We selected two (MGMT [O-6-
methylguanine-DNA methyltransferase], SLC5A8 [solute carrier 
family 5 (iodide transporter), member 8]) (Esteller et al., 2000; 
Li et al., 2003) from Class B-I (unmethylated in all NTT) and 
two (PYCARD [PYD and CARD domain containing], RUNX3 
[runt-related transcription factor 3]) (Conway et al., 2000; Li 
et al., 2002c) from Class B-II (unmethylated in a number of 
NTT).  We first used bisulphite sequencing of multiple clones 
to determine accurately the promoter DNA methylation status 
of these genes in hESC and normal primary tissue (Fig. 4-8). 
In all cases, bisulphite sequencing data corroborated the array 
results and showed that hypermethylation in hESC affected the 
majority of CpG surrounding the transcription start-site of the 
genes selected. MGMT and SLC5A8 showed dense promoter 
hypermethylation in hESC, but not in normal differentiated 
tissues (Fig. 4A, B, Fig. 5A, B, Fig. 6A, B), whilst Class B-II 
genes were frequently hypermethylated in hESC and sometimes 
in normal tissues (Fig. 7A, B, Fig. 8A, B).  To better understand 
the role of promoter hypermethylation of these TSG in hESC 
and NTT, we used quantitative real time PCR (q-RT-PCR) to 
A B
0
0.2
0.4
0.6
0.8
1
%
 re
la
tiv
e
m
et
hy
la
tio
n
0
40
80
120
160
200
I3
H1
4
Po
ol 
lym
ph
oc
yte
s
No
rm
al 
bre
as
t
U9
37
MD
A-
MB
-23
1
%
 re
la
tiv
e 
ex
pr
es
si
on
 
V
s 
G
A
P
D
H
hESCs Normal Cancer
MGMT
MGMT
I3
Pool
lymphocytes
Normal
breast
H14
hESCs
Normal primary tissues
-390 bp
-65 bp
U937
MDA-MB-231
Cancer cell lines
Figure 4.  Promoter DNA hypermethylation and MGMT repression in hESC.  (A) Bisulphite genomic sequencing of multiple 
clones of the MGMT promoter in hESC (I3, H14), NPT (pooled lymphocytes, normal breast) and two CCL of lymphoid and 
breast origin (U937 and MDA-MB-231, respectively).  Black, methylated CpG; white, unmethylated CpG; red, CpG not present. 
The green bar above the diagram of the MGMT CpG island indicates the location of the probe used in the methylation arrays.  
(B) Relationship between MGMT promoter hypermethylation and expression in hESC, NPT, and CCL.  We show the relative 
methylation signal obtained with methylation arrays (top) and MGMT mRNA expression levels relative to GAPDH (bottom).
62 EPIGENETIC REGULATION OF DEVELOPMENT62
MGMT
Shef-1
H181
I3
Pool
lymphocytes
Pool
neutrophils
Shef-4
H14
Shef-7
Brain
MRC5
hESC
Normal primary tissues
-390 bp
-65 bp
Heart
0
0.2
0.4
0.6
0.8
1
1.2
S
he
f-
1
S
he
f-
4
S
he
f-
5
S
he
f-
7 H
7
H
14
H
18
1 I3
P
oo
l l
ym
ph
oc
yt
es
P
oo
l n
eu
tr
op
hi
ls
Le
uc
oc
yt
es
 F
1
Le
uc
oc
yt
es
 F
2
Le
uc
oc
yt
es
 F
3
Le
uc
oc
yt
es
 F
4
Le
uc
oc
yt
es
 M
1
Le
uc
oc
yt
es
 M
2
Le
uc
oc
yt
es
 M
3
Le
uc
oc
yt
es
 M
4
M
us
cl
e 
1
M
us
cl
e-
2
M
us
cl
e-
3
M
us
cl
e-
4
M
us
cl
e-
5
M
us
cl
e-
6
B
re
as
t-
1
B
re
as
t2
H
ea
rt
1
H
ea
rt
2
B
ra
in
M
D
A
-M
B
-2
31
-1
M
D
A
-M
B
-2
31
-2
H
C
C
19
37
B
T
-4
74
H
C
T
11
6
D
LD
1
S
W
48
-1
S
W
48
-2
H
C
T
11
5-
1
H
C
T
15
-2
Lo
V
o
C
o1
15
H
T
29
R
K
O
H
L6
0-
1
H
L6
0-
2
R
A
JI
-1
R
A
JI
-2
U
93
7-
1
U
93
7-
2
A
K
A
T
A
F
A
R
A
G
E
K
A
R
P
A
S
R
A
M
O
S
S
iH
a
C
as
K
i
H
eL
a
IV
D
-1
IV
D
-2
%
 r
el
at
iv
e 
m
et
h
yl
at
io
n
hESC Normal primary tissues Cancer cell lines
0
50
100
150
200
Sh
ef
-1 
Sh
ef
-4
Sh
ef
-5
Sh
ef
-7 H7 H1
4
H1
81 I3
Po
ol 
lym
ph
oc
yte
s
Po
ol 
ne
ut
rop
hil
s
Br
ain
He
ar
th
Liv
er
Lu
ng
Co
lon
Br
ea
st
Lim
ph
 no
de
hESC Normal primary tissues
%
 r
el
at
iv
e 
ex
pr
es
si
o
n 
to
po
ol
 ly
m
ph
oc
yt
es MGMT/GAPDH
Class B-I: MGMTA
B
C
Figure 5.  MGMT methylation status in hESC, NPT and CCL.  (A) MGMT gene methylation profile obtained by Illumina arrays 
and expressed as relative methylation from fully unmethylated (0) to fully methylated (1).  (B) Bisulphite genomic sequencing 
of multiple clones of the MGMT promoter in hESC and NPT.  Colour code as for Fig. 4.  (C) Relative expression of MGMT in 
hESC and NPT.  q-RT-PCR data are normalised to GAPDH expression and presented as a percentage of normal lymphocytes 
(100%).
SLC5A8
-137 bp
+152 bp
E1
Shef-1
H181
I3
Pool
lymphocytes
Pool
neutrophils
Shef-4
Shef-5
H14
Shef-7
Brain
MRC5
hESC
Normal primary tissues
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
S
he
f-
1
S
he
f-
4
S
he
f-
5
S
he
f-
7 H
7
H
14
H
18
1 I3
P
oo
l l
ym
ph
oc
yt
es
P
oo
l n
eu
tr
op
hi
ls
Le
uc
oc
yt
es
 F
1
Le
uc
oc
yt
es
 F
2
Le
uc
oc
yt
es
 F
3
Le
uc
oc
yt
es
 F
4
Le
uc
oc
yt
es
 M
1
Le
uc
oc
yt
es
 M
2
Le
uc
oc
yt
es
 M
3
Le
uc
oc
yt
es
 M
4
M
us
cl
e 
1
M
us
cl
e-
2
M
us
cl
e-
3
M
us
cl
e-
4
M
us
cl
e-
5
M
us
cl
e-
6
B
re
as
t-
1
B
re
as
t2
H
ea
rt
1
H
ea
rt
2
B
ra
in
M
D
A
-M
B
-2
31
-1
M
D
A
-M
B
-2
31
-2
H
C
C
19
37
B
T
-4
74
H
C
T
11
6
D
LD
1
S
W
48
-1
S
W
48
-2
H
C
T
11
5-
1
H
C
T
15
-2
Lo
V
o
C
o1
15
H
T
29
R
K
O
H
L6
0-
1
H
L6
0-
2
R
A
JI
-1
R
A
JI
-2
U
93
7-
1
U
93
7-
2
A
K
A
T
A
F
A
R
A
G
E
K
A
R
P
A
S
R
A
M
O
S
S
iH
a
C
as
K
i
H
eL
a
IV
D
-1
IV
D
-2
%
 r
el
at
iv
e 
m
et
h
yl
at
io
n
hESC Normal primary tissues Cancer cell lines
900000
1200000
 
  
 0
10000
20000
30000
40000
Sh
ef
-1 
Sh
ef
-4
Sh
ef
-5
Sh
ef
-7 H7 H1
4
H1
81 I3
Po
ol 
lym
ph
oc
yte
s
Po
ol 
ne
ut
rop
hil
s
Br
ain
He
ar
th
Liv
er
Lu
ng
Co
lon
Br
ea
st
Lim
ph
 no
de
hESC Normal primary tissues
%
 r
el
at
iv
e 
ex
pr
es
si
o
n 
to
po
ol
 ly
m
ph
oc
yt
es
SLC5A8/GAPDH
Class B-I: SLC5A8A
B
C
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Figure 7. PYCARD hypermethylation in hESC.  (A) PYCARD gene methylation profiles obtained by Illumina arrays and expressed 
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for Fig. 4.  (C) Relative expression of PYCARD in hESC and NPT.  q-RT-PCR data are normalised to GAPDH expression and 
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measure their expression in both sample groups (Fig. 4C, 5C, 
6C, 7C, 8C).
Promoter hypermethylation was always associated with 
gene repression, but its absence in somatic primary tissues 
did not necessarily involve the upregulation of the gene; for 
example, whilst SLC5A8 was hypomethylated in all normal 
tissues analyzed (Fig. 6A), it was only overexpressed in brain, 
liver, and colon (Fig. 6B).
Loss of promoter hypermethylation and gene activation 
during hESC differentiation in vitro
To demonstrate further that hESC differentiation is 
associated with less DNA methylation at the promoter region 
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Figure 10.  Loss of promoter DNA methylation during hESC differentiation in vitro.  (A) Number of sequences hypomethylated 
during Shef-1 neural (red circle) and spontaneous (blue circle) differentiation, and their overlap with Class B-I and B-II genes 
(black circles).  (B)  Bisulphite genomic sequencing of multiple clones of the DLC1 promoter in Shef-1 stem cell line (top), 
and the same cells after neural differentiation (centre) and spontaneous differentiation to fibroblast-like cells (bottom).  The 
colour code is as for Figure 4.  (C) Relationship between DLC1 promoter hypermethylation and expression during Shef-1 
differentiation.  Relative methylation signal obtained with the methylation arrays (top) and DLC1 mRNA expression levels 
relative to GAPDH (bottom).
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of certain genes, we induced in vitro differentiation of the hESC 
line Shef-1 in two cell lineages (fibroblast-like cells [F-L] and 
neural precursors; Fig. 9A).  We assessed lineage specification 
using previously published markers (Cai et al., 2006) (Fig. 9A, 
right), then used methylation arrays to identify genes that were 
hypomethylated during differentiation.  We found that 12.98% 
(37/285) of the genes hypermethylated in Shef-1 (which were 
not methylated in all NTT analysed) were demethylated during 
in vitro differentiation.  Of these, 12 genes were demethylated 
during neuron differentiation and 25 during F-L differentiation 
(Table S6).  Three of these genes were common to both groups 
(Fig.10A), two of which belonged to Class B-II.  Whilst 9/25 
of the genes demethylated during F-L differentiation were 
Class B-II, none of the 12 genes demethylated during neuron 
differentiation belonged to this category.  To show that some 
TSG that are frequently hypermethylated in cancer and hESC 
can lose methylation during differentiation, we focused our 
attention on DLC1 (deleted in liver cancer 1), chosen because 
the methylation arrays showed that it lost promoter methylation 
during F-L differentiation of Shef-1, and because it is a TSG 
that is frequently hypermethylated in cancer (Fig. 11) (Ying et 
al., 2007; Yuan et al., 2003).
Bisulphite sequencing of multiple clones corroborated 
methylation array results and showed that the DLC1 promoter 
is hypermethylated in Shef-1 and is demethylated during 
spontaneous, but not neural, differentiation (Fig. 10B).  In q-RT-
PCR experiments, DLC1 was poorly expressed in the Shef-1 
cells and was overexpressed during spontaneous, but not neural 
differentiation (Fig. 10C).
TSG repressed by promoter hypermethylation in 
haematopoietic stem cell progenitors
Having shown that some cancer genes are hypermethylated 
and repressed in hESC, and that they can lose methylation 
during hESC differentiation in vitro, we studied whether 
this phenomenon is restricted to embryonic development 
or, conversely, is an epigenetic mechanism associated with 
stemness status regardless of the cell ontogenetic stage.  We 
used methylation arrays to identify genes hypermethylated in 
CD34+ somatic stem cell progenitors compared to peripheral 
blood lymphocytes and neutrophils, two types of adult primary 
cells derived from CD34+ haematopoietic progenitors.  We 
identified 362 hypermethylated sequences in CD34+ cells (array 
signal > 0.7) (Table S7).
The great majority of these sequences (92.27%, 334/362) 
were also methylated in hESC, and most of these sequences were 
frequently hypermethylated in CCL (83.43%, 302/362) (Fig. 
12A; Table S6).  These results suggest that the hypermethylation 
of cancer genes can occur in stem cells regardless of ontogenetic 
stage (embryo vs. adult).  We next identified nine sequences 
that were hypermethylated in CD34+ cells relative to peripheral 
lymphocytes, and 16 sequences that were hypermethylated in 
these progenitor cells relative to neutrophils (Table S8).  Most of 
the sequences identified were also frequently hypermethylated 
in hESC (8/9 for lymphocytes, 14/16 for neutrophils) and CCL 
(6/9 for lymphocytes, 13/16 for neutrophils).  There were no 
sequences common to lymphocytes and neutrophils; most of 
these sequences and were occasionally hypermethylated in 
NPT.  Of these sequences, 28 had previously been classified as 
Class B-II genes, whilst none was from Class B-I (Fig. 12A).
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Figure 11. DLC1 hypermethylation in hESC. DLC1 gene methylation profiles obtained by Illumina arrays and expressed as 
relative methylation, from fully unmethylated (0) to fully methylated (1).
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Finally, to demonstrate that some cancer hypermethylated 
genes are also frequently hypermethylated in somatic progenitor 
stem cells and that their methylation is important for lineage 
specification, we evaluated two genes, RUNX3 and AIM2. 
RUNX3 was selected because, in accordance with published 
data (Kang et al., 2007), our methylation arrays showed that 
relative to CD34+ cells, RUNX3 was hypomethylated in 
peripheral lymphocytes and less so in peripheral neutrophils. 
AIM2 was chosen as it is frequently hypermethylated in cancer 
(Fig. 13) (Woerner et al., 2007) and because, unlike RUNX3, it 
is demethylated specifically in the myeloid lineage (Fig. 11B, 
C).  The bisulphite sequencing data confirmed the array results, 
showing that CD34+ cells and peripheral lymphocytes were 
densely methylated at the AIM2 promoter, whilst the peripheral 
neutrophils were almost unmethylated (Fig. 12B).  To determine 
the role of AIM2 and RUNX3 promoter hypermethylation in 
haematopoietic differentiation, we used qRTPCR to analyze 
their expression in our groups of samples (Fig. 12C). In both 
genes, promoter hypermethylation was always associated with 
gene repression, and loss of promoter methylation in AIM2 and 
RUNX3 was associated with their re-expression in peripheral 
lymphocytes and neutrophils, respectively (Fig. 4C).
Whole genome promoter DNA methylation analysis by 
Infinium Array
To extend our analysis of promoter methylation changes 
during cell differentiation, we used the more complete 
HumanMethylation27 BeadChip Infinium Methylation Array, 
which provides quantitative methylation measurement at 
27,578 CpG loci covering 14,495 gene promoters or regulatory 
regions.  This includes a large part of the genes characterised in 
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Figure 12.  Cancer genes hypermethylated in somatic stem 
cells.  (A) Numbers of sequences hypermethylated in CD34+ 
cells and hypermethylated in hESC and CCL (left panel).  Note 
that most sequences hypermethylated in somatic stem cells 
are also hypermethylated in hESC.  Number of sequences 
hypermethylated in CD34+ cells (black circle) classified as 
Class B-II genes (red circle).  Sequences hypermethylated in 
CD34+ cells were never classified as Class B-I genes (blue 
circle) (right panel).  (B) Bisulphite genomic sequencing of 
multiple clones of the AIM2 promoter in Shef-1 and I3 stem 
cell lines (top), CD34+ haematopoietic stem cell progenitors 
(centre), and terminally differentiated haematopoietic cells 
(peripheral lymphocytes and neutrophils; bottom).  Colour 
code as for Fig. 4.  (C) Relationship between AIM2 and 
RUNX3 promoter hypermethylation and expression in 
CD34+ cells and terminally differentiated haematopoietic 
cells (peripheral lymphocytes and neutrophils).  Top panels, 
relative methylation signal in the methylation arrays; bottom 
panels, AIM2 and RUNX3 mRNA expression levels relative to 
GAPDH.
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the human genome that possess CpG in their promoter both at 
high and at low density (Table S9).
We compared the DNA methylation status of 10 distinct 
undifferentiated hESC lines and 10 differentiated normal 
tissues (1 brain, 3 colon, 2 sperm, 2 total blood, 1 lymphocyte 
sample and 1 neutrophil sample), and focused analysis on 
genes that undergo demethylation during differentiation (Table 
S10).  Again, due to the different origin of each sample, we 
excluded sex chromosome-linked genes to avoid interference 
of Xinactivation-dependent methylation.  We identified 7513 
sequences corresponding to 4962 genes (35% of the total 
array) hypermethylated in stem cells (array signal > 0.7 in ≥ 
40% (4/10) of the samples).  Here we used stricter criteria, 
because the larger number of starting genes would yield gene 
populations in numbers suitable for statistical analysis.  Of 
these hESC hypermethylated sequences, we identified 1954 
sequences, corresponding to 1582 distinct gene promoters, 
that become unmethylated (array signal < 0.3) in at least one 
normal tissue.  This corresponds to 11.4% (1585/13890) of the 
total genes in the array and to 31.9% (1585/4962) of all genes 
hypermethylated in stem cells.  After performing gene ontology 
analysis through the DAVID interface, we observed that 
biological function and cellular localisation of gene products are 
not distributed stochastically.  Biological processes concerning 
immune-related functions such as immune response, defence 
response to bacteria, and inflammatory response are strongly 
enriched, as is cellular localisation in the plasma membrane or 
extracellular region (Table 3).  Many of these genes seem to have 
a characterised function in the definition of the mesodermal-
derived tissues, such as the immune system and muscle. 
Moreover, many of these genes have a signal peptide and are 
localised in the external part of the membrane or are secreted. 
Eighty percent (1268/1585) of the probes are classified by the 
Illumina array spreadsheet as false CpG islands, meaning that 
the promoters have a low CpG density in the region surrounding 
that of interest.  Loss of methylation during differentiation in 
vivo to normal tissue thus appears to be quite a frequent feature 
in the genome.
Whole genome DNA methylation analysis of in vitro 
differentiation to mesodermal lineage
To expand our analysis of DNA methylation in in vitro 
differentiation, we specifically analysed promoter demethylation 
in Shef-1 differentiation to a mesodermic lineage, as we had 
with the Goldengate platform.  Here we compared Shef-1 
undifferentiated ES cells and their differentiated counterpart, 
fibroblast-like cells (F-L), selecting probes whose array 
methylation signal shows >40% change between the two 
samples (Table S11).  We found that 217 probes, corresponding 
to 202 genes, are demethylated specifically in this lineage 
differentiation, corresponding to 12.7% (202/1575) of the genes 
previously identified as demethylated during differentiation to 
normal tissue.  Only 25 genes were found to be hypermethylated 
during this process.  Gene ontology processing showed that 
these genes are enriched in the same biological function and 
cellular localisation as the genes discussed above, which 
encode mainly membrane and extracellular proteins related 
to immune system function (Table 4).  We also found genes, 
transcription factors or chromatin-regulating genes involved 
in regulation of mesodermal-immune differentiation, such as 
RUNX1 and HDAC9, in addition to the previously described 
GO TERM (Biological process)  Nº of genes p value 
GO:0006955~immune response 196 1.04E-48 
GO:0006952~defense response 157 4.48E-30 
GO:0042742~defense response to bacterium 35 8.95E-12 
GO:0006954~inflammatory response 73 7.53E-11 
GO:0009617~response to bacterium 49 1.71E-10 
GO TERM (Cell component)    
GO:0005576~extracellular region 301 1.12E-17 
GO:0005886~plasma membrane 464 2.50E-14 
GO:0005887~integral to plasma membrane 202 9.08E-12 
GO:0031226~intrinsic to plasma membrane 203 2.51E-11 
GO:0044459~plasma membrane part 312 7.84E-10 
 
Table 3. GO terms significantly enriched in hESC hypermethylated genes 
undergo demethylation during in vivo differentiation.
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DLC1.  Comparison of our gene list with published data on 
promoter occupation by the PRC2 subunit Suz12 (Lee et al., 
2006a) and on the presence of the bivalent mark (Zhao et al., 
2007) showed that only 11 genes (0.6%) are PRC2 targets in 
hESC cells, and only 6 (0.3%) display a bivalent mark, whereas 
137 (68%) showed neither of the two marks (trimethyl-K4 
and trimethyl-K27).  There is thus a certain percentage of late 
developmental genes, most with a function in mesodermal 
lineage and/or the immune system, that are repressed in stem 
cells whose promoter, even if not CpG-dense, is hypermethylated 
in embryonic stem cells; other repression marks like Polycomb 
repression and the bivalent mark are mostly absent.  These 
genes can be demethylated during differentiation both in vivo 
and in vitro, and this phenomenon is likely to be related to the 
regulation of their expression in mesodermal-immune system 
differentiated cells.
DNA methylation alteration due to prolonged hESC culture 
in vitro
Using this larger Infinium platform, we were interested 
in further quantitative analysis of how in vitro maintenance 
of hESC alters the epigenetic status in terms of promoter 
methylation.  Previous reports showed that some genes can 
be hypermethylated after prolonged stem cell culture in vitro, 
but that these changes were not extensive and appeared to be 
cell line-dependent rather than a common feature (Allegrucci 
et al., 2007; Maitra et al., 2005). hESC cultured for an large 
passage number are often subject to a phenomenon termed 
culture adaptation, that implies many genetic, phenotypic, and 
biochemical changes.  We analysed promoter DNA methylation 
from two pairs of cell lines, at low and high passage number 
(Table S12).  The original low passage cells showing a “normal” 
phenotype were H7S14 and H14S9, and their “adapted” 
counterparts H7S6 and H14BJI; both normal clones are estimated 
to be at passage ~30-35, while adapted clones are cultured for 
more than 100 additional passages (Baker et al., 2007; Enver 
et al., 2005).  We found that 205 genes were hypermethylated 
(array signal difference > 40%) and 67 genes were demethylated 
in adapted compared to normal H7 cells; similarly, 197 genes 
were hypermethylated and 153 genes demethylated in adapted 
compared to normal H14 cells.  This indicates that in both cell 
lines, ~2% of the genes in the Infinium platform are subject to 
alterations in DNA methylation.  Only 34 genes (~15%) are 
commonly hypermethylated in these two cell lines, and only 3 
are demethylated in both; there is thus apparently a low degree 
of coincidence in the aberrant mechanisms that lead to promoter 
hypermethylation.  Gene ontology analysis for these gene groups 
showed that both hypermethylated genes in adapted vs. normal 
H7 and H14 cells are significantly enriched for transcription 
factor containing a Zn++ finger domain (in particular C2H2; 
17 for H7 and 44 for H14; Table 5).  This probably indicates 
that this protein family is prone to hypermethylation during 
prolonged hESC culture in vitro.  Demethylated genes showed 
no tendency toward a specific gene ontology term.
GO TERM (Biological process)  Nº of genes p value 
GO:0006955~immune response 24 3.43E-06 
GO:0006952~defense response 21 2.69E-05 
GO:0042742~defense response to bacterium 9 3.97E-05 
GO:0009617~response to bacterium 11 6.83E-05 
GO:0002684~positive regulation of immune 
system process 
12 7.37E-05 
GO TERM (Cell component)    
GO:0005887~integral to plasma membrane 29 4.52E-04 
GO:0005576~extracellular region 42 5.04E-04 
GO:0031226~intrinsic to plasma membrane 29 6.34E-04 
Uniprot sequence feature    
disulfide bond 70 4.00E-13 
glycosylation site:N-linked (GlcNAc...) 82 2.33E-10 
signal peptide 71 2.36E-10 
 
 
 
Table 4. GO terms significantly enriched in genes demethylated during in vitro differentiation to F-L.
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 H14 H7 
GO TERM (Biological process)  genes p value genes p value 
GO:0006350~transcription 52 1.38E-15 32 1.29E-04 
GO:0034961~cellular biopolymer biosynthetic process 55 2.31E-13 34 1.72E-03 
GO:0043284~biopolymer biosynthetic process 55 2.70E-13 34 1.83E-03 
GO:0045449~regulation of transcription 51 3.65E-11 33 2.62E-03 
GO TERM (Cell component)      
GO:0008270~zinc ion binding 52 4.22E-13 30 3.82E-04 
GO:0003677~DNA binding 49 4.58E-11 33 3.26E-03 
UNIPROT SEQUENCE FEATURE      
zinc finger region:C2H2-type 8 40 5.39E-34 14 6.54E-06 
zinc finger region:C2H2-type 7 40 1.01E-32 14 1.47E-05 
zinc finger region:C2H2-type 10 36 4.69E-32 14 6.04E-07 
 
Table 5. GO terms significantly enriched in genes hypermethylated during hESC culture adaptation.
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PART II: Histone modification in hESC differentiation and 
developmental gene activation
Global histone H4 acetylation increase during differentiation
To study new pathways in chromatin regulation during 
stem cell differentiation, we began with analysis of histone 
modifications during in vitro differentiation.  As described in 
the introduction, a specific histone mark signature characterises 
hESC, based on methylation of histone H3 (methylated at 
K4 and K27 the bivalent domain) (Bernstein et al., 2006). 
Nevertheless, there are few data on histone acetylation, an 
important modification in the regulation of gene expression. 
We first studied global acetylation of histone H4 by HPLC 
purification of total H4, and top-down mass spectrometry of this 
purified histone (Fig. 14).  We found that the profile of the H4 
sample from Shef-1 ES differed from that of EB after 14 days 
of differentiation.  The most relevant difference was observed 
in the peaks corresponding to the mono- and diacetylated forms 
of this histone, which appear higher in the EB.  Acetylation 
on H4 is thought to occur sequentially (Clarke et al., 1993; 
Turner, 1989) and involves residues K16, K12 and K8/K5; 
H4K16 is thus probably responsible for the difference observed. 
This residue is specifically deacetylated by SirT1, an enzyme 
implicated in differentiation of several cell types; we therefore 
examined whether SirT1 has a role in hESC differentiation.
SirT1 downregulation during hESC differentiation
To study the putative role of SirT1 in hESC differentiation, 
we measured SirT1 mRNA levels during the course of in vitro 
differentiation of the Shef-1 and H-181 hESC lines.  Withdrawal 
of basic fibroblast growth factor (bFGF) and feeder cells causes 
spontaneous differentiation of both of these lines into embryonic 
bodies (EB) (Li et al., 2009).  At 15 days after the induction of 
differentiation, SirT1 mRNA levels were 60% lower in Shef-1 
cells and 50% lower in H-181 cells (Fig. 15, top).  Consistent 
with this, there was a marked reduction in SirT1 protein levels in 
15-day EB compared to hESC (Fig. 15, bottom), in accordance 
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Figure 14. Top-down mass spectrometry analysis of HPLC-
purified histone H4 in Shef-1 cells, undifferentiated (ES) 
and differentiated to embryo bodies for 14 days (EB).  Peaks 
represent signal intensity at a defined mass-to-charge (m/z) 
ratio. Higher peaks represent distinct acetylation levels 
(arrows indicate mono- and diacetylated forms), while lower 
peaks are probably due to other modifications, particularly 
methylation.
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Figure 15.  Downregulation of SirT1 during hESC differentiation. q-RT-PCR analyses of SirT1 mRNA levels in hESC (ES) cells 
and 15-day EB (EB15) from Shef-1 and H-181 lines (top).  Results are represented as the amount of SirT1 mRNA relative to 
control GAPDH mRNA.  Western blot analysis of the same samples (bottom) using anti-SirT1 antibody and anti-α-tubulin as 
loading control.
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with previous findings in mice (Kuzmichev et al., 2005).  To 
further characterise SirT1 downregulation during hESC 
differentiation, we performed immunofluorescence staining of 
SirT1 in hESC and 15-day EB.  SirT1 staining in hESC was 
mostly nuclear except during mitosis, when it was diffused 
in the cytoplasm (Fig. 16).  In 15-day EB, we found lower 
SirT1 staining levels and heterogeneous distribution within 
different cell populations (Fig. 16).  To characterise precisely 
the downregulation of SirT1 during hESC differentiation, we 
assessed RNA and proteins levels in a time-course experiment 
during spontaneous differentiation of Shef-1 cells into EB and 
subsequently into fibroblast-like cells (F-L cells) (Fig. 17A). 
F-L cells were obtained by inducing EB attachment, followed 
by culture for a further 15 days (Li et al., 2009).  SirT1 mRNA 
levels decreased gradually during hESC differentiation, whilst 
SirT1 protein levels dropped markedly only 7 days after 
induction of differentiation, and remained low throughout the 
process (30 days) (Fig. 17B); this suggests that SirT1 regulation 
during hESC differentiation might occur at several levels.
SirT1
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Merged
ES EB15
75 µm
Figure 16.  SirT1 immunostaining during hESC differentiation. 
Confocal fluorescence microscopy assay showing the cellular 
localization of SirT1 (green) in Shef-1 undifferentiated hESC 
and 15-day EB.  Nuclei are stained with DAPI (blue).
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Figure 17. Time-course of SirT1 downregulation during hESC differentiation. (A) Flowchart of in vitro hESC 
differentiation . Representative images of hESC (ES), EB and F-L cells were obtained by phase-contrast microscopy. 
hESC differentiated to EB after bFGF withdrawal and growth in suspension for 15 days. F-L cells were obtained by 
attachment of EB on gelatin-coated plates and culture in DMEM + 15% FBS.  (B) Time-course expression study of 
SirT1 by q-RT-PCR (relative to GAPDH) and WB during hESC Shef-1 differentiation.  SirT1 is not detected in feeder 
cells (mitomycin C-treated MEF), which could contaminate the hESC sample.
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SirT1 mRNA stabilisation through CARM1-dependent 
HuR methylation
To study the molecular mechanisms involved in SirT1 
downregulation during hESC differentiation, we first tested 
a number of potential ways to regulate SirT1 expression, 
including SirT1 promoter epigenetic status and activity.  As the 
SirT1 promoter contains a large CpG island, DNA methylation 
is a likely candidate for the regulation of its expression.  We 
observed that SirT1 promoter is unmethylated in all conditions 
studied: in hESC Shef-1 and H-181 as well in differentiated 
EB from these cell lines, and in a differentiated tissue (PBL 
lymphocytes) (Fig. 18).
Transcriptional activity of a gene promoter 
can be evaluated by different methods, including 
the binding of RNA-Pol II, the presence of 
activation marks such as trimethyl-H3K4 or 
chromatin condensation marks such as acetylation 
of histones H3 and H4.  The first two possibilities 
were discarded in the case of embryonic stem 
cells, as it has been reported that RNA-pol and 
trimethyl-H3K4 are detectable even in inactive 
gene promoters in hESC (Efroni et al., 2008; 
Guenther et al., 2007).  We performed a q-ChIP 
assay (Fig. 19) for global acetylation as a marker 
of promoter activation in two regions of the SirT1 
promoter, and validated its suitability using a gene 
whose expression is negatively regulated during 
SIRT1 promoter
H-181 ES
H-181 EB
Shef-1 ES
Shef-1 EB
-207 bp
PBL
+45 bp
Figure 18. Methylation status of the SirT1 promoter.  
Bisulphite genomic sequencing of multiple clones of the 
SirT1 promoter in two hESC lines (H-181, Shef-1), the 
corresponding differentiated sample (EB), and peripheral 
blood lymphocytes (PBL).  Black box, methylated CpG; white 
box, unmethylated CpG.
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Figure 19.  SirT1 promoter activity. q-ChIP of 
global acetylated histone H4 and histone H3 
in Shef-1 hESC and EB.  q-PCR corresponding 
to promoters of rDNA as a negative control, 
POU5F1 (OCT4) as a positive control of 
downregulation of activation markers in 
differentiation, and two regions of the SirT1 
promoter located up- and downstream of 
the transcription start site.  Final results are 
expressed as the percentage of bound/unbound 
ratio of DNA copy number for each IP, further 
normalised with respect to total H3 enrichment, 
considered constant in chromatin.
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differentiation (POU5F1, Oct4) as well as an unregulated 
gene (rDNA, which encodes the rRNA precursor).  Whereas 
promoter acetylation of POU5F1 decreased notably during 
differentiation, neither of the SirT1 regions selected appeared 
to be deacetylated.  We therefore concluded that the main 
regulation of SirT1 expression during differentiation is not at 
the promoter level.
As SirT1 mRNA is first downregulated, once we excluded 
the mRNA synthesis rate, the other possibility for regulation 
of mRNA levels is mRNA degradation.  In cancer cells, SirT1 
mRNA stability can be regulated by the RNA-binding protein 
HuR (Abdelmohsen et al., 2007), which also has a role in cell 
differentiation (Figueroa et al., 2003); we thus hypothesised that 
HuR regulates SirT1 RNA stability during hESC differentiation. 
To test this, we examined the stability of SirT1 RNA by treating 
cells with actinomycin D to inhibit de novo transcription.  We 
monitored levels of SirT1 mRNA and the housekeeping control 
GAPDH mRNA by q-RT-PCR, and found that SirT1 mRNA 
was notably less stable in differentiating EB than in pluripotent 
hESC (Fig. 20).  GAPDH mRNA, which is not a HuR target 
(Lopez de Silanes et al., 2004), showed no differences between 
hESC and EB.  To determine whether the decrease in SirT1 
stability was due specifically to HuR, we measured the amount 
of SirT1 mRNA bound to HuR during hESC differentiation, 
using immunoprecipitation (IP) assays with an anti-HuR 
antibody in conditions that preserved HuR-mRNA complex 
composition and by monitoring RNA using q-RT-PCR.  There 
was a clear decrease in the amount of SirT1 RNA bound to HuR 
in 15-day EB compared to hESC (Fig. 21A), which suggests 
that the decrease in SirT1 RNA during hESC differentiation is 
mediated by loss of HuR/SirT1 mRNA binding.
To confirm SirT1 regulation by HuR, we depleted HuR in 
the Shef-1 hESC line with siRNA.  HuR silencing resulted in 
a marked reduction of SirT1 (Fig. 21B), further evidence of 
HuR-mediated regulation of SirT1 mRNA stability in hESC. 
HuR binding to β-catenin, another independent HuR target, also 
decreased during hESC differentiation (Fig. 22), suggesting 
that global HuR activity is also regulated during hESC 
differentiation. 
Figure 20.  mRNA stability assay.  q-RT-PCR of SirT1 
and GAPDH in Shef-1 hESC (ES) and EB at 3 days of 
differentiation, after actinomycin D treatment and collection at 
the times indicated.  Data are relative to mRNA levels at t = 0 
h for each sample.
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Figure 21.  SirT1 mRNA binds by HuR.  (A) RNA 
immunoprecipitation of HuR in hESC (ES) and EB 
differentiated for 15 days (EB15) of Shef-1 and H-181 hESC 
lines.  SirT1 levels were detected by q-RT-PCR (relative to 
GAPDH).  (B) HuR interference.  Western blot of HuR, SirT1 
and α-tubulin in Shef-1 cells, 3 days post-transfection with 
control siRNA (SCR) and HuR-specific siRNA (iHuR).
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 I : Figure 22.  HuR 
binding to β-catenin 
RNA.  RNA 
immunoprecipitation 
of HuR in hESC (ES), 
EB differentiated for 
15 days (EB15) and 
fibroblast-like cells 
(F-L) of Shef-1 and 
H-181 hESC lines. β 
catenin levels were 
detected by q-RT-
PCR (data relative to 
GAPDH).
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 To test this possibility, we measured HuR mRNA levels in 
hESC and 15-day EB, but only found minor differences between 
the two cell types (Fig. 23).  In accordance with this, the HuR 
protein level did not change during hESC differentiation (Fig. 
24, 25B).  As HuR activity was reported to be regulated by its 
nucleo-cytoplasmic shuttling (Fan and Steitz, 1998; Kim et al., 
2008a), we examined HuR cellular localization during hESC 
differentiation.  Western blot (WB) of nuclear and cytoplasmic 
extracts of hESC and 15-day EB in the Shef-1 and H-181 cell 
lines showed that, in both cases, HuR was primarily nuclear and 
its location did not change during hESC differentiation.  This 
implies that nucleo-cytoplasmic shuttling of HuR is not the main 
mechanism that regulates HuR activity in hESC.  HuR binding to 
target mRNA is regulated by CHK2-dependent phosphorylation 
in cancer cells (Abdelmohsen et al., 2007).  To determine 
whether HuR is also regulated by phosphorylation during stem 
cell differentiation, we immunoprecipitated total HuR in Shef-1 
stem cells and EB, and analysed the phosphorylation status of 
HuR using an antibody to phosphorylated serine.  Phosphorylated 
HuR levels did not change notably during hESC differentiation 
(Fig. 25A), suggesting that serine phosphorylation is not 
the primary mechanism of HuR regulation during stem cell 
differentiation.
HuR is regulated by CARM1 (coactivator-associated 
arginine methyltransferase 1)-dependent methylation at Arg217 
(Li et al., 2002a).  To determine whether HuR is regulated by 
methylation during hESC differentiation, we assessed methyl-
HuR levels in hESC and 15-day EB, and found a marked 
reduction in methylated HuR in differentiated cells (Fig. 25B).  
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Figure 23. HuR mRNA expression. Time-
course expression study of HuR by qRT-
PCR (relative to GAPDH) in hESC Shef-1 
(ES), Shef-1 EB differentiated for 7 and 14 
days (EB7 and EB14, respectively), and for 
30 days to fibroblast-like cells (F-L), H-181 
hESC and EB.
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Figure 24.  HuR localisation.  Western blot of HuR cytoplasmic 
and nuclear protein fractions of Shef-1 and H-181 hESC (ES) 
and EB.  Nucleolin and α-tubulin were used as nuclear and 
cytoplasmic markers, respectively.
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Figure 25.  HuR modification.  (A) Densitometric quantification 
of phosphorylated HuR detected after immunoprecipitation 
with an anti-phospho-Ser antibody and WB analysis in Shef-1 
ES and EB after 14 days of differentiation.  Data are relative 
to total HuR levels.  (B) Western blot of HuR cytoplasmic and 
nuclear protein fractions of Shef-1 and H-181 hESC (ES) 
and EB.  Nucleolin and α-tubulin were used as nuclear and 
cytoplasmic markers, respectively.
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To determine whether this decrease depends specifically 
on CARM1, we used three siRNA to deplete this arginine 
methyltransferase in Shef-1 hESC.  CARM1 knock-down 
resulted in the loss of methyl-HuR and in a marked decrease 
in SirT1 (Fig. 26A).  To verify that CARM1-dependent HuR 
methylation regulates SirT1 mRNA stability during hESC 
differentiation, we measured CARM1 levels in hESC and EB 
over time and determined methyl-HuR binding to SirT1 during 
hESC differentiation.  In line with our hypothesis, the decrease 
in SirT1 during hESC differentiation was associated with a 
decrease in CARM1 (Fig. 26B) and methyl-HuR binding to 
SirT1 was much lower in EB than in hESC (Fig. 26C).
To confirm that HuR methylation influences HuR binding 
to SirT1 mRNA during hESC differentiation, we compared the 
amount of SirT1 mRNA bound to HuR in Shef-1 cells transfected 
with two Arg217 HuR mutants (Arg217/Lys, Arg217/Ala) 
that are resistant to CARM1-dependent methylation to Shef-1 
cells transfected with WT HuR.  While the Arg217/Lys mutant 
mimics the unmethylated positive-charged wild type residue but 
cannot be methylated (at least by CARM1), Arg217/Ala lacks 
the entire side chain of the residue.  We performed IP assays 
using an anti-V5 antibody (an epitope tag in the WT and mutant 
HuR constructs) and a control antibody to methyl-HuR.  The 
HuR mutants that are resistant to CARM1 methylation bound 
considerably less SirT1 mRNA than did WT HuR and methyl-
HuR (Fig. 27).  These results suggest that SirT1 downregulation 
during hESC differentiation is mediated by a CARM1-dependent 
decrease in methyl-HuR/SirT1 mRNA binding.
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Figure 26.  CARM1 methylation of HuR.  (A) WB of CARM1, methyl-HuR, total HuR, SirT1 and α-tubulin in Shef-1 cells 
at day 3 post-transfection with control siRNA (SCR) and three specific siRNA oligonucleotides for CARM1 (iCARM1 
ol1, ol2, ol3).  (B) WB of CARM1 in undifferentiated Shef-1 hESC and EB differentiated for 5, 10 and 15 days (EB5, 
EB10, and EB15) and fibroblast-like (F-L) cells.  SirT1 and Oct4 (POU5F1) were detected in the same gel.  (C) RNA 
immunoprecipitation assay of methyl-HuR in hESC (ES) and EB differentiated for 15 days (EB15) of Shef-1 and H-181 
hESC.
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Figure 27.  Mutation of HuR Arg217 impedes SirT1 mRNA 
binding.  RNA immunoprecipitation assay with an anti-V5 
antibody in Shef-1 cells transfected with pCDNA3.3 plasmid 
expressing WT HuR, an R217/K or an R217/A mutant HuR 
with V5 tag (WT, R217/K and R217/A, respectively). As 
control, Shef-1 cells were transfected with an empty plasmid 
and immunoprecipitated with an antibody to methyl-HuR 
(CTR) and tested in the same conditions.
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As the drop in SirT1 protein levels appears more marked 
than that of mRNA, we studied other possible mechanisms for 
SirT1 protein level regulation.  SirT1 translation is regulated 
by miR34a (Yamakuchi et al., 2008).  We thus measured 
levels of this miRNA in our samples relative to RNU19 
(Fig. 28), whose expression is considered constant in these 
conditions (a “housekeeping ncRNA”).  This miRNA appears 
to be downregulated during hESC differentiation, excluding 
a possible role in SirT1 downregulation.  Protein stability is 
also important in the steady-state levels of SirT1 protein, and 
the JNK2-dependent phosphorylation of SirT1 in the Ser27 
correlates well with SirT1 stability (Ford et al., 2008).  We 
found that phosphorylation of SirT1 at Ser27 is downregulated, 
as is the total protein level during hESC differentiation, but 
the extent of this downregulation is slightly higher than that 
of the total SirT1 protein decrease (Fig. 29).  We thus cannot 
exclude that protein destabilisation due to inhibition of SirT1 
phosphorylation contributes to its downregulation during hESC 
differentiation.
SirT1 regulation of developmental gene promoters during 
hESC differentiation
We next investigated the role of SirT1 in hESC and the 
functional implication of its downregulation during hESC 
differentiation.  SirT1 has multiple targets, including histones 
and transcription factors, as well as other enzymes and structural 
proteins.  As our start point was a global hyperacetylation of 
histone H4 in hESC differentiation, we examined the role of 
SirT1 as a histone deacetylase.  SirT1 was recently shown to 
regulate the promoter of the MashI gene in somatic stem cell 
neural differentiation in mice (Prozorovski et al., 2008); we 
therefore focused on the direct regulation of promoter histone 
acetylation during differentiation.  We hypothesised that SirT1 
might contribute to the negative regulation of some gene 
ncRNA in pluripotent hESC, and that its downregulation could 
contribute to the correct reactivation of these genes during 
differentiation.
To identify the downstream effects of SirT1 downregulation 
in hESC differentiation, we performed chromatin 
immunoprecipitation (ChIP) experiments in Shef-1 hESC 
using an anti-SirT1 antibody.  We subsequently hybridised 
the immunoprecipitated DNA fragments on an Agilent human 
promoter ChIP-on-chip microarray containing 474,392 probes, 
which covered almost all described human promoters and many 
of the known regulatory regions.  These experiments showed 
that SirT1 bound 428 probes (0.09% of the total), corresponding 
to 353 gene promoters (since some have more than one probe 
and some are divergent promoters that regulate two genes), four 
intergenic regions and four microRNA promoters; the exact 
genomic location of each SirT1-positive probe is shown in 
Table S13.  Gene ontology (GO) analysis of the SirT1-bound 
genes showed non-random distribution, largely with respect to 
molecular function (Table 6, S14, S15).  SirT1-bound genes 
in hESC are greatly enriched (p = 1010 – 10-4, Table 5) for 
GO terms related to development and differentiation, such as 
developmental process, multicellular organismal development 
and cell differentiation (Table 6).  Of the 353 SirT1-positive 
genes, 97 (1.76-fold enrichment; p = 3.05·10-9) are described by 
the highest-ranking GO term 0032502~developmental process 
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Figure 28.  MiR34a expression in hESC differentiation.  Time-
course expression study of miR34a by q RT-PCR (relative to 
RNU19) in hESC Shef-1 (ES) and differentiation to EB for 7 
and 14 days (EB7 and EB14, respectively).
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Figure 29.  Phosphorylation of SirT1 Ser27.  Western blot 
analysis of hESC Shef-1 (ES) and EB differentiated for 7 
and 14 days (EB7 and EB14, respectively) with antibodies to 
phosphorylated-Ser27 of SirT1, total SirT1 and α-tubulin as a 
loading control.
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(Table 6).  These observations suggest that SirT1 is involved in 
the regulation of specific developmental genes in hESC.
To validate the ChIP-on-chip data, we performed ChIP 
experiments in Shef-1 hESC and EB using antibodies to SirT1 
and to AcK16-H4 and AcK9-H3, two known histone targets of 
SirT1 (Prozorovski et al., 2008; Vaquero et al., 2007b).  The 
relative abundance of specific DNA fragments within the 
immunoprecipitated chromatin was assessed by quantitative 
PCR (q-ChIP).  For this validation, we randomly selected 10 
of the 97 SirT1-positive genes classified within the GO term 
“developmental process”.  These genes were delta-like 4 
(DLL4), a Notch ligand required for normal embryonic vascular 
development; LIM homeobox 1 (LHX1), a homeodomain-
containing transcription factor (TF) involved in developmental 
processes such as axon guidance; paired box 6 (PAX6), a TF 
involved in neuroectodermal definition and oculogenesis; 
member 6 of the wingless-type MMTV integration site family 
(WNT6), a secreted glycoprotein important for myocardial 
and neural crest development; bone morphogenetic protein 
1 (BMP1), a metalloprotease that participates in embryonic 
patterning by cleaving matrix proteins and morphogens; Hairy/
enhancer of split 7 (HES7), a TF involved in somite segmentation; 
T-box 3 (TBX3), a TF that affects developmental events such as 
sinoatrial node determination, limb bud positioning and retinal 
dorso-ventral patterning; serpin peptidase inhibitor, clade E 
member 1-plasminogen activator inhibitor type 1 (SERPINE1), 
a secreted protease inhibitor regulating TGFβ and EGF 
signalling; homeobox A5 (HOXA5), a homeobox-containing 
TF important in lung, intestinal and thyroid morphogenesis 
and blood cell differentiation; and TIMP metallopeptidase 
inhibitor 1 (TIMP1), a matrix protein that regulates proteases of 
importance in development; with GAPDH and rDNA controls. 
These experiments showed that all 10 genes were enriched in 
SirT1 in hESC (significant in most cases, p<0.05; Fig. 28, 29), 
confirming the consistency of the entire ChIP-on-chip data set. 
We also observed a marked increase in 15-day EB (which have 
very low SirT1 levels relative to hESC) for the best-known SirT1 
histone targets, AcK16-H4 and AcK9-H3, in most target genes 
analysed (Fig. 30, 31).  GAPDH and rDNA controls showed 
no SirT1 enrichment or significant changes in AcK16-H4 or 
AcK9-H3.  To confirm that these genes are regulated directly 
by SirT1, we depleted its activity by siRNA in Shef-1 cells 
and used q-PCR to measure the mRNA levels of five target 
genes (DLL4, TBX3, SERPINE1, WNT6 and PAX6), with 
GAPDH as control.  SirT1 knock-down resulted in significant 
upregulation of all five targets (p<0.05; Fig. 30C), supporting 
its role in regulating selected genes in hESC.  In addition, we 
found that mRNA levels of eight genes were clearly upregulated 
in 7- and 14-day EB and in neuroectodermal cells, which are 
characterised by low SirT1 levels (Fig. 32).  Together, these 
data suggest that SirT1 regulation of specific developmental 
GO TERM (Biological process) (p<0.001) Nº of 
 
p value 
GO:0032502~developmental process 97 3.05E-09 
GO:0032501~multicellular organismal process 104 3.01E-08 
GO:0007275~multicellular organismal development 73 1.50E-07 
GO:0048856~anatomical structure development 68 2.75E-07 
GO:0048731~system development 54 1.76E-05 
GO:0009653~anatomical structure morphogenesis 39 3.54E-05 
GO:0030154~cell differentiation 53 1.08E-04 
GO:0048869~cellular developmental process 53 1.08E-04 
GO:0035270~endocrine system development 6 2.45E-04 
GO:0003008~system process 43 4.13E-04 
GO:0007154~cell communication 94 7.75E-04 
GO:0048513~organ development 38 8.78E-04 
 Table 6. GO terms significantly enriched in SirT1-bound genes
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Figure 30.  SirT1 binding and regulation of developmental gene promoters.  (A) q-ChIP of SirT1 in Shef 1 hESC.  
Enrichment relative to a chromatin sample immunoprecipitated with no antibody (NAB) for the SirT1-bound regions 
of DLL4, TBX3, SERPINE1, WNT6 and PAX6 was studied by q-RT-PCR. Final results are expressed as the percent 
enrichment of the bound/unbound ratio (DNA copy number) of the SirT1 IP relative to the NAB IP in two sets of 
ChIP experiments (ChIP1, ChIP2).  The enrichment value of the Agilent Human Promoters Array Probe (ChIP-chip 
probe) is also shown as the percentage of the normalised IP signal divided by the normalised input signal for the most 
positive probe of each gene represented (see Table S8).  Primers for q-ChIP were designed around the positive probe 
in the ChIP-on-chip array.  The GAPDH promoter was included as a negative control for SirT1 binding and histone 
modifications. (B) q-ChIP of acetyl-lysine 16 of histone H4 (AcH4K16) and acetyl-lysine 9 of histone H3 (AcH3K9) 
in Shef-1 hESC and EB cells.  q-PCR corresponding to the same genomic regions described above.  Final results are 
expressed as the bound/unbound percentage ratio (DNA copy number) for each IP and further normalised for the 
total H3 enrichment considered constant in chromatin.  (C) Expression of these genes was measured by q-PCR in 
Shef-1 hESC, 3 days post-transfection with a control siRNA (SCR) and an siRNA oligo for SirT1 (iSirT1).  Data are 
normalised with respect to GAPDH, relative to the undifferentiated hESC sample (GAPDH expression is set manually 
to 100%).
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Figure 31. ChIP-on-chip validation.  (A) q-ChIP of SirT1 in Shef-1 hESC.  Enrichment with respect to a chromatin 
sample immunoprecipitated with no antibody (NAB) for the SirT1-bound regions of BMP1, HES7, LHX1, HOXA5 and 
TIMP1 was studied by q-RT-PCR.  Final results are expressed as in Fig. 28.  The promoter of the ribosomal RNA gene 
(rDNA) was included as a negative control for SirT1 binding and histone modifications.  (B) q-ChIP of AcH4K16 and 
AcH3K9 in Shef-1 hESC and EB.  q-PCR corresponds to the same genomic regions described above.  Final results are 
expressed as in Fig. 30.
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Figure 32.  Expression of SirT1-bound genes during EB and neural differentiation.  Gene expression was measured by 
q-RT-PCR in Shef-1 hESC, in differentiation to EB at 7 and 14 days (EB7 and EB14, respectively), and in the neuron-
enriched sample derived from the in vitro differentiation to neuroectodermal cells.  Data are normalised with respect 
to GAPDH, relative to the undifferentiated hESC sample (GAPDH expression is set manually to 100%).
genes during hESC differentiation is mediated by epigenetic 
mechanisms that involve its histone deacetylase activity.
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Figure 33.  SirT1 knock-down in hESC.  (A) Western blot 
of SirT1, acetyl-lysine 382 of p53, total p53, AcH4K16 and 
α-tubulin in Shef-1, 3 days post-transfection with a control 
siRNA (SCR) and SirT1-specific siRNA (iSirT1).  (B) Western 
blot in the same samples of hESC markers Oct4, Nanog, Sox2, 
E cadherin.
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Functional role of SirT1 in lineage specification during 
hESC differentiation
To study the functional role of SirT1 downregulation 
during hESC differentiation, we used the TaqMan Human 
Stem Cell Pluripotency Array and WB to compare the relative 
expression of stemness and differentiation markers during in 
vitro differentiation of siRNA-mediated SirT1-depleted Shef-
1 cells, mouse SirT1 knockout ES cells ,and mouse ES cells 
genetically modified to overexpress SirT1 (Pfluger et al., 2008) 
with their respective wild-type controls.  SirT1 downregulation 
by siRNA resulted in increased acetylation of the SirT1 target 
p53 (Fig. 31A), consistent with previously published data (Han 
et al., 2008).  Global acetylation of H4K16, another SirT1 
substrate (Vaquero et al., 2006), remained unchanged (Fig. 
31A), further supporting the idea that SirT1 histone deacetylase 
activity is largely restricted to gene promoters (Fig. 33A). 
siRNA-mediated depletion of SirT1 did not notably alter the 
expression of the pluripotency markers OCT4, NANOG, SOX2 
and E-cadherin (Fig. 33B).  
Accordingly, SirT1 silencing during hESC differentiation 
had a greater effect on the expression of developmental markers 
(50% in 9-day EB) than on the expression of pluripotency 
markers (31% in 9-day EB) (Fig. 34).  These results are further 
evidence that SirT1 regulates specific developmental programs 
during hESC differentiation.
To study the functional role of SirT1 during ES differentiation 
in greater detail, we used several mouse ES cell (mESC) lines 
in which Sirt1 was either inactivated by deletion of exon 4 
containing the catalytic domain (Cheng et al., 2003), which we 
term Sirt1 KO, or was increased by insertion of an additional 
copy of the Sirt1 gene (Pfluger et al., 2008), termed Super-Sirt1. 
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Figure 34. SirT1 knockdown in hESC differentiation.  A Taq-
Man Human Stem Cell Pluripotency Array testing the expres-
sion of 98 genes was used to analyse Shef-1 hESC transfected 
with control (SCR) and SirT1 siRNA (iSirT1), at 2 days post-
transfection, and after 3 (EB3) and 9 (EB9) days of differentia-
tion of control and knocked-down samples.  Results are shown 
as the percentage of genes catalogued as pluripotency- or 
differentiation-related whose expression changed by more than 
two-fold between control and SirT1 knocked-down samples at 
each differentiation stage.
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Figure 35.  Sirt1 expression in mESC lines.  (A) WB analysis of Sirt1 levels in mES lines: TC1 (WT1), TC1 bearing the deletion 
of Sirt1 exon 4 (SIRT KO), mES clone with one copy of the Sirt1 gene (see Experimental Procedures) (WT2), and mES clone 
bearing extra copies of the Sirt1 gene (Super-Sirt1).  (B) WB of Sirt1 in the same mESC lines differentiated into EB for 3, 7 and 
14 days (EB3, EB7, EB14, respectively).  α-tubulin was used as a loading control.
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Figure 36.  SirT1 modulation in mESC differentiation.  (A) TaqMan Mouse Stem Cell Pluripotency Array was used to 
analyse TC1 mouse ES cells, the same cell line knocked-out for SirT1, and the same two lines differentiated in vitro to 
EB for 15 days.  Results are expressed as in Fig. 31.  (B) A TaqMan Mouse Stem Cell Pluripotency Array was used to 
study SuperSirt1 and the corresponding WT mESC, and the same two lines differentiated in vitro to EB for 15 days.  
Results are expressed as in Fig. 34.
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Figure 37.  Expression of differentiation markers in the differentiation of Sirt1 KO (Sirt1-/-) or SuperSirt1 (Sirt1+++) 
mES cells.  Three markers each for neuro-ectodermal (NeuroD1, Syp and Nes), mesodermal (Col2a1, Brachyury and 
Des) and endodermal (Fn1, Gata4 and Lama1) cells were measured by q-RT-PCR in mESC (ES) and EB at 15 days 
after induction of differentiation.  Data (relative expression) are normalised with respect to Gapdh expression, relative 
to the undifferentiated ES sample for each line. Black column, WT; grey column, Sirt1 KO; white column, SuperSirt1
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Figure 38.  Expression of pluripotency markers in differentiation of Sirt1 KO (Sirt1-/-) or SuperSirt1 (Sirt1+++) mES 
cells.  Six undifferentiated ESC markers (Fgf4, Nanog, Nodal, Rest, Tdfcp2l1 and Tdgf1) were measured by q-RT-
PCR in mESC (ES) and EB at 15 days post-induction of differentiation.  Data are normalised with respect to Gapdh 
expression, relative to the undifferentiated ES sample for each line. Black column, WT; grey column, Sirt1 KO; white 
column, SuperSirt1
Sirt1 expression was verified by WB in these mESC lines (Fig. 
35A) and during in vitro differentiation (Fig. 35B).  Genetic 
deficiency in SirT1, as well as its overexpression, had a greater 
effect on the expression of developmental markers than on that 
of pluripotency markers (Fig. 36).
We used q-RT-PCR to analyse the expression of six 
pluripotency markers (Fgf4, Tdgf1, Nanog, Nodal, Rest and 
Tdfcp2l1), three of neuro-ectoderm (NeuroD1, Syp and Nes), 
three of mesoderm (Col2a1, Brachyury and Des) and three 
of the endodermal layer (Fn1, Gata4 and Lama1) (Fig. 37, 
38).  Results showed that Sirt1 knockout or overexpression in 
undifferentiated mES cells has little impact on the expression 
of developmental markers (Fig. 37).  As previously observed 
in hESC, Sirt1 KO mES cells showed no clear alteration in the 
expression of pluripotency markers (Fgf4, Nanog, Nodal, Rest, 
Tdfcp2l1 and Tdgf1), although in this case Nanog appeared to 
be downregulated markedly. In contrast, Super-Sirt1 mESC 
notably overexpressed these pluripotency markers (Fig. 38). 
In addition, although Sirt1 KO EB showed no clear changes 
in pluripotency marker expression, Super-Sirt1 EB retained 
notable expression of these markers, which in most cases was 
comparable to their expression in WT mESC.  These results 
suggest that the functional role of Sirt1 in mouse and human ES 
cells might not be identical and that, in contrast to human ES 
cells, Sirt1 could contribute to the maintenance of pluripotency 
in mouse ES cells.
During differentiation of Sirt1 genetically modified mESC, 
we observed that both lack and overexpression of Sirt1 resulted 
in a marked alteration of most of the developmental markers 
analysed (Fig. 33), which is in accordance with our results in 
human ES cells.  The markers that showed major alterations 
were those corresponding to the neuro-ectodermal layer; all 
three markers analysed in this layer (NeuroD1, Syp and Nes) 
were overexpressed in Sirt1 KO EB and notably downregulated 
in Super-Sirt1 EB.  These findings concur with the data for 
human ES cells and indicate that, in humans and in mice, SirT1 
might have an important role in the establishment of the neuro-
ectodermal layer.
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DISCUSSION
Since its birth, epigenetics has been closely connected to 
development and differentiation.  Considering that a single cell 
generates a plethora of distinct specialised cells, all of which share 
the same genetic information, epigenetics (“above the gene”) 
must be involved in this process.  Although our knowledge of 
development-related epigenetic mechanisms has undergone an 
exponential growth in recent decades, some aspects of this field 
are still foggy.  Moreover, as epigenetics has been implicated in 
the pathogenesis of various common diseases, including cancer, 
autoimmune disease, atherosclerosis, psychiatric disturbances 
and various forms of mental retardation, detailed study of 
epigenetic processes is now central to nearly all biomedical 
fields.
DNA methylation is considered a very stable epigenetic 
modification, because it is inherited in cell division through a 
well-defined mechanism and is abundant in the promoters of 
many stably repressed genes.  In the first ontogenic steps from 
germ-line definition to early embryonic stages, it nevertheless 
undergoes radical changes.  There are two waves of genome-
wide demethylation-remethylation, which is even more 
surprising considering that there is no univocally recognised 
enzyme that catalyses DNA demethylation.  Changes are more 
subtle later in the life cycle, but many genes are still regulated 
by DNA methylation during embryonic development, and even 
during adult tissue ageing.  As a means of gene inactivation, 
methylation has been fully implicated in the process of stable 
silencing of undifferentiated stem cell-related genes, such as 
OCT4 and NANOG.  Although a considerable group of genes is 
hypermethylated in embryonic stem cells, to date, demethylation 
processes in cell differentiation have been considered of 
secondary importance.  Our principal finding in this regard 
is that expression of certain genes is regulated through DNA 
demethylation during hESC differentiation.  These genes share 
common specific functions, particularly in late differentiation 
processes of mesodermal-immune system specification.  From 
an evolutiionary perspective, this indicates that proteins with 
this specific function could have evolved to be regulated through 
DNA methylation in differentiation.
Another process in which genomic methylation is profoundly 
altered is cancer.  Aberrant DNA methylation in cancer has 
its own features, consisting of a loss of global methylation 
and hypermethylation of gene promoters, especially in genes 
whose inactivation offers an advantage for cancer progression, 
commonly termed tumour suppressor genes (TSG) (Feinberg 
and Tycko, 2004; Jones and Baylin, 2007).  Genes undergoing 
such alterations in cancer are reported to be repressed in hESC 
by the establishment an ES-specific mark, bivalent chromatin 
domains consisting of activating (H3K27 trimethylation) and 
repressing (H3K4 trimethylation) histone marks that keep 
them poised for activation while predisposing them to aberrant 
promoter hypermethylation in adult cancers (Ohm et al., 2007; 
Schlesinger et al., 2007; Widschwendter et al., 2007) (Fig. 39). 
Here we attempted to analyse another level of complexity, 
whereby some genes that are often aberrantly hypermethylated 
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Figure 39.  Classical model for bivalent domain-mediated promoter hypermethylation in cancer.  TSG promoters are 
frequently marked in hESC with the bivalent domain and are unmethylated.  Following differentiation, these genes are 
normally activated in the differentiated cell.  During tumour transformation, these promoters are aberrantly methylated 
at CpG, leading to gene silencing (based on (Ohm et al., 2007; Schlesinger et al., 2007; Widschwendter et al., 2007).
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in cancer are also frequently hypermethylated in hESC.
Based on promoter methylation status in hESC, we 
established two categories of cancer hypermethylated genes: 
Class A genes, which are frequently unmethylated in hESC, and 
Class B genes, which are frequently hypermethylated in hESC. 
As we unexpectedly found that a substantial proportion of genes 
in both groups were also frequently hypermethylated in normal 
differentiated tissues, we established two new subcategories of 
cancer hypermethylated genes: subcategory I for genes that are 
generally unmethylated in normal tissue, and subcategory II for 
genes that are generally hypermethylated in normal tissue.  The 
biological interpretation of aberrant methylation within Class A 
and B TSG and their two subcategories is completely different. 
Class A-I genes are frequently hypermethylated in cancer but 
not in normal tissues or hESC.  These genes are assumed not to 
be regulated by DNA methylation during normal development, 
and their hypermethylation in cancer would thus always 
be interpreted as aberrant.  Class A-II genes are frequently 
methylated in CCL and sometimes in normal tissues, but rarely 
in hESC.  Methylation of these genes might be important for 
lineage specification, and should be considered aberrant only 
when found in a tumour type in whose corresponding normal 
tissue it is not hypermethylated.  Class B-I genes (excluding 
ASCL2, NPY, and SLC5A8 genes, whose promoter DNA 
hypermethylation in hESC lines could be due to the culture 
process) are frequently hypermethylated in hESC and cancer 
cell lines, but never in normal tissues; this suggests that loss of 
methylation at the promoters of these genes might be important in 
the loss of pluripotency during development.  Hypermethylation 
of Class B-I genes in cancer should always be considered 
aberrant.  Class B-II genes are frequently hypermethylated 
in hESC and in cancer cells but, as they are also sometimes 
methylated in normal tissues, their hypermethylation in cancer 
should only be considered aberrant in tumour types in whose 
normal tissue counterparts they are completely unmethylated. 
The fact that not all genes frequently hypermethylated in cancer 
are completely unmethylated in all normal tissues is a very 
important finding in cancer epigenetics (Feinberg and Tycko, 
2004), because promoter hypermethylation of a gene in a 
specific tumour type should not be considered aberrant when it 
is hypermethylated in the normal counterpart.
Comparison of our DNA methylation results with previous 
data on the histone modification profile and Polycomb occupancy 
of these genes in embryonic stem cells (Lee et al., 2006a; 
Mikkelsen et al., 2007; Zhao et al., 2007) showed that only 
around one-third of the genes frequently hypermethylated in 
cancer presented the bivalent chromatin domain (trimethyl-K4/
K27H3) in hESC.  This indicates that, at least among genes 
tested here, promoter occupancy with PRC and the bivalent 
domain in stem cells can be considered predictive of and 
predisposing to cancer promoter hypermethylation for less 
than half of the genes.  Within our four gene categories, Class 
A genes were more enriched in Polycomb and bivalent marks 
than Class B genes.  This suggests that a scenario involving 
bivalent chromatin domains and Polycomb occupancy of cancer 
methylated genes in embryonic stem cells (Ohm et al., 2007; 
Schlesinger et al., 2007; Widschwendter et al., 2007) could be 
more frequent in Class A than in Class B genes.  The Class II 
genes, which we suggest are involved in lineage specification 
since their promoter methylation is tissue-dependent, were much 
less frequently occupied by Polycomb proteins and showed 
fewer bivalent marks than Class I genes, which we implicate in 
early differentiation.  Lower levels of the bivalent mark in Class 
II genes were due primarily to low levels in Class BII genes, 
implying that Class BII is relevant to lineage specification. 
Zhao et al. (Zhao et al., 2007) proposed that genes harbouring 
bivalent marks are involved primarily in early differentiation, 
whilst those that lack both are involved in lineage specification. 
We found that Class I genes are enriched in the bivalent mark 
and Class B-II genes are frequently depleted of both marks. 
Our gene ontology classification of all four classes of genes 
associated Class I genes with biological processes involved in 
early differentiation, and most Class B-II genes with lineage 
specification processes (Table S16), coinciding with the data 
from Zhao et al.
Analysis of the DNA methylation and expression status of 
four of the genes identified in the methylation arrays (MGMT 
and SLC5A8 (Esteller et al., 2000; Li et al., 2003) from Class 
B-I, and PYCARD and RUNX3 (Conway et al., 2000; Li et al., 
2002c) from Class B-II) showed that promoter hypermethylation 
was always associated with gene repression, but its absence 
in somatic primary tissues did not necessarily involve gene 
upregulation.  This was the case for SLC5A8, in which there 
was no overexpression following promoter demethylation 
in peripheral lymphocytes.  We therefore hypothesised that 
promoter hypermethylation of the Class B cancer methylated 
genes in hESC (excluding those whose promoter DNA 
hypermethylation depends on prolonged in vitro culture) can 
be a natural process used by stem cells to ensure silencing of 
genes whose expression is associated with stemness.  When 
stem cells differentiate, these genes can lose their promoter 
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hypermethylation, which would allow gene expression.  This 
does not imply, however, that the gene has necessarily been 
activated; this is shown by the fact that some of these genes 
remain repressed in differentiated tissues.  Loss of promoter 
methylation during differentiation could simply maintain 
these genes poised for activation until they are later required 
by the somatic cell.  The lack of hypomethylation-associated 
activation in some mature tissues suggests that signals other 
than the absence of methylation are necessary for activation of 
these genes.
By forcing the in vitro differentiation of the hESC line Shef-
1, we identified 12 and 25 genes that are demethylated during 
neuron and F-L differentiation, respectively.  Three of these 
genes are common to both groups, suggesting that they might be 
involved in early differentiation processes, further supported by 
the fact that two of the genes were Class B-I, which we found to 
be involved in early development.  Whilst the majority of genes 
demethylated during F-L differentiation were Class B-II, none 
of those demethylated during neuron differentiation belonged 
to this category.  This could be explained by the finding that 10 
genes, which were demethylated during neuron differentiation 
and belonged to neither Class I nor II, were not classified as 
“unmethylated in at least one normal tissue type analysed” as 
their intermediate methylation levels in normal tissues did not 
allow classification into any of the four categories.  Moreover, 
there were many more hypomethylated genes (relative to Shef-
1) in normal brain than in neural Shef-1-derived cells.  These 
observations suggest that i) in vitro hESC differentiation does 
not reproduce all epigenetic features of in vivo differentiation 
and ii) the unguided F-L differentiation of our hESC achieves 
more epigenetic hits in vivo than does neural differentiation.
When we extended the analysis of F-L differentiation-
associated gene demethylation to a larger gene set comprising 
most of the genome, we observed that the proportion of 
demethylated genes is maintained.  More than 200 genes were 
specifically demethylated in this lineage, mainly associated to 
specific, late mesodermal differentiation.  Most were implicated 
in immune system function and immune cell differentiation 
or in cell signalling, and were localised in membranes or 
secreted.  This is interesting because F-L cells have mesodermal 
differentiation markers, but are not specifically directed towards 
the haematopoietic lineage.  We therefore hypothesise that 
expression of these genes is unlocked earlier in mesodermal 
differentiation and is later activated through other mechanisms 
at specific stages in immune cell development.  This could have 
important implications, as it has long been known that many 
alterations in DNA methylation are linked to immune cell 
diseases, due both to uncontrolled proliferation, as is the case 
of leukaemia and lymphomas, and to uncontrolled activation 
in the case of autoimmune diseases (Javierre et al., 2008). 
For example, the ICF syndrome is a rare genetic condition 
characterised by severe congenital immunodeficiency that 
leads to death before adulthood, due to mutation of the DNA 
methyltransferase DNMT3B (Ehrlich et al., 2008).
The observation that genes like DLC1 are demethylated 
and overexpressed specifically during F-L, but not neural 
differentiation of Shef-1 cells suggests that loss of DNA 
methylation-dependent expression of this gene is involved in 
lineage specification.  This is supported by the essential role 
of DLC1 in embryonic development, whereby DLC1-deficient 
mice are non-viable (Durkin et al., 2005).
Finally, we wondered whether the methylation-dependent 
repression of cancer genes in hESC is a molecular process 
associated with embryonic development or if, in contrast, 
it is an epigenetic mechanism involved in the maintenance 
of stemness.  CD34+ somatic stem cell progenitors featured 
numerous genes frequently hypermethylated in cancer that are 
repressed by promoter hypermethylation.  This suggests that, 
at least for these genes, the process could be associated with 
stemness status regardless of the ontogenetic stage of the cell, 
rather than being an event restricted to embryonic development. 
Since CD34+ cells are primary non-cultured cells, we can also 
discount the possibility that in vitro culture of the hESC is 
responsible for hypermethylation, in accordance with previous 
findings (Bibikova et al., 2006; Rugg-Gunn et al., 2005; Rugg-
Gunn et al., 2007).
By comparing the DNA methylation status of CD34+ 
progenitor cells with those of two types of primary cells that are 
terminally differentiated from the former (PBL and neutrophils), 
we identified several genes that lost methylation specifically 
in just one lineage.  In conjunction with the fact that most 
sequences identified were sometimes hypermethylated in NPT 
and most were previously classified as Class B-II genes, this 
suggests that genes hypermethylated in CD34+ progenitor cells 
that are demethylated during differentiation are those primarily 
involved in lineage specification.  That none of the sequences 
identified in the CD34+ progenitor cells was of Class B-I might 
well be because CD34+ cells are not the primary hematopoietic 
progenitors and because Class B-I genes lose methylation in 
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the transition from earlier progenitor stem cells to CD34+ cells. 
This explanation is consistent with the putative role of Class 
B-I genes in early development (Zhao et al., 2007), but requires 
further study.
From our point of view, the finding that some cancer 
methylated genes are also frequently hypermethylated in adult 
stem cells is particularly important to our understanding of 
aberrant methylation in cancer.  This phenomenon could be 
relevant in a specific aspect of cancer biology.  In recent years,  a 
new theory supported by several findings postulates the existence 
of a stem cell subpopulation in the cancer cell population; these 
stem cells would be responsible for tumour generation and 
maintenance (Polyak and Hahn, 2006; Vermeulen et al., 2008). 
The tumour mass would be generated by a small population 
of cancer stem cells, which exclusively retain the ability for 
self-renewal and tumorigenicity.  This subpopulation has been 
defined for several tumour types by specific markers (CD133 for 
brain, colon, lung, liver, pancreas and prostate cancer, CD44 for 
colon, breast, pancreas, prostate, head and neck tumours, and 
CD34+/CD38- for haematological malignancies (Vermeulen et 
al., 2008)).  The tumourigenicity of these cells is assayed by their 
ability to give rise to neoplasias at very low cell titres in NOD/
SCID mice, whereas the total cancer cell population depleted of 
these cells is unable to generate a tumour in this model.  These 
cancer stem cells (CSC) appear to share many characteristics 
with other stem cell types, such as self-renewal, asymmetric 
division giving rise to more differentiated progenitors, and a 
slow replication rate that could decrease sensitivity to current 
cancer treatments.  The definition of this subpopulation is highly 
controversial, as it is difficult to fully define a very small, peculiar 
population in the sea of a heterogeneous tumour mass, based on 
an in vivo assay in immunodeficient mice.  For example, the 
degree of immunodeficiency in the mouse model can greatly 
alter the result of the serial dilution tumour xenograft tests, 
thereby altering the definition of the CSC population (Quintana 
et al., 2008).
We found that a group of TSG is hypermethylated in hESC, 
and that many of are still methylated in adult stem cells, as 
observed in the CD34+ population.  This raises the question as 
to whether these genes are in fact aberrantly hypermethylated 
in cancer, or if cancer derives from a cell subpopulation that 
was unable to be efficiently demethylated at these promoters, 
which would activate these TSG/differentiation genes.  This 
population would possibly behave as a cancer stem cell 
intermediate, sharing features of both stem cells and cancer 
cells. In the context of the hypothesis of the stem cell origin of 
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Figure 40.  Model for promoter hypermethylation in cancer.  Model for a Class A TSG (top).  These promoters are 
inactivated in stem cells by the presence of the bivalent mark and are unmethylated.  Following differentiation, 
these genes are normally activated in the differentiated cell.  During tumour transformation, these promoters are 
aberrantly methylated at CpG, leading to gene silencing.  Model for a Class B TSG (bottom).  These genes do not 
usually have the bivalent mark in hESC, but are inactivated by promoter hypermethylation.  Methylation is reversed 
during differentiation in tissues that potentially express these genes, although additional histone modification-based 
mechanisms are likely to be necessary for their full activation.  In cancer, these genes are again hypermethylated.  
Cancer hypermethylation might be the result of aberrant remethylation of the promoter (as for class A genes) or 
might represent a remnant of hESC methylation, maintained by some cells that have not achieved the appropriate 
demethylated state during differentiation, and thereby have an advantage in the first steps of cancerogenesis.
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cancer, the hypermethylation of some Class B genes in adult 
stem cells suggests that their aberrant methylation in cancer 
can be understood as a defect in establishing an unmethylated 
promoter during differentiation, rather than as an anomalous 
process of de novo hypermethylation (Fig. 40).
Using this approach, we identified two genes, AIM2 and 
RUNX3, that were hypermethylated and repressed in CD34+ 
haematopoietic progenitor cells and that were demethylated 
and expressed in myeloid and lymphoid lineages, respectively. 
Both genes are aberrantly hypermethylated in cancer (Li 
et al., 2002c; Woerner et al., 2007), which indicates that 
genes frequently hypermethylated in cancer can be naturally 
repressed by promoter methylation not only in hESC, but also 
in somatic stem cells.  Moreover, the lineage-specific loss of 
methylation and upregulation of these two genes suggests that 
their expression is important in lineage specification during 
haematopoietic differentiation and, more importantly, that this 
process can be regulated by DNA methylation.  RUNX3 is a 
well-known transcription factor that regulates lineage-specific 
gene expression in developmental processes (Levanon et al., 
2003).  Our observation that RUNX3 loses methylation and is 
expressed during lymphoid, but not myeloid development is 
consistent with studies showing the need for RUNX3 in T cell 
development during thymopoiesis (Egawa et al., 2007; Woolf 
et al., 2003), and that RUNX3 knockout mice have a defined T 
cell phenotype (Levanon et al., 2002; Li et al., 2002c).  Finally, 
considering the available evidence and following similar 
reasoning, the aberrant hypermethylation of RUNX3 in the 
Raji human lymphoid CCL could be understood as a failure 
of CD34+ cells to lose the promoter methylation necessary to 
reactivate the gene during haematopoietic differentiation.
In addition to DNA methylation, histone modification is 
a potential mechanism for epigenetic gene regulation during 
hESC differentiation.  The second part of this study addressed 
histone modification-based mechanisms in stem differentiation. 
Some of these mechanisms have been identified as central to 
hESC pluripotency and differentiation; these processes are based 
principally on the interplay of a web of key transcription factors 
and chromatin-modifying enzymes that act mainly through 
histone methylation.  Histone acetylation has been analysed in 
some studies of hESC differentiation, but no compelling role has 
yet been identified.  Golob et al. (Golob et al., 2008) reported 
that global acetylation of H3K9 increases during mESC and 
hESC F-L differentiation, while Krejci et al. (Krejci et al., 2009) 
showed that this same residue loses acetylation during retinoic 
acid-induced endoderm-like differentiation of hESC.  Other 
research pointed to a role for HAT and HDAC complexes in 
pluripotency maintenance and ESC differentiation.  For example, 
Baltus et al. (Baltus et al., 2009) showed a positive role for 
mSin3A-HDAC complex in mESC pluripotency maintenance; 
Zhong et al. (Zhong and Jin, 2009) demonstrated that HAT p300 
deletion, although it did not affect self-renewal capacity when 
mESC were maintained in undifferentiated conditions, caused 
an abnormal expression pattern of germ layer markers when 
differentiation was induced by EB formation.  Recent evidence 
from mouse models indicates that SirT1 is a central regulator of 
embryonic (Han et al., 2008) and somatic (Prozorovski et al., 
2008) stem cell function.  Our results extend these observations 
by showing that SirT1 might also be an important regulator of 
hESC differentiation, and suggest a possible molecular pathway 
for SirT1 regulation in stem cells.  Indeed, we show that SirT1 
downregulation during hESC differentiation ultimately depends 
on CARM1-dependent HuR Arg217 methylation.  It was 
recently suggested that Carm1 helps to maintain pluripotency 
in mESC through regulation of histone methylation at the 
promoters of specific pluripotency genes (Torres-Padilla et 
al., 2007; Wu et al., 2009).  In addition, Wu et al. showed that 
developmental factors are overexpressed by iCarm1, although 
they did not address how these genes are upregulated.  As there 
is an overlap between the genes overexpressed after Carm1 
interference in mESC with those whose promoters are bound 
by SirT1 in hESC (Table S17).  We consider that our data and 
those of Wu et al. help to explain the central role of CARM1 
in pluripotency.  CARM1 downregulation can have a direct 
effect on pluripotency by regulating chromatin structure, and an 
indirect effect on priming developmental genes through SirT1 
(Fig. 41).
During differentiation, the decrease in CARM1 is associated 
with a decrease in HuR methylation and, consequently, of HuR/
SirT1 binding.  This results in less SirT1 mRNA and protein, as 
well as the epigenetic reactivation of its target developmental 
genes.  This hypothesis would explain our observation that, 
at difference from iCARM1, iSirT1 alone cannot induce 
hESC differentiation.  CARM1 acts on both pluripotency and 
differentiation genes, and its knock-down is thus able to force 
differentiation.  Repression of pluripotency genes is absolutely 
necessary to induce ES cell differentiation and, in hESC, SirT1 
acts only on developmental genes.
As the principal mechanism thought to regulate HuR 
function is a change in its cytoplasmic abundance (Kim et al., 
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2008a), we would have predicted this as the cause of reduced 
association between HuR and the SirT1 transcript.  Our results 
nonetheless suggest that HuR/SirT1 mRNA binding relies on 
CARM1-dependent HuR methylation; this is consistent with 
a report showing the ability of CARM1 to methylate HuR 
and increased HuR/RNA binding activity mediated by HuR 
methylation at Arg217 (Li et al., 2002a). HuR regulation of 
SirT1 mRNA is not a new finding; HuR was recently found to 
regulate SirT1 in cancer cells (Abdelmohsen et al., 2007).  Here 
we demonstrate that HuR also regulates SirT1 during hESC 
differentiation; in conjunction with the reported role of HuR in 
myogenic differentiation (Figueroa et al., 2003), this suggests 
that HuR regulation of SirT1 could be a shared mechanism of 
stem cell differentiation.
Our data indicate that Sirt1 might help to maintain 
pluripotency in mouse but not in human ESC.  In mouse, we 
found that several pluripotency markers, including Fgf4, 
Nanog, Nodal, Tdgf1, Rest and Tdfcp2l1, are overexpressed in 
Super-Sirt1; some of these markers are downregulated in Sirt1 
KO mESC.  In addition, although Sirt1 KO embryonic bodies 
showed virtually no changes in pluripotency marker expression, 
Super-Sirt1 EB retained notable expression of these markers 
that, in most cases, was comparable to that in WT ES cells. 
These data indicate that Sirt1 might contribute to pluripotency 
maintenance in mESC.  Even if Sirt1 would help to maintain 
pluripotency in mESC, it is not strictly necessary, as Sirt1 KO 
mESC do not differentiate spontaneously, Super-Sirt1 mES 
can differentiate into EB, and both Sirt1 KO and Super-Sirt1 
mice are viable (Cheng et al., 2003; McBurney et al., 2003b; 
Pfluger et al., 2008).  In man, however, SirT1 does not appear 
to have a clear role in hESC pluripotency, as iSirt1 in Shef-1 
cells does not in itself induce differentiation.  Moreover, iSirT1 
does not result in downregulation of pluripotency markers, 
which could explain the lack of phenotypic differentiation after 
SirT1 downregulation.  In contrast to mice, therefore, SirT1 
downregulation in hESC does not appear to affect expression 
of pluripotency markers; this might indicate that the role of 
SirT1 role in ES cells in this regard is not identical in mouse 
and human cells.
Our results show that SirT1 downregulation is necessary 
to establish correct, specific differentiation programs during 
human and mouse ESC differentiation for two reasons: i) SirT1 
binds to and epigenetically regulates specific developmental 
genes in pluripotent hESC, and ii) expression of markers of 
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Figure 41.  Model for SirT1 action on developmental gene promoters during hESC differentiation.  As described by 
Wu et al. (Wu et al., 2009), Carm1 regulates pluripotency gene promoters by histone methylation in mouse ES cells.  In 
pluripotent hESC, CARM1 methylation of HuR increases HuR/SirT1 binding and, consequently, SirT1 mRNA stability 
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developmental genes such as DLL4, PAX6 and WNT6.
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pluripotency and, above all, of differentiation is clearly altered in 
differentiating SirT1-knocked-down hESC and Sirt1 KO/Super-
Sirt1 mESC.  We show that some downstream effects of SirT1 
downregulation are mediated by the epigenetic reactivation of 
specific developmental genes, which is consistent with the role 
of Sirt1 in cell differentiation as a component of the Polycomb 
repressive complex 4 (PRC4) (Kuzmichev et al., 2005).  The 
role of SirT1 in hESC function must nonetheless be more 
complex, as SirT1 downregulation is also associated with p53 
hyperacetylation (this study and (Cheng et al., 2003; Han et 
al., 2008)).  Of the ten SirT1 target genes we selected for ChIP 
validation, three (LHX1, PAX6 and WNT6) have been associated 
with neural development (Kania et al., 2000; Schmidt et al., 
2007; Wawersik and Maas, 2000) and another three (DLL4, TBX3 
and PAX6) are reported to have a role in retinal morphogenesis 
(Lobov et al., 2007; Wawersik and Maas, 2000).  This suggests 
that SirT1 contributes to neural fate determination and retinal 
formation during embryonic development.  This possibility 
is supported by the following arguments: i) expression of the 
neuro-ectodermal markers NeuroD1, Syp and Nes was clearly 
upregulated during differentiation of mESC lacking Sirt1 
and strongly downregulated during differentiation of Sirt1-
overexpressing mESC, ii) SirT1 involvement in determining the 
fate of neural progenitors, and iii) the notable developmental 
defects of the retina in SirT1-deficient mice (Cheng et al., 2003; 
McBurney et al., 2003b).
Based on evidence from our work, a previously 
undescribed epigenetic pathway appears to be involved in 
hESC differentiation, in which SirT1 regulates differentiation 
in a HuR-CARM1-dependent fashion (Fig. 40).  This pathway 
involves the epigenetic regulation of key developmental genes 
such as the neuro-retinal morphogenesis effectors DLL4, 
TBX3 and PAX6.  In conjunction with the phenotype shown 
by different strains of Sirt1-deficient and Super-Sirt1 mice, 
our results indicate that whereas SirT1 has a minor role in 
promoting or impairing hESC differentiation, it contributes 
to the establishment of specific developmental/differentiation 
programmes of particular relevance for neuro-ectodermal fates.
The SirT1-mediated modulation of stemness and 
developmental genes might not be merely an additional piece 
in the developmental epigenetic puzzle.  Sirtuins, and especially 
SirT1, are studied intensively for their roles in cell survival, 
apoptosis and differentiation, which has led to the development 
of many small molecule modulators to activate or inhibit their 
activity. The application SirT1 inhibitors centres mainly on 
cancer therapy, as many cancers overexpress SirT1, and SirT1 
inhibitors induce apoptosis in cancer cell lines and in vivo. 
Sirtinol and some of its derivatives arrest cell cycling in breast 
and lung cancer (Mai et al., 2005).  Both cambinol and tenovins 
are also able to inhibit cancer growth and to induce apoptosis 
(Heltweg et al., 2006; Lain et al., 2008).  Salermide treatment 
leads to growth arrest and a pronounced apoptotic effect in 
various cancer cell lines without affecting a non-cancerous 
fibroblast line (Lara et al., 2009).  Other potential applications 
for sirtuin inhibitors include Parkinson therapy (Outeiro et 
al., 2007) HIV replication blockade (Pagans et al., 2005) and 
Leishmania infantum treatment (Vergnes et al., 2005).
Our data suggest that SirT1 inhibition in differentiation 
enables the correct expression of specific developmental genes. 
This aspect could have an interesting application in the context 
of cancer therapy, as a specific goal of sirtuin inhibition could be 
to reactivate differentiation genes in cancers characterised by a 
low degree of differentiation.  It could also have applications in 
regenerative medicine, to modulate and direct differentiation in 
stem cell-based therapies.
Given to the effects of SirT1 on longevity, rejuvenation and 
counteracting ageing, the pharmaceutical, “nutraceutical”, and 
cosmetic industries are also interested in the development of 
small molecule SirT1 activators (Alcain and Villalba, 2009). 
Resveratrol, a natural compound present in traces in some 
red wines, has a demonstrated sirtuin-activating effect.  This 
polyphenol mimics the anti-ageing effects of calorie restriction 
in simple organisms, and in mice fed a high-fat diet ameliorates 
insulin resistance, increases mitochondrial content, and prolongs 
survival (Baur et al., 2006b; Lagouge et al., 2006; Wood et al., 
2004).  Resveratrol might help in the treatment or prevention of 
obesity, as well as the ageing-related decline in heart function 
and neuron loss.  As resveratrol has low bioavailability and 
specificity, medicinal chemists are developing new molecules 
to overcome these obstacles.  SirT1 activators up to 1000 times 
more effective than resveratrol have recently been developed; 
they improve the response to insulin and increase the number 
and activity of mitochondria in obese mice.  Human trials with 
an improved bioavailability formulation of resveratrol and with 
a synthetic SirT1 activator are in progress.  The goal is to treat 
ageing-related diseases such as type 2 diabetes, and early data 
from mouse models are quite promising (Milne et al., 2007). 
Food supplements containing resveratrol at high concentrations 
are already available in pharmacies and nutrition shops.  A 
commercial boom has centred the attention of the cosmetic 
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industry on SirT1 and its activators, and many laboratories are 
producing and selling preparations containing sirtuin activators 
(Moreau et al., 2007).
In essence, we basically propose that SirT1 has a positive 
role in stemness, aiding in the silencing of differentiation genes. 
This finding could be interesting, as one explanation of sirtuin 
activator action is that it contributes to maintaining a “stemness-
like” status in cell populations involved in tissue regeneration. 
Our results could provide a useful starting point from which 
to study the potential teratogenicity of SirT1-modulating 
compounds, a factor to be considered for molecules rapidly 
coming into use in clinical practice and in everyday life.
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Figure 42.  New mechanism in epigenetic regulation of hESC differentiation.  This study highlights two undescribed 
activating mechanisms for developmental genes. Some “late differentiation” genes are hypermethylated in hESC and 
are activated through promoter demethylation during differentiation.  Other genes are maintained silent in hESC, in 
part through SirT1-mediated promoter deacetylation, and are expressed later in development, modulated by SirT1 
downregulation and promoter acetylation.
In summary, this study addressed two epigenetic mechanisms 
responsible for downregulation of developmental gene 
expression in embryonic stem cells and modulation of correct 
spatio-temporal activation during cell differentiation (Fig. 42). 
The first is based on promoter DNA methylation, and is used 
by a subset of genes whose promoter has low CpG density 
and lacks bivalent mark/Polycomb-based signature in hESC; 
these genes are important for late lineage specification and are 
involved mainly in immune system functions.  The second, 
SirT1-based mechanism, is more likely to be a modulatory 
effect that contributes with other repressive elements (e.g., 
Polycomb itself, as shown in mESC (Kuzmichev et al., 2005)) 
to the regulation of some developmental genes important in 
neuroectodermal and other lineage specification.
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CONCLUSIONS
On the role of DNA methylation in ES cell differentiation
1. Promoter DNA methylation is an important gene regulation mechanism in embryonic and adult stem 
cells, as a means of developmental gene promoter repression.
2. The activation of a subset of differentiation genes, mainly immune system-related, during late ESC 
differentiation is mediated primarily by promoter DNA demethylation.
3. Twenty percent of the genes frequently hypermethylated in cancer (tumour suppressor genes, TSG) 
are also frequently hypermethylated in hESC.  In contrast with other TSG frequently hypermethylated 
in cancer, these genes do not show bivalent domain histone marks (trimethyl-H3K4 and K27) at their 
promoters in hESC. 
4. Promoter methylation can thus be regarded as alternative to bivalent domain-mediated repression for 
a subset of development-related/cancer hypermethylated genes.
On the role of histone modification in ES cell differentiation
5. The class III histone deacetylase SirT1 is regulated precisely during ES differentiation by a mechanism 
that involves the mRNA-binding protein HuR and the arginine methyltransferase CARM1.  CARM1-
dependent HuR methylation at Arg217 in pluripotent hESC increases HuR-dependent SirT1-mRNA 
stabilisation.  CARM1 downregulation during ES differentiation results in a decrease in methyl-HuR 
and, consequently, in SirT1 donwregulation.
6. In pluripotent ESC, SirT1 binds to and epigenetically represses promoters of a subset of developmental 
genes, many of which are involved in neural fate specification. SirT1 downregulation during 
differentiation leads to activation of these genes through H4K16 and/or H3K9 acetylation, enabling 
the expression necessary for correct lineage specification.  SirT1 might thus have an important role in 
establishment of the neuro-ectodermal layer.
7. SirT1 depletion in human and mouse ESC does not induce differentiation, but alters cell fate during in 
vitro difererentiation.  SirT1 thus has a modulatory role in developmental gene regulation, contributing 
to correct spatiotemporal patterning in the differentiating embryo.
8.  SirT1 overexpression in mouse ESC enhances the expression of pluripotency markers and delays their 
downregulation during differentiation, while also perturbing differentiation patterns.
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INTRODUCCION
La epigenética fue definida por Conrad Waddington en 1942 
como la ciencia que estudia cómo los genotipos dan lugar a 
fenotipos a través de cambios programados durante el desarrollo 
(Waddington, 1942).  El desarrollo se considera el proceso que 
conduce a la formación de un organismo completo a partir de 
una sola célula mediante cambios progresivos.  Después de 
la fecundación del óvulo, el cigoto se divide dando lugar a 
blastómeros, células consideradas totipotentes, ya que tienen 
el potencial de originar cualquier tipo celular diferenciado.  En 
el estadío de dieciséis células, la mórula está constituida por 
células externas que dan lugar al trofoblasto, y por un pequeño 
grupo de células internas del que deriva el proprio embrión, 
denominado masa celular interna (ICM) (Barlow et al., 1972). 
El aislamiento de la ICM en esta etapa y su propagación in vitro 
en condiciones adecuadas, conduce a la derivación de líneas de 
células madre embrionarias (Moon et al., 2006).  Estas células 
se definen como pluripotentes, ya que, aunque pueden formar 
cualquier linaje de células del embrión, ya han superado el 
primer paso de diferenciación.  En 1998 se derivaron células 
madre embrionarias humanas (hESC) demostrando que estas 
células podían ser propagadas indefinidamente en cultivo 
y diferenciadas a varios linajes celulares (Gearhart, 1998; 
Thomson, 1998).  Las células madre son una herramienta muy 
útil hoy en día para el estudio molecular de las primeras fases del 
desarrollo y, en un futuro, podrían ser utilizadas para producir 
nuevas células funcionales en situaciones patológicas en las que 
está comprometida la función celular (Deb and Sarda, 2008).  
El conocimiento de nuevos mecanismos moleculares que 
conciernen a la epigenética ha llevado a añadir nuevos conceptos 
a la definición original.  Consideramos un proceso epigenético 
aquel que afecte a la expresión de genes sin que para ello se 
vea alterada la secuencia de nucleótidos, de forma que puedan 
ser heredados a través de la división celular (Holliday, 1987). 
En el núcleo de células eucariotas, el ADN está organizado 
en nucleosomas (Oudet et al., 1975), una estructura modular 
formada por 147 pares de bases de ADN de doble cadena 
que rodean a un octámero de histonas (compuesto por dos 
dímeros de histonas H2A-H2B y un tetrámero de histonas H3-
H4).  La maquinaria epigenética se encarga de determinar la 
accesibilidad de la información contenida en el ADN utilizando 
un código formado por modificaciones covalentes en el ADN 
o en las histonas (Kouzarides, 2007).  Las variaciones que la 
maquinaria epigenética introduce en la estructura cromosómica 
determinan diferencias en la compactación de la cromatina 
que se correlacionan estrechamente con estados de actividad o 
inactividad génica.  
Las histonas poseen colas peptídicas que sobresalen de los 
nucleosomas y pueden ser modificadas en muchos residuos 
de aminoácidos.  Hay por lo menos 30 sitios potenciales de 
modificación de histonas para cada nucleosoma y ocho tipos 
de modificaciones (metilación, acetilación, fosforilación, 
ubiquitinación, sumoilación, ADP-ribosilación, isomerización 
de prolina y biotinilación), algunas de las cuales pueden tener 
diferentes configuraciones (por ejemplo, la lisina pueden ser 
mono-, di- o trimetilada).  La información contenida en las 
distintas combinaciones de las modificaciones de las histonas 
determina el estado funcional del ADN ; este lenguaje suele ser 
denominado código de histonas (Jenuwein and Allis, 2001).
La metilación del ADN se produce principalmente en 
citosinas que preceden a guaninas (CpGs).  Estos dinucleótidos 
CpG se distribuyen asimétricamente en el genoma.  Las regiones 
densas son las denominadas “islas CpG”, y se encuentran en 
la región promotora de aproximadamente la mitad de todos los 
genes.  Estas islas CpG generalmente se encuentran no metiladas 
en las células normales (Illingworth and Bird, 2009).  La falta 
de metilación permite la expresión de estos genes.  Durante el 
desarrollo, ciertas islas CpG están sometidas a modificaciones 
en el patrón de metilación relacionadas con la diferenciación 
de los tejidos y el desarrollo.  La diferenciación de las células 
madre embrionarias humanas (hESC) exige la represión de 
los factores de transcripción implicados en el mantenimiento 
de la pluripotencia, así como la activación de los genes de 
desarrollo.  Ambos procesos son dirigidos por determinados 
mecanismos epigenéticos.  Un ejemplo del primer tipo es la 
hipermetilación del promotor de los genes encargados del 
mantenimiento de la pluripotencia, como NANOG y OCT4 
(Lagarkova et al., 2006) (Fig. I-8).  Hasta ahora, hay pocos 
estudios sobre el proceso de desmetilación en la activación de 
genes de desarrollo durante la diferenciación de células madre. 
Sin embargo, se conoce que estos genes se encuentran, en su 
mayoría, en un estado reprimido durante las primeras etapas 
de desarrollo, debido a un patrón específico de modificaciones 
de las histonas, denominado “dominio bivalente”, que consiste 
en la coexistencia de metilación de la lisina 27 y de la lisina 
4 de la histona H3 (Bernstein et al., 2006) (Fig. I-8).  Este 
estado de represión de la cromatina está mediado por proteínas 
del grupo de Polycomb (Lee et al., 2006a; Sparmann and Van 
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Lohuizen, 2006).  Se describió además que esta modificación 
predispone a una hipermetilación aberrante de promotores de 
genes supresores tumorales (TSG) en cáncer (Fig. 39) (Ohm et 
al., 2007; Schlesinger et al., 2007; Widschwendter et al., 2007).
Otro aspecto importante de la epigenética es la acetilación 
de histonas, una modificación asociada con activación de la 
transcripción génica (Shogren-Knaak et al., 2006).  Las enzimas 
histonas desacetilasas se encargan de eliminar la acetilación de 
los nucleosomas, ejerciendo así una acción inhibidora de la 
trascripción.  La Sirtuina 1 (SirT1) es una lisina desacetilasa 
dependiente del co-factor NAD+ que participa en múltiples 
procesos celulares, incluyendo la remodelación de la cromatina, 
el silenciamiento de la transcripción, la mitosis, las respuestas 
al estrés, la reparación del ADN, la apoptosis, el ciclo celular, la 
estabilidad genómica, la regulación de insulina, y el control de 
la longevidad (Vaquero, 2009), así como un papel destacado en 
el desarrollo.  En mamíferos, la función de SirT1 está mediada 
por su actividad desacetilasa, no sólo sobre las colas de las 
histonas (principalmente K16 y K9 de la histona H3 (Pruitt et 
al., 2006; Vaquero et al., 2007b), sino también por su actividad 
sobre factores de transcripción clave, como la proteína p53 y 
factores de transcripción FOXO (forkhead box protein), entre 
otros (Guarente and Picard, 2005).  Estudios recientes realizados 
sobre modelos de ratones sugieren que SirT1 es importante en la 
diferenciación de células madre, así como en la diferenciación 
neuronal y glial de precursores neuronales (Prozorovski et al., 
2008) y en la diferenciación de mioblastos esqueléticos en 
respuesta a la disponibilidad de glucosa (Fulco et al., 2003). 
Además, los ratones deficientes en SirT1 presentan graves 
defectos neurales, incluyendo neuro exencefalia y trastornos de 
la morfogénesis de la retina (Cheng et al., 2003; McBurney et al., 
2003b).  Sin embargo, la función de SirT1 en la diferenciación 
de hESC está todavía sin explorar.
OBJETIVOS
Nuestro estudio se ha centrado en dos aspectos de la epigenética 
en células madre embrionarias: la metilación del ADN y la 
modificación de las histonas por la histona desacetilasa SirT1.
Las células madre embrionarias tienen un patrón epigenético 
especifico.  Bibikova et al. describieron 23 genes cuyo estado 
de metilación del promotor era exclusivo de hESC (Bibikova 
et al., 2006).  La metilación del ADN también se ha asociado 
a la inactivación estable de genes de pluripotencia durante la 
diferenciación de hESC.  Ciertos genes de diferenciación tardía 
que poseen un promotor con baja densidad de CpG y que no 
presentan marca bivalente, se encuentran con frecuencia 
hipermetilados en células madre (Fouse et al., 2008; Meissner 
et al., 2008).  Sin embargo, la activación de genes durante el 
desarrollo mediante desmetilación del promotor aún no ha sido 
completamente investigada.  Nos centraremos en este punto 
para definir los genes metilados específicamente en hESC en 
relación con los tejidos normales.  Como la hipermetilación 
del promotor de TSG es una característica de muchos tipos de 
cáncer (Esteller, 2008), se analizaron además las similitudes 
entre la metilación de promotores de genes entre células madre 
y cáncer, lo que puede ayudar a comprender el proceso de 
metilación aberrante de TSG en cáncer.
Estudios recientes realizados en hESC confirman que la 
mayoría de los genes de desarrollo se reprimen por los 
complejos represivos Polycomb (PRC) y por una combinación 
de marcas de histonas llamada dominio bivalente, mediada 
principalmente por PRC2 y otros complejos con actividad 
histona metiltransferasa (Bernstein et al., 2006).  Aunque se 
haya caracterizado ampliamente el papel de la metilación de las 
histonas en la regulación genética del desarrollo, la acetilación 
de las histonas en este contexto está menos estudiada.  La histona 
desacetilasa SirT1 fue anteriormente implicada en procesos de 
diferenciación de los tejidos, como músculo, tejido adiposo y 
neuronas (Fulco et al., 2003; Picard et al., 2004; Prozorovski 
et al., 2008).  SirT1 está altamente expresada en células madre 
y colocaliza en la cromatina con los componentes de PRC 
(Kuzmichev et al., 2005).  Los ratones deficientes (KO) para 
SirT1 muestran importantes problemas en el desarrollo, aunque 
en muchos casos superan las primeras etapas embrionarias 
(Cheng et al., 2003; McBurney et al., 2003b).  Por lo tanto, se ha 
estudiado el papel de SirT1 en la diferenciación de hESC, para 
determinar su implicación en la modulación de la expresión 
génica a través de la modificación de la cromatina.
Los objetivos concretos de esta tesis doctoral fueron los 
siguientes:
1. Caracterizar el papel de la metilación del ADN en 
la diferenciación de células madres embrionarias 
humanas, centrando especialmente nuestra atención 
en la regulación génica mediada por desmetilación 
de promotores.
2. Definir el papel en la regulación génica desempeñado 
por la modificación de histonas por parte de SirT1 a 
lo largo de la diferenciación de células madre.
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RESULTADOS y DISCUSIÓN
En primer lugar hemos analizado los patrones de metilación 
del DNA en la diferenciación de las hESC.  Primero estudiamos 
la metilación de dos líneas de células madre embrionarias y de 
las mismas líneas diferenciadas in vitro mediante la técnica de 
la amplificación de secuencias inter-metiladas (AIMS).  Esta 
técnica utiliza enzimas de restricción sensibles a metilación para 
distinguir la metilación del ADN.  Identificamos 23 secuencias 
de las que solo ocho están metiladas de forma preferente en la 
diferenciación celular (Figura 1 y Tabla 1).
Posteriormente utilizamos una técnica que permite el estudio 
simultáneo de muchos sitios CpG localizados específicamente 
en promotores génicos: el array de metilación GoldenGate, 
Illumina, que contiene información sobre la metilación de 807 
genes, muchos de ellos relevantes en cáncer (Figura 2 y Tabla 
S2).  Comparando los resultados obtenidos en 8 líneas de hESC, 
21 muestras de tejido primario normal (NPT) y 21 muestras de 
líneas de cáncer (CCL) encontramos que cada uno de estos tipos 
celulares posee su propia firma epigenética.  El 34.69%  de los 
genes analizados en el estudio están hipermetilados en hESC 
(Tabla S2).  Un 12,5% de los genes presentes en este array se 
encuentra hipermetilado en hESC y se desmetila en al menos un 
tejido normal, confirmando así que el proceso de activación de 
genes mediante desmetilación de promotor es detectable y no es 
secundario en la diferenciación in vivo.  Muchos genes además se 
hipermetilan en cáncer, de los cuales aproximadamente el 20% 
también lo está en células madre y se encuentra desmetilado por 
lo menos, en una muestra de tejido normal, indicando que en 
algún momento de la diferenciación, este gen será activado.  En 
base a los resultados obtenidos, realizamos una clasificación de 
los genes hipermetilados en cáncer, comúnmente considerados 
genes supresores de tumor (TSG).  Consideramos como TGS de 
clase A-I los que solo están hipermetilados en cáncer; Clase A-II 
los que también se hipermetilan en muchos tejidos a lo largo de 
la diferenciación; Clase B-I los que están metilados en líneas 
hESC y se desmetilan a lo largo de la diferenciación en todos 
los tejidos, y clase B-II los que están metilados en líneas hESC 
y se desmetilan específicamente solo en algún tejido (Figura 3 y 
Tabla 2 y S2).  Estos datos demuestran que existe una proporción 
sustancial de los genes hipermetilados en cáncer que también 
está metilado en las primeras fases del desarrollo.  Comparando 
en el mismo array los resultados de metilación de una muestra 
de células madre adulta, los precursores hematopoyéticos 
CD34+, con las hESC, observamos que ~92% de los genes 
hipermetilados en hESC lo seguía estando en esta muestra, 
indicando que probablemente la hipermetilación de estos genes 
es importante para todas las células con características de células 
madre, y abriendo la posibilidad a que la hipermetilación de 
algunos de estos genes en tumores pueda ser el resultado de un 
fallo del proceso de desmetilación a lo largo de la diferenciación, 
en lugar de la adquisición de novo de metilación aberrante 
durante la trasformación tumoral (Figura 12, tablas S7).  El 
hecho de que muchos genes pierdan metilación a lo largo del 
desarrollo también es un resultado interesante.  Todos los genes 
de la clase B están hipermetilados y, por lo tanto, inactivos 
en hESC.  Los de la clase B-I probablemente se desmetilan 
en fases muy tempranas del desarrollo, ya que se encuentran 
desmetilados en la mayoría de los tejidos adultos.  Los de la 
Clase B-II se desmetilan específicamente en uno o pocos tejidos, 
predisponiéndose así para una expresión especifica de tejido. 
Estos genes están involucrados en procesos de diferenciación 
tardía (Tabla S16).  Comparando nuestros resultados con los 
datos publicados de otros arrays observamos que mientras que 
los genes de clase A se comportan como está previsto para 
los TGS, estando en su mayoría pre-marcados en hESC con 
proteínas del grupo Polycomb y dominio bivalente, los de clase 
B, y particularmente los de clase B-II no suelen tener ninguna 
de estas marcas.  Esto significa que la hipermetilación de estos 
genes puede ser un proceso alternativo para la represión al que 
fue previamente propuesto, el dominio bivalente (Figura 3 A y B, 
Tablas S4 y S5).  También pudimos reproducir la desmetilación 
de promotores en un modelo in vitro de diferenciación de hESC 
en el que diferenciamos la línea Shef-1 a neuronas y a células 
mesodérmicas (fibroblastos; Figura 9 y Tabla S6).  Encontramos, 
respetivamente, 12 y 25 genes que pierden metilación durante 
estas diferenciaciones, y sólo tres de ellos eran comunes a los 
dos linajes, indicando que la desmetilación de genes puede ser 
un proceso específico de linaje durante la diferenciación.  Esta 
misma observación se pudo hacer en estadios más avanzados 
de diferenciación, comparando los genes hipermetilados en 
precursores hematopoyéticos que se desmetilan específicamente 
en linaje linfoide (9) y mieloide (16) (Figura 12 y Tabla S8). 
El patrón de metilación de muchos de estos genes analizado en 
el array fue validado por secuenciación de bisulfito (Figuras 
4, 5, 6, 7, 8, 10 y 12).  Además se cuantificó la expresión del 
ARN mensajero de estos genes por la reacción en cadena de 
la polimerasa (PCR) cuantitativa, relacionando metilación 
génica con represión transcripcional.  Sin embargo,  la falta 
de metilación de un gen no siempre implicaba una activación 
transcripcional (Figuras 4, 5, 6, 7, 8, 10 y 12).  Esto confirma que 
en muchos casos es necesaria la implicación de otros factores 
epigenéticos para la inducción de la transcripción.
Realizamos un estudio aún más amplio y detallado de la 
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metilación génica en hESC, empleando otro array de metilación 
que contiene información sobre más de 14000 genes, casi la 
totalidad de los genes regulados por metilación en el genoma 
humano (Tabla S9).  Comparamos 10 muestras de líneas 
de hESC y 10 muestras de tejidos primarios diferenciados 
y observamos que un 35% de los genes de todo el array se 
encuentra hipermetilado en hESC y que un 32% de estos 
últimos pierde metilación en al menos un tejido (Tabla S10). 
Mediante la interfaz de la red DAVID, una herramienta de 
estudio de la ontología génica, buscamos una función común 
para estos genes.  Un porcentaje significativamente alto de estos 
genes ejerce funciones asociadas al sistema inmune y respuesta 
inflamatoria (Tabla 3).  Además, muchos de ellos codifican 
para proteínas de membrana o secretadas.  Esta observación 
encaja con la anterior, que los genes hipermetilados en hESC 
suelen tener funciones específicas en el desarrollo tardío.  En 
el análisis de los datos ofrecidos por este array en muestras 
diferenciadas in vitro desde las hESC a células mesodérmicas, 
obtuvimos resultados muy parecidos: más de 200 genes, de los 
que muchos están relacionados con la respuesta inmune, se 
desmetilan específicamente durante este tipo de diferenciación 
(Tablas 4 y S11).  Este resultado indica que estos genes 
parecen desbloquear su expresión en estadios iniciales de 
la diferenciación mesodérmica y que después, en el linaje 
hematopoyético, se activan probablemente a través de otros 
mecanismos epigenéticos.  Por último se compararon los perfiles 
de metilación de promotores de líneas hESC cultivadas a corto o 
largo pase de cultivo, siendo la diferencia de número de pases de 
alrededor de 100.  En estas líneas se observó que alrededor de un 
2 % de los genes del array estaban sujetos a hipermetilación, y 
muy pocos a desmetilación.  Se detectó una familia particular de 
genes, los factores de transcripción con un dominio de dedo de 
zinc, que parecen estar sujetos a hipermetilación en el proceso 
de adaptación al cultivo de las células madre (Tablas 5 y S12).
En segundo lugar, estudiamos la regulación de la estructura 
cromatínica por acetilación de histonas en la diferenciación 
de hESC.  Datos de espectrometría de masas “top-down” nos 
mostraron que los niveles globales de la forma mono y di-
acetilada de la histona H4 aumentaban sensiblemente en las 
primeras fases de la diferenciación in vitro de hESC (Figura 
14).  Ya que la histona desacetilasa SirT1 es la única que se 
ha demostrado que desacetila la forma monoacetilada de la 
histona H4 (en la lisina 16) (Vaquero et al., 2007b), decidimos 
estudiar la expresión de la enzima SirT1 en hESC.  Los niveles 
de expresión de SirT1 son elevados en las hESC y dicha 
expresión, tanto a nivel de ARN como de proteína, decae 
rápidamente en la diferenciación in vitro a cuerpos embrioides 
(EB) y a fibroblastos (F-L) (Figura 15 y 17).  SirT1 parece estar 
localizada principalmente en el núcleo, excepto en las células 
en fase de mitosis, en las que se encuentra difusa por toda la 
célula (Figura 16).  En primer lugar, nos planteamos explicar 
las razones por la que la expresión de esta enzima descendía 
durante la diferenciación.  No encontramos diferencias a nivel de 
su promotor tanto en metilación (Figura 18) como en actividad 
transcripcional, analizada mediante la acetilación global de las 
histonas H3 y H4 (Figura 19).  Sin embargo, como los niveles 
de ARN mensajero descendían, decidimos evaluar la estabilidad 
de su tránscrito.  Detectamos que el tránscrito de SirT1 se 
hace más inestable tan solo a los tres días de diferenciación 
(Figura 20).  Había sido descrito que la proteína HuR regula la 
estabilidad del tránscrito de SirT1 en cáncer (Abdelmohsen et 
al., 2007).  Analizamos, por lo tanto, la posible implicación de 
esta proteína que estabiliza ARN en células madre.  Observamos 
que la unión de HuR al transcrito de SirT1 sufre una repentina 
bajada en la diferenciación (Figura 21A) y que la eliminación 
de HuR (generada mediante interferencia del ARN) determina 
una bajada de la expresión de SirT1 (Figura 21B).  Como la 
actividad de HuR está regulada en otros sistemas por medio de 
su localización sub-celular y su fosforilación, analizamos estos 
procesos en diferenciación, sin encontrar ninguna diferencia 
significativa (Figuras 23, 24 y 25A).  Como se había descrito 
previamente que la metilación de HuR en la arginina 217 
determinaba un incremento de la unión de HuR a sus dianas en 
un sistema de neutrófilos de ratón (Li et al., 2002a), analizamos 
los niveles de metilación de este residuo en nuestro sistema y 
pudimos detectar una bajada de metilación de HuR durante la 
diferenciación (Figura 25B).  Este residuo está metilado por 
la arginina metiltransferasa CARM1 (Li et al., 2002a), así que 
estudiamos su implicación en los fenómenos observados.  Este 
enzima se regula negativamente durante la diferenciación y su 
eliminación mediante interferencia de ARN provoca una bajada 
de los niveles de HuR metilado y consecuentemente de SirT1 
(Figura 26).  Comprobamos además que la metilación de la 
arginina 217 de HuR era realmente responsable de un cambio de 
su actividad en la unión al transcrito de SirT1 en nuestro sistema. 
Para aquello transfectamos las células con unos plásmidos que 
codifican para mutantes de la proteína HuR en el residuo 217, 
convertido en lisina y en alanina.  En ambos casos observamos 
que las proteínas mutantes expresadas en hESC unían el ARN 
mensajero de SirT1 con una eficiencia mucho menor que la 
proteína salvaje (Figura 27).
A continuación estudiamos las dianas moleculares de SirT1 
en hESC.  Para ello realizamos un estudio genómico de los 
sitios de unión de SirT1 a secuencias de ADN mediante un 
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experimento de inmuno-precipitación de cromatina (ChIP), 
usando un anticuerpo especifico de SirT1 e hibridando el DNA 
inmuno-precipitado en un array que contiene los promotores de 
prácticamente todos los genes humanos descritos.  Encontramos 
así 353 genes a los que la SirT1 se une en hESC (Tabla S13). 
Analizando mediante algoritmos de ontología génica la función 
de estos genes encontramos que estaban relacionados con 
funciones de desarrollo y diferenciación celular (Tabla 6). 
Por lo tanto, formulamos la hipótesis de que SirT1 contribuye 
a mantener silenciados genes de diferenciación en células 
madre.  Para comprobar esta hipótesis elegimos 10 genes de 
desarrollo, y dos controles negativos de genes expresados 
de forma constitutiva y medimos en ellos, a través de ChIP 
cuantitativo, la unión de SirT1 y los niveles de acetilación de los 
residuos lisina 16 de la histona H4 y lisina 9 de la histona H3, 
las dos dianas mejor caracterizadas de esta histona desacetilasa 
(Figura 30 y 31).  Detectamos en los promotores de estos genes 
un enriquecimiento de SirT1 y un aumento de los niveles de 
acetilación de las histonas, paralelo a un aumento de expresión 
en la diferenciación (Figura 32).  Además, silenciando la 
expresión de SirT1 mediante interferencia de ARN detectamos 
en muchos casos un aumento de la expresión de estos genes en 
hESC (Figura 30).
Finalmente nos propusimos investigar la posible función de 
SirT1 en la diferenciación celular.  Para ello observamos el 
comportamiento de las células madre embrionarias después 
de la interferencia de SirT1 (Figura 33).  Las células madre no 
presentaron ningún cambio fenotípico aparente provocado por 
la ausencia de SirT1.  Además, los marcadores de pluripotencia 
y de diferenciación no sufrieron una modificación relévate 
en estas condiciones (Figura 34).  Sin embargo, cuando 
indujimos la diferenciación de estas células a EB pudimos 
observar una alteración más importante de los niveles de 
marcadores de diferenciación (Figura 34).  Analizamos además 
el comportamiento de células madre de ratón en las que la 
expresión de SirT1 está silenciada por eliminación del gen 
(Sirt1 KO) o aumentada por inserción de copias adicionales 
del gen (SuperSirt1; Figura 35).  El hecho de que estas células 
puedan generar ratones vivos, que en el caso de los SirT1 KO 
presentan problemas de desarrollo pero en muchos casos llegan 
al nacimiento (Cheng et al., 2003), y en el caso de SuperSirt1 no 
presentan ningún fenotipo especifico de desarrollo,  nos indicaba 
que SirT1 no es esencial para los procesos clave del desarrollo 
(Pfluger et al., 2008).  Probablemente Sirt1 desempeña, más 
bien, un papel en la modulación de la expresión de los genes 
de desarrollo.  Observamos que la ausencia de Sirt1 tiene un 
efecto moderado sobre las células en su estadio indiferenciado, 
pero un efecto más acusado cuando se induce su diferenciación. 
Sin embargo, las células madre SirT1 KO mostraban una 
reducción moderada en la expresión de los seis marcadores de 
pluripotencia analizados (FGF4, Nanog, Nodal, Rest, Tdfcp2l1 
y Tdgf1), mientras que las células madre SuperSirt1 tienden a 
sobre-expresar estos marcadores de pluripotencia (Figura 38). 
Además, aunque las células Sirt1 KO diferenciadas a EB no 
mostraron cambios claros en la expresión de marcadores de 
pluripotencia, los EB de la línea Super-Sirt1 mantuvieron una 
expresión notable de estos marcadores que, en la mayoría de 
los casos, era comparable a su expresión en las células madres 
salvajes.  Estos resultados sugieren que la función de Sirt1 en 
células madre podría no ser idéntica en ratón y humano y que, a 
diferencia de las células madre humanas, Sirt1 puede contribuir 
al mantenimiento de la pluripotencia de células madre de ratón. 
Durante la diferenciación, se observó que tanto la ausencia como 
la sobreexpresión de Sirt1 dan lugar a una profunda alteración 
de la mayoría de los marcadores de desarrollo analizados (Fig. 
37); observación que se relaciona con nuestros resultados en 
las células madre humanas.  Los marcadores que mostraron 
alteraciones importantes son los correspondientes a la capa 
neuro-ectodérmica (Neurod1, Syp y Nes), que se sobreexpresan 
en Sirt1 KO EB y se regulan negativamente en Super-Sirt1 
EB.  Estos resultados indican que SirT1 podría tener un papel 
importante en la creación de la capa neuro-ectodérmica.
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CONCLUSIONES
Respecto al papel de la metilación del ADN en la diferenciación de células madre 
1. La metilación del ADN en los promotores es un mecanismo importante de regulación génica  en células 
madre adultas y en el desarrollo embrionario como herramienta de represión de los genes de desarrollo.
2. La activación durante la diferenciación tardía de células madre de determinados genes de desarrollo, 
principalmente los relacionados con el sistema inmune, está mediada fundamentalmente por la desmetilación 
de sus promotores. 
3. El 20% de los genes hipermetilados frecuentemente en cáncer (genes supresores tumorales, TSG) están 
también frecuentemente hipermetilados en células madre embrionarias. A diferencia de otros TSG, en las 
células madre estos genes no presentan en sus promotores la marca de histonas de dominio bivalente (K4 
y K27 de la histona H3 trimetiladas) característica. 
4. La metilación de los promotores se puede considerar una alternativa a la represión génica mediada por el 
dominio bivalente para un subconjunto de genes de desarrollo frecuentemente hipermetilados en cáncer.
Respecto al papel de la modificación de las histonas en la diferenciación de células madre 
5. La histona desacetilasa de clase III SirT1 está regulada durante la diferenciación de células madre 
embrionarias por un mecanismo que involucra a la proteína HuR, que se une al ARNm de SirT1 , y la 
arginina metiltransferasa CARM1. La metilación de HuR mediada por CARM1 en la Arg217 aumenta 
la estabilidad del ARNm de SirT1 en células madres pluripotentes. El nivel de expresión de CARM1 
desciende durante la diferenciación de células madre, provocando así una disminución de HuR metilado y, 
consecuentemente, una disminución de SirT1.
6. En células madre embrionarias, SirT1 se une a los promotores de un subconjunto de genes del desarrollo, 
muchos de ellos implicados en la diferenciación neural, y los reprime epigenéticamente. La disminución de 
los niveles de Sirt1 durante la diferenciación provoca la activación de estos genes mediante la acetilación 
de la Lys16 de la histona H4 y/o de la  Lys9 de la histona H3, permitiendo la expresión génica necesaria 
para la diferenciación celular al linaje correcto.  Por lo tanto, SirT1 podría desempeñar un papel importante 
en la formación de la capa neuro-ectodérmica. 
7. La eliminación de SirT1 en células madre humanas y murinas no induce diferenciación, sin embargo, altera 
el destino celular durante la diferenciación in vitro. Por lo tanto, SirT1 posee una función moduladora en la 
regulación de los genes de desarrollo, contribuyendo al correcto patrón espacio-tiempo de expresión génica 
durante el desarrollo embrionario.
8. La sobreexpresión de Sirt1 en células madre murinas aumenta la expresión de los genes implicados en la 
pluripotencia y retrasa su disminución durante la diferenciación, alterando así los patrones de diferenciación.
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